Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 1747 articles:
HTML format



Single Articles


    July 2022
  1. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    PubMed     Abstract available


    June 2022
  2. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    PubMed    


  3. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    PubMed    


  4. HU G, Jin WP, Yang ZH, Lv SY, et al
    Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00768.
    PubMed     Abstract available


  5. AL-MUSTAPHA AI, Okechukwu O, Olayinka A, Muhammed OR, et al
    A national survey of COVID-19 vaccine acceptance in Nigeria.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00818.
    PubMed     Abstract available


  6. LOHMANN S, Albarracin D
    Trust in the public health system as a source of information on vaccination matters most when environments are supportive.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00759.
    PubMed     Abstract available


  7. HUANG L, Wasserman M, Grant L, Farkouh R, et al
    Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00773.
    PubMed     Abstract available


  8. ZHAO Z, Liao Y, Li Y, Jiang G, et al
    Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00776.
    PubMed     Abstract available


  9. MAERTENS K, Leuridan E, Munoz FM, Zimmermann P, et al
    Impact of vaccination during pregnancy on infants' immune responses to vaccinations- definitions and statistical approaches.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00811.
    PubMed    


  10. BRAZ HMB, Silva MF, Carvalho TP, Silva LAD, et al
    Pathogenesis of Brucella ovis in pregnant mice and protection induced by the candidate vaccine strain B. Ovis DeltaabcBA.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00812.
    PubMed     Abstract available


  11. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    PubMed     Abstract available


  12. SOARES GH, Sethi S, Hedges J, Jamieson L, et al
    Disparities in Human Papillomavirus vaccination coverage among adolescents in Australia: A geospatial analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00777.
    PubMed     Abstract available


  13. WANG L, Zhang J, Meng S, Ge L, et al
    Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00784.
    PubMed     Abstract available


  14. HONDA-OKUBO Y, Cartee RT, Thanawastien A, Seung Yang J, et al
    A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00809.
    PubMed     Abstract available


  15. ULANOVA M, Huska B, Dubois S, McCready W, et al
    Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00810.
    PubMed     Abstract available


  16. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    PubMed     Abstract available


  17. KASAIJA PD, Contreras M, Kabi F, Mugerwa S, et al
    Oral vaccine formulation combining tick Subolesin with heat inactivated mycobacteria provides control of cross-species cattle tick infestations.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00804.
    PubMed     Abstract available


  18. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    PubMed     Abstract available


  19. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    PubMed     Abstract available


  20. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    PubMed     Abstract available


  21. TAY S, Bowen AC, Blyth CC, Clifford P, et al
    A quality improvement study: Optimizing pneumococcal vaccination rates in children with cochlear implants.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00769.
    PubMed     Abstract available


  22. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    PubMed     Abstract available


  23. TSENG HF, Sy LS, Ackerson BK, Lee GS, et al
    Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00756.
    PubMed     Abstract available


  24. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    PubMed     Abstract available


  25. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    PubMed     Abstract available


  26. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    PubMed     Abstract available


  27. HERNANDEZ LM, Sumathy K, Sahastrabuddhe S, Excler JL, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00753.
    PubMed     Abstract available


  28. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    PubMed     Abstract available


  29. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    PubMed     Abstract available


  30. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    PubMed     Abstract available


  31. SHOOTS-REINHARD B, Lawrence ER, Schulkin J, Peters E, et al
    Excluding numeric side-effect information produces lower vaccine intentions.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00747.
    PubMed     Abstract available


  32. ROLLIER CS, Dold C, Blackwell L, Linder A, et al
    Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00539.
    PubMed     Abstract available


  33. HEININGER U
    Referring to: Wilkinson K, Righolt CH, Elliott LJ, Fanella S, Mahmud SM. Pertussis vaccine effectiveness and duration of protection - a systematic review and meta-analysis. Vaccine. 2021 May 27;39(23):3120-3130.
    Vaccine. 2022;40:3530.
    PubMed    


  34. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    In response to: JVAC-D-21-02863, detection of a potential error in the results of the manuscript, dementia risk following influenza vaccination in a large veteran cohort, that could call into question the main conclusion.
    Vaccine. 2022;40:3529.
    PubMed    


  35. VUICHARD-GYSIN D, Schoenenberger A
    Detection of a potential error in the results of the manuscript "Dementia risk following influenza vaccination in a large veteran cohort" that could eventually call into question the main conclusion.
    Vaccine. 2022;40:3528.
    PubMed    


  36. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    PubMed     Abstract available


  37. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    PubMed     Abstract available


  38. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    PubMed     Abstract available


  39. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    PubMed     Abstract available


  40. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    PubMed     Abstract available


  41. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    PubMed     Abstract available


  42. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    PubMed     Abstract available


  43. LEAV B, Straus W, White P, Leav A, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00752.
    PubMed     Abstract available


  44. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    PubMed     Abstract available


  45. LIGHTOWLER MS, Manangazira P, Nackers F, Van Herp M, et al
    Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00552.
    PubMed     Abstract available


  46. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00715.
    PubMed     Abstract available


  47. OKUNO H, Satoh H, Morino S, Arai S, et al
    Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guerin vaccination: A national surveillance study in Japan from 2013 to 2017.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00672.
    PubMed     Abstract available


  48. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    PubMed     Abstract available


  49. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    PubMed     Abstract available


  50. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    PubMed     Abstract available


  51. SMITH WJ, Ahl PL, Wang B, Hamm M, et al
    Analytical technology development to monitor the stability of Polysaccharide-Protein conjugate vaccines.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00673.
    PubMed     Abstract available


  52. SLOTTE P, Karlsson LC, Soveri A
    Attitudes towards mandatory vaccination and sanctions for vaccination refusal.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00697.
    PubMed     Abstract available


  53. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    PubMed     Abstract available


  54. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    PubMed     Abstract available


  55. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    PubMed     Abstract available


  56. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    PubMed     Abstract available


  57. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    PubMed     Abstract available


  58. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    PubMed     Abstract available


  59. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    PubMed     Abstract available


  60. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    PubMed     Abstract available


  61. SLARVE M, Holznecht N, Reza H, Gilkes A, et al
    Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00674.
    PubMed     Abstract available


  62. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    PubMed     Abstract available


  63. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    PubMed     Abstract available


  64. JANSSEN DF
    A familiar species of Crank: Anti-Vaccinationists in medical history.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00665.
    PubMed     Abstract available


  65. BILGIN GM, Lokuge K, Glass K
    Modelling the impact of maternal pneumococcal vaccination on infant pneumococcal disease in low-income settings.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00684.
    PubMed     Abstract available


    May 2022
  66. AHMED S, Iqbal J, Sadiq K, Umrani F, et al
    Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants.
    Vaccine. 2022;40:3444-3451.
    PubMed     Abstract available


  67. PILLSBURY M, Carias C, Samant S, Greenberg D, et al
    Comparison of performance of varicella vaccines via infectious disease modeling.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00574.
    PubMed     Abstract available


  68. HISYAM BIN ISMAIL CMK, Raihan Mohammad Shabani N, Chuah C, Hassan Z, et al
    Shigella iron-binding proteins: An insight into molecular physiology, pathogenesis, and potential target vaccine development.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00679.
    PubMed     Abstract available


  69. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    PubMed     Abstract available


  70. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    PubMed     Abstract available


  71. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    PubMed     Abstract available


  72. HEMMING-HARLO M, Gylling A, Herse F, Haavisto I, et al
    Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018).
    Vaccine. 2022 May 28. pii: S0264-410X(22)00584.
    PubMed     Abstract available


  73. KLEINWAKS G, Schmit V, Morrison J
    Corrigendum to "Considering human challenge trials for tuberculosis vaccine development" [Vaccine 40(2) (2022) 173-174].
    Vaccine. 2022 May 28. pii: S0264-410X(22)00675.
    PubMed    


  74. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
    Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
    PubMed     Abstract available


  75. SHIOHARA M, Suzuki S, Shichinohe S, Ishigaki H, et al
    Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00640.
    PubMed     Abstract available


  76. RODES-SANCHEZ M, Spencer J, Tantri A, Mitrovich R, et al
    Working towards a sustainable, healthy market for vaccines: A framework to support evidence-based policymaking.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00671.
    PubMed    


  77. MACDONALD NE, Dube E, Comeau JL
    Have vaccine hesitancy models oversimplified a complex problem to our detriment? The Adapted Royal Society of Canada vaccine uptake framework.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00669.
    PubMed    


  78. SAVULESCU C, Krizova P, Valentiner-Branth P, Ladhani S, et al
    Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00581.
    PubMed     Abstract available


  79. LAI X, Li M, Hou Z, Guo J, et al
    Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00606.
    PubMed     Abstract available


  80. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    PubMed     Abstract available


  81. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    PubMed     Abstract available


  82. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    PubMed     Abstract available


  83. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    PubMed     Abstract available


  84. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    PubMed     Abstract available


  85. MOUSSAOUI S, Combes S, Ibanez G, Gautier A, et al
    Are immigrants living in France more reluctant to receive vaccines than native-born French citizens? findings from the national health Barometer study.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00636.
    PubMed     Abstract available


  86. ILESANMI MM, Adeyinka DA, Olakunde BO
    Sustainable Development Goals and childhood measles vaccination in Ekiti State, Nigeria: Results from spatial and interrupted time series analyses.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00632.
    PubMed     Abstract available


  87. LARSEN L, Bistrup C, Sorensen SS, Boesby L, et al
    Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: A non-blinded, randomized clinical trial.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00635.
    PubMed     Abstract available


  88. TAFURI S, Bianchi FP, Stefanizzi P
    The public health and the question of the "best vaccine".
    Vaccine. 2022 May 26. pii: S0264-410X(22)00639.
    PubMed    


  89. HOFFMAN BL, Batra Hershey T, Chu KH, Sidani JE, et al
    Moving vaccination beyond partisan politics.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00664.
    PubMed    


  90. ZHOU Y, Hu X, Chen R, Wu J, et al
    Impact of maternal and pre-existing antibodies on immunogenicity of inactivated rotavirus vaccines.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00620.
    PubMed     Abstract available


  91. JANKO MM, Joffe J, Michael D, Earl L, et al
    Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00637.
    PubMed     Abstract available


  92. DUBE E, Gagnon D, MacDonald N
    Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
    PubMed    


  93. GAGHAN C, Adams D, Mohammed J, Crespo R, et al
    Characterization of vaccine-induced immune responses against coccidiosis in broiler chickens.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00638.
    PubMed     Abstract available


  94. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    PubMed     Abstract available


  95. BECK E, Biundo E, Devlin N, Doherty TM, et al
    Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
    PubMed     Abstract available


  96. MALTER KB, Tugel ME, Gil-Rodriguez M, de la Guardia G, et al
    Corrigendum to "Variability in non-core vaccination rates of dogs and cats in veterinary clinics across the United States" [Vaccine 40(7) (2022) 1001-1009].
    Vaccine. 2022 May 23. pii: S0264-410X(22)00619.
    PubMed    


  97. QUINN MK, Edmond KM, Fawzi WW, Hurt L, et al
    Non-specific effects of BCG and DTP vaccination on infant mortality: An analysis of birth cohorts in Ghana and Tanzania.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00536.
    PubMed     Abstract available


  98. CHANG CM, Awanye AM, Marsay L, Dold C, et al
    Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial.
    Vaccine. 2022 May 21. pii: S0264-410X(22)00616.
    PubMed     Abstract available


  99. MOLLER A, Schwamborn K, Spillmann A, Hoogstraate J, et al
    Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?
    Vaccine. 2022 May 21. pii: S0264-410X(22)00611.
    PubMed     Abstract available


  100. OSMAN S, Crowcroft N, McLachlan E, Hatchette T, et al
    Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2022;40:3228-3235.
    PubMed     Abstract available


  101. LLAVE CL, Uy MEV, Lam HY, Aldaba JG, et al
    The cost-effectiveness of human papillomavirus vaccination in the Philippines.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00609.
    PubMed     Abstract available


  102. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    PubMed     Abstract available


  103. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    PubMed     Abstract available


  104. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    PubMed     Abstract available


  105. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    PubMed     Abstract available


  106. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    PubMed     Abstract available


  107. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    PubMed     Abstract available


  108. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    PubMed     Abstract available


  109. ZHANG Y, Lin L, Yang J, Lv Q, et al
    Two Bordetella bronchiseptica attenuated vaccine candidates confer protection against lethal challenge with B. Bronchiseptica and Pasteurella multocida toxin in mouse models.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00604.
    PubMed     Abstract available


  110. POSTMA M, Biundo E, Chicoye A, Devlin N, et al
    Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts.
    Vaccine. 2022 May 18. pii: S0264-410X(22)00442.
    PubMed     Abstract available


  111. VESIKARI T, Saez-Llorens X, Blazevic V, Lopez P, et al
    Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00550.
    PubMed     Abstract available


  112. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    PubMed     Abstract available


  113. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    PubMed     Abstract available


  114. NAZURDINOV A, Azizov Z, Mullojonova M, Sadykova U, et al
    Impact and effectiveness of monovalent rotavirus vaccine in Tajik children.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00589.
    PubMed     Abstract available


  115. SULIS G, Horn M, Borrow R, Basta NE, et al
    A comparison of national vaccination policies to prevent serogroup B meningococcal disease.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00568.
    PubMed     Abstract available


  116. POLAND GA, van Dijk N
    John D. Bailey retiring after more than 20years of service to Vaccine.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00618.
    PubMed    


  117. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    PubMed     Abstract available


  118. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    PubMed     Abstract available


  119. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    PubMed     Abstract available


  120. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    PubMed     Abstract available


  121. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    PubMed     Abstract available


  122. LI F, Freed D, Heidecker G, Galli J, et al
    A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00569.
    PubMed     Abstract available


  123. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    PubMed     Abstract available


  124. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    PubMed     Abstract available


  125. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    PubMed     Abstract available


  126. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.
    PubMed    


  127. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    PubMed     Abstract available


  128. OSTER G, Bornheimer R, Ottino K, Stevenson C, et al
    Adult immunization against hepatitis B: Does the number of jabs matter?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00534.
    PubMed     Abstract available


  129. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    PubMed     Abstract available


  130. SHAUM A, Mujuru HA, Takamiya M, Ticklay I, et al
    Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00551.
    PubMed     Abstract available


  131. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Corrigendum to "Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study" [Vaccine 40(2) (2022) 275-281].
    Vaccine. 2022 May 11. pii: S0264-410X(22)00537.
    PubMed    


  132. ISLAM N, Xu C, Lau CL, Mills DJ, et al
    Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00535.
    PubMed     Abstract available


  133. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    PubMed     Abstract available


  134. KITRO A, Sirikul W, Thongkum W, Soponpong S, et al
    Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Vaccine. 2022;40:2915-2924.
    PubMed     Abstract available


  135. MARTIN J, Barrett ADT, Lei D, Minor P, et al
    WHO working group meeting to amend WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00548.
    PubMed     Abstract available


  136. ZOLA MATUVANGA T, Lariviere Y, Lemey G, De Bie J, et al
    Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00544.
    PubMed     Abstract available


  137. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    PubMed     Abstract available


  138. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    PubMed     Abstract available


  139. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus sero
    Vaccine. 2022 May 6. pii: S0264-410X(22)00571.
    PubMed    


  140. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    PubMed     Abstract available


  141. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    PubMed     Abstract available


  142. COLE JW, Chen AMH, McGuire K, Berman S, et al
    Erratum to "Motivational interviewing and vaccine acceptance in children: The MOTIVE study" [Vaccine 40(12) (2022) 1846-1854].
    Vaccine. 2022 May 5. pii: S0264-410X(22)00538.
    PubMed    


  143. VELICER C, Luxembourg A, Chen YT, Kohn M, et al
    Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00542.
    PubMed    


  144. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    PubMed     Abstract available


  145. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    PubMed     Abstract available


  146. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    PubMed     Abstract available


  147. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    PubMed     Abstract available


  148. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    PubMed     Abstract available


  149. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    PubMed     Abstract available


  150. GUTIERREZ-TOBAR IF, Londono-Ruiz JP, Marino-Drews C, Beltran-Higuera S, et al
    Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008-2019.
    Vaccine. 2022;40:2875-2883.
    PubMed     Abstract available


  151. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    PubMed     Abstract available


  152. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    PubMed     Abstract available


  153. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    PubMed     Abstract available


    April 2022
  154. TOLL M, Li A
    Vaccine mandates on childcare entry without conscientious objection exemptions: A quasi-experimental panel study.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00461.
    PubMed     Abstract available


  155. GREYSON D, Carpiano RM, Bettinger JA
    Support for a vaccination documentation mandate in British Columbia, Canada.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00247.
    PubMed     Abstract available


  156. TAMURA K, Kohnoe M, Takashino A, Kobayashi K, et al
    TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00518.
    PubMed     Abstract available


  157. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    PubMed     Abstract available


  158. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    PubMed     Abstract available


  159. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    PubMed     Abstract available


  160. TAMURA K, Chang B, Shimbashi R, Watanabe H, et al
    Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00502.
    PubMed     Abstract available


  161. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    PubMed     Abstract available


  162. LV H, Wang S, Liang Z, Yu W, et al
    Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00205.
    PubMed     Abstract available


  163. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    PubMed    


  164. JAFFLIN K, Deml MJ, Schwendener CL, Kiener L, et al
    Parental and provider vaccine hesitancy and non-timely childhood vaccination in Switzerland.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00472.
    PubMed     Abstract available


  165. KOULIDIATI JL, Kabore R, I Nebie E, Sidibe A, et al
    Timely completion of childhood vaccination and its predictors in Burkina Faso.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00497.
    PubMed     Abstract available


  166. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    PubMed     Abstract available


  167. KRUPP K, Galea J, Madhivanan P, Gerald L, et al
    Conversational artificial intelligence: A new approach for increasing influenza vaccination rates in children with asthma?
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00496.
    PubMed    


  168. YUKI Y, Nojima M, Kashima K, Sugiura K, et al
    Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00491.
    PubMed     Abstract available


  169. ZHU FC, Zeng H, Li JX, Wang B, et al
    Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00462.
    PubMed     Abstract available


  170. PERCIACCANTE A, Asensi V, Cucu AI, Charlier P, et al
    War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00465.
    PubMed    


  171. BEYER WEP, Palache AM, Boulfich M, Osterhaus ADME, et al
    Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00489.
    PubMed     Abstract available


  172. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    PubMed     Abstract available


  173. ONNIS V, Moriconi A, Paludi M, Giannini S, et al
    Clinically proven specification setting for a meningococcal serogroup a conjugate vaccine.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00493.
    PubMed     Abstract available


  174. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.
    PubMed    


  175. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    PubMed     Abstract available


  176. HAMID FA, Marker CL, Raleigh MD, Khaimraj A, et al
    Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00364.
    PubMed     Abstract available


  177. SEPPALA E, Brathen Kristoffersen A, Boas H, Frimann Vestrheim D, et al
    Pertussis epidemiology including direct and indirect effects of the childhood pertussis booster vaccinations, Norway, 1998-2019.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00466.
    PubMed     Abstract available


  178. BEULENS C, Raven SFH, van Jaarsveld CHM, van Loo I, et al
    Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00470.
    PubMed     Abstract available


  179. STALPERS CAL, Retmana IA, Pennings JLA, Vandebriel RJ, et al
    Corrigendum to "Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines" [Vaccine 39(18) (2021) 2506-2516].
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00475.
    PubMed    


  180. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    PubMed     Abstract available


  181. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    PubMed     Abstract available


  182. ORTIZ JR, Spearman PW, Goepfert PA, Cross K, et al
    Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Vaccine. 2022 Apr 21. pii: S0264-410X(22)00366.
    PubMed     Abstract available


  183. CAN G, Acar HC, Aydin SN, Balkan II, et al
    Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers.
    Vaccine. 2022;40:2574-2579.
    PubMed     Abstract available


  184. LEBLANC JJ, ElSherif M, Ye L, MacKinnon-Cameron D, et al
    Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
    Vaccine. 2022;40:2635-2646.
    PubMed     Abstract available


  185. THOMPSON D, Metz SW, Abad C, Beaty S, et al
    Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00435.
    PubMed     Abstract available


  186. GARTNER BC, Weinke T, Wahle K, Kwetkat A, et al
    Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00440.
    PubMed     Abstract available


  187. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    PubMed     Abstract available


  188. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    PubMed     Abstract available


  189. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    PubMed     Abstract available


  190. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    PubMed     Abstract available


  191. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    PubMed     Abstract available


  192. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    PubMed     Abstract available


  193. ANDERSON A
    Attitudes towards vaccination and knowledge about antibiotics: Analysis of Wellcome Monitor survey data.
    Vaccine. 2022 Apr 15. pii: S0264-410X(22)00429.
    PubMed     Abstract available


  194. BAROUTSOU V, Wymann M, Zens K, Sinniger P, et al
    National and regional variations in timely adherence to recommended measles vaccination scheme in 2-years old in Switzerland, 2005-2019.
    Vaccine. 2022 Apr 15. pii: S0264-410X(22)00424.
    PubMed     Abstract available


  195. KUSHNER T, Huang V, Janssen R
    Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review.
    Vaccine. 2022 Apr 13. pii: S0264-410X(22)00443.
    PubMed     Abstract available


  196. FENOLLAR F, Thomas L, Raoult D, Gautret P, et al
    Screening for SARS-CoV-2 antibodies to save vaccine doses.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00444.
    PubMed    


  197. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    PubMed     Abstract available


  198. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00441.
    PubMed     Abstract available


  199. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    PubMed     Abstract available


  200. ZHU XM, Yan W, Sun J, Liu L, et al
    Patterns and influencing factors of COVID-19 vaccination willingness among college students in China.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00433.
    PubMed     Abstract available


  201. SHINJOH M, Furuichi M, Kobayashi H, Yamaguchi Y, et al
    Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00449.
    PubMed     Abstract available


  202. SPRINGER S, Kaatz M, Zieger M
    Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00430.
    PubMed     Abstract available


  203. CEYLAN ME, Onen Unsalver B, Donmez A, Kaya Yertutanol FD, et al
    A case of myocarditis and isolated hypopotassemia after Biontech-Pfizer vaccine for Covid-19.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00432.
    PubMed    


  204. LJUNG R, Feychting M, Burstrom B, Moller J, et al
    Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00431.
    PubMed     Abstract available


  205. OKTARIA V, Bines JE, Murni IK, Dinari R, et al
    Timeliness of routine childhood vaccinations in Indonesian infants in the first year of life.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00420.
    PubMed     Abstract available


  206. BENINGER P
    Need for a contingency dimension when planning vaccine development in a pandemic environment.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00401.
    PubMed    


  207. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Corrigendum to 'Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice' [Vaccine 39 (2021) 6213-6220].
    Vaccine. 2022 Apr 9. pii: S0264-410X(22)00221.
    PubMed    


  208. AINSLIE KEC, Riley S
    Is annual vaccination best? A modelling study of influenza vaccination strategies in children.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00384.
    PubMed     Abstract available


  209. TIANSHUO Z, Hanyu L, Bingfeng H, Bei L, et al
    Evaluation of the reliability and validity of a vaccine hesitancy scale on knowledge, attitude, trust and vaccination environment (KATE-S) in Chinese parents.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00388.
    PubMed     Abstract available


  210. MAYFIELD HJ, Lau CL, Sinclair JE, Brown SJ, et al
    Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00418.
    PubMed     Abstract available


  211. BELDA F, Mora O, Lopez Martinez M, Torres N, et al
    Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00419.
    PubMed     Abstract available


  212. ERFANI P, Sandoval RS, Rich KM, Ojo A, et al
    Ask Me Anything": Lessons learned in implementing a COVID-19 vaccine information initiative in Massachusetts jails.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00439.
    PubMed     Abstract available


  213. KENIGSBERG TA, Hause AM, McNeil MM, Nelson JC, et al
    Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00426.
    PubMed     Abstract available


  214. LINKINS LA, Iorio A, Little J, Lavis J, et al
    Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00422.
    PubMed    


  215. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    PubMed     Abstract available


  216. SHAH S, Gui H, Chua PEY, Tan JB, et al
    Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
    Vaccine. 2022 Apr 5. pii: S0264-410X(22)00381.
    PubMed     Abstract available


  217. HASSAN PM, Ali T, Saber E, Asghar A, et al
    Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00385.
    PubMed     Abstract available


  218. LEWIS RM, Markowitz LE
    Disparities in human papillomavirus vaccination coverage in the United States, National Health and Nutrition Examination Survey, January 2017-March 2020.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00317.
    PubMed     Abstract available


  219. WALTERS JN, Schouest B, Patel A, Reuschel EL, et al
    Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00368.
    PubMed     Abstract available


  220. ENTRICAN G, Francis MJ
    Applications of platform technologies in veterinary vaccinology and the benefits for one health.
    Vaccine. 2022 Apr 2. pii: S0264-410X(22)00371.
    PubMed     Abstract available


  221. FRISE R, Baillon L, Zhou J, Kugathasan R, et al
    A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00383.
    PubMed     Abstract available


  222. MA C, Sun W, Tang T, Jia M, et al
    Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00386.
    PubMed     Abstract available


  223. SUGHAYER MA, Souan L, Abu Alhowr MM, Al Rimawi D, et al
    Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00387.
    PubMed     Abstract available


    March 2022
  224. GERTOSIO C, Licari A, De Silvestri A, Rebuffi C, et al
    Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis.
    Vaccine. 2022 Mar 31. pii: S0264-410X(22)00341.
    PubMed     Abstract available


  225. TEJADA RA, Malagon T, Franco EL
    Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis.
    Vaccine. 2022 Mar 31. pii: S0264-410X(22)00357.
    PubMed     Abstract available


  226. VANDOORN E, Parys A, Chepkwony S, Chiers K, et al
    Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00362.
    PubMed     Abstract available


  227. BURNY W, Herve C, Caubet M, Yarzabal JP, et al
    Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00361.
    PubMed     Abstract available


  228. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a rando
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00367.
    PubMed     Abstract available


  229. EFUA SACKEY M, Markey K, Grealish A
    Healthcare professional's promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00365.
    PubMed     Abstract available


  230. TADDIO A, Gudzak V, Jantzi M, Logeman C, et al
    Impact of the CARD (Comfort Ask Relax Distract) system on school-based vaccinations: A cluster randomized trial.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00224.
    PubMed     Abstract available


  231. MCRAE J, Blyth CC, Cheng AC, Quinn HE, et al
    Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00353.
    PubMed    


  232. ESTIVARIZ CF, Kovacs SD, Mach O
    Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00304.
    PubMed     Abstract available


  233. ISITT C, Sjoholm D, Hergens MP, Granath F, et al
    The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00372.
    PubMed     Abstract available


  234. KATO H, Miyakawa K, Ohtake N, Yamaoka Y, et al
    Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00369.
    PubMed     Abstract available


  235. LI K, Yu T, Seabury SA, Dor A, et al
    Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00370.
    PubMed     Abstract available


  236. JUDDOO V, Juddoo S, Megarbane B
    Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00363.
    PubMed    


  237. BREAKWELL L, Marke D, Kaiser R, Tejada-Strop A, et al
    Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00360.
    PubMed     Abstract available


  238. FUNK PR, Yogurtcu ON, Forshee RA, Anderson SA, et al
    Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00329.
    PubMed     Abstract available


  239. WELLS K, Moore KL, Bednarczyk R
    Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00339.
    PubMed    


  240. RICKETSON LJ, Bettinger JA, Sadarangani M, Halperin SA, et al
    Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vaccine. 2022 Mar 26. pii: S0264-410X(22)00359.
    PubMed     Abstract available


  241. SIMMONS LA, Whipps MDM, Phipps JE, Satish NS, et al
    Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00355.
    PubMed     Abstract available


  242. FARAH W, Breeher L, Shah V, Hainy C, et al
    Disparities in COVID-19 vaccine uptake among health care workers.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00356.
    PubMed     Abstract available


  243. NOMURA Y, Noda K, Oohashi Y, Okuda S, et al
    Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00354.
    PubMed     Abstract available


  244. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    PubMed     Abstract available


  245. ST JEAN DT, Rogawski McQuade ET, Edwards JK, Thompson P, et al
    Effect of early life antibiotic use on serologic responses to oral rotavirus vaccine in the MAL-ED birth cohort study.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00300.
    PubMed     Abstract available


  246. LEACH K, Checchi F
    The utilisation of vaccines in humanitarian crises, 2015-2019: A review of practice.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00335.
    PubMed     Abstract available


  247. VOORMAN A, Lyons H, Bennette C, Kovacs S, et al
    Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00277.
    PubMed     Abstract available


  248. LIU X, Yu W, Yin Z, Rodewald L, et al
    Vaccine events raising public concern and associated immunization program policy and practice changes, China, 2005-2021.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00334.
    PubMed     Abstract available


  249. ABDEL-QADER DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, et al
    IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00265.
    PubMed    


  250. SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
    Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
    PubMed     Abstract available


  251. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Decreasing routine vaccination rates in children in the COVID-19 era.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00333.
    PubMed    


  252. FANO V, Crielesi A, Coviello E, Fabiani M, et al
    Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00208.
    PubMed     Abstract available


  253. FERDINANDS JM, Patel M
    Influence of disease attenuation on relative influenza vaccine effectiveness by vaccine type.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00274.
    PubMed     Abstract available


  254. JIAN-BIN L, Lau EYH, Chan DKC
    Why do Hong Kong parents have low intention to vaccinate their children against COVID-19? testing health belief model and theory of planned behavior in a large-scale survey.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00340.
    PubMed     Abstract available


  255. YUEN WLP, Loh SYJ, Wang DB
    SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00337.
    PubMed     Abstract available


  256. ZERBO O, Modaressi S, Goddard K, Lewis E, et al
    Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00331.
    PubMed     Abstract available


  257. CALLAGHAN T, Washburn D, Goidel K, Nuzhath T, et al
    Imperfect messengers? An analysis of vaccine confidence among primary care physicians.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00302.
    PubMed     Abstract available


  258. ESPOSITO S, Nauta J, Lapini G, Montomoli E, et al
    Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00263.
    PubMed     Abstract available


  259. BILGIN H, Marku M, Yilmaz SS, Karahasan Yagci A, et al
    The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00264.
    PubMed     Abstract available


  260. GRUHN S, Witte J, Greiner W, Damm O, et al
    Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Vaccine. 2022;40:1932-1947.
    PubMed     Abstract available


  261. WANG H, Ypma E, Nicolay U
    Managing multiplicity in clinical vaccine studies - A case study using a gatekeeping testing strategy.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00244.
    PubMed     Abstract available


  262. GRAFFIGNA G, Palamenghi L, Barello S, Boccia S, et al
    Erratum to ""Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy" [Vaccine 38(48) (2020) 7585-7586].
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00295.
    PubMed    


  263. BATOOL R, Yousafzai MT, Qureshi S, Ali M, et al
    Corrigendum to "Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study". [Vaccine 39 (2021) 5858-5865].
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00294.
    PubMed    


  264. MACKLIN G, Peak C, Eisenhawer M, Kurji F, et al
    Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00195.
    PubMed     Abstract available


  265. SADIGH K, Fox G, Khetsuriani N, Gao H, et al
    Policy and practice of checking vaccination status at school in 2018, a global overview.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00266.
    PubMed     Abstract available


  266. GAO Z, Chen L, Song T, Pan X, et al
    A candidate multi-epitope vaccine against porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae induces robust humoral and cellular response in mice.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00296.
    PubMed     Abstract available


  267. GUL A, Doskaya M, Can H, Karakavuk M, et al
    Immunogenicity of a xenogeneic multi-epitope HER2(+) breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205.
    Vaccine. 2022 Mar 16. pii: S0264-410X(22)00279.
    PubMed     Abstract available


  268. BEESLAAR J, Mather S, Absalon J, Eiden JJ, et al
    Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
    Vaccine. 2022;40:1872-1878.
    PubMed     Abstract available


  269. KHETSURIANI N, Zaika O, Slobodianyk L, Scobie HM, et al
    Diphtheria and tetanus seroepidemiology among children in Ukraine, 2017.
    Vaccine. 2022;40:1810-1820.
    PubMed     Abstract available


  270. CAMARA J, Gonzalez-Diaz A, Barrabeig I, Fernandez-Huerta M, et al
    SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00303.
    PubMed     Abstract available


  271. ROTOLO B, Dube E, Vivion M, MacDonald SE, et al
    Hesitancy towards COVID-19 vaccines on social media in Canada.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00301.
    PubMed     Abstract available


  272. MOSCARDINO U, Musso P, Inguglia C, Ceccon C, et al
    Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.
    Vaccine. 2022 Mar 14. pii: S0264-410X(22)00293.
    PubMed     Abstract available


  273. MORGA A, Kimura T, Feng Q, Rozario N, et al
    Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination.
    Vaccine. 2022 Mar 12. pii: S0264-410X(22)00269.
    PubMed     Abstract available


  274. LAMORI J, Feng X, Pericone CD, Mesa-Frias M, et al
    Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    Vaccine. 2022 Mar 12. pii: S0264-410X(22)00268.
    PubMed     Abstract available


  275. HUANG HJ, Yang M, Chen HW, Wang S, et al
    A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.
    Vaccine. 2022 Mar 11. pii: S0264-410X(22)00225.
    PubMed     Abstract available


  276. GU YOON J, Jang AY, Ja Kim M, Bin Seo Y, et al
    Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era: Serotype-dependent difference in ceftriaxone susceptibility.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00267.
    PubMed     Abstract available


  277. KAKATSAKI I, Vergadi E, Paraskakis E, Galanakis E, et al
    Attitudes of junior healthcare professionals towards mandatory vaccination.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00275.
    PubMed     Abstract available


  278. HARUTYUNYAN V, Quddus A, Pallansch M, Zipursky S, et al
    Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00204.
    PubMed     Abstract available


  279. VAN DEN HOOGEN LL, Smits G, van Hagen CCE, Wong D, et al
    Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00272.
    PubMed     Abstract available


  280. THOMAS CM, Searle K, Galvan A, Liebman AK, et al
    Healthcare worker perspectives on COVID-19 vaccines: Implications for increasing vaccine acceptance among healthcare workers and patients.
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00276.
    PubMed     Abstract available


  281. WILKINSON K, Righolt CH, Kwong JC, Schwartz KL, et al
    Corrigendum to "A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study" [Vaccine 37(48) (2019) 7132-7137].
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00240.
    PubMed    


  282. YUEN VWH
    Political attitudes and efficacy of health expert communication on the support for COVID-19 vaccination program: Findings from a survey in Hong Kong.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00261.
    PubMed     Abstract available


  283. BANSAL P, Raj A, Mani Shukla D, Sunder N, et al
    COVID-19 vaccine preferences in India.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00241.
    PubMed     Abstract available


  284. ULRICH AK, Sundaram ME, Basta NE
    Supporting individual vaccine decision-making: A role for vaccination counselors.
    Vaccine. 2022 Mar 4. pii: S0264-410X(22)00135.
    PubMed    


  285. MASCHERINI M, Nivakoski S
    Social media use and vaccine hesitancy in the European Union.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00206.
    PubMed     Abstract available


  286. KLUMPP M, Monfared IG, Vollmer S
    Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00259.
    PubMed     Abstract available


  287. COULAUD PJ, Ablona A, Bolduc N, Fast D, et al
    COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00260.
    PubMed     Abstract available


  288. ROBERTSON LJ, Price R, Moore JS, Curry G, et al
    IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00262.
    PubMed     Abstract available


  289. KREPS SE, Kriner DL
    How do COVID-19 vaccine mandates affect attitudes toward the vaccine and participation in mandate-affected activities? Evidence from the United States.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00258.
    PubMed     Abstract available


  290. WONDIMU A, Postma MJ, van Hulst M
    Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00245.
    PubMed     Abstract available


  291. YU M, Yao X, Liu G, Wu J, et al
    Barriers and facilitators to uptake and promotion of influenza vaccination among health care workers in the community in Beijing, China: A qualitative study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00207.
    PubMed     Abstract available


  292. POINTON L, Howe AS, Hobbs M, Paynter J, et al
    Evidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00243.
    PubMed     Abstract available


  293. LAI FTT, Leung MTY, Chan EWW, Huang L, et al
    Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Vaccine. 2022;40:1390-1396.
    PubMed     Abstract available


  294. DENNY L
    HPV vaccine introduction and implementation in LMICs.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00227.
    PubMed    


  295. GU J, Dor A, Li K, Broniatowski DA, et al
    The impact of Facebook's vaccine misinformation policy on user endorsements of vaccine content: An interrupted time series analysis.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00209.
    PubMed     Abstract available


  296. SEXSON TEJTEL SK, Munoz FM, Al-Ammouri I, Savorgnan F, et al
    Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:1499-1511.
    PubMed     Abstract available


  297. MOURA C, Truche P, Sousa Salgado L, Meireles T, et al
    The impact of COVID-19 on routine pediatric vaccination delivery in Brazil.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00242.
    PubMed     Abstract available


    February 2022
  298. SINGH JA, Kochhar S, Wolff J, Atuire C, et al
    WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00175.
    PubMed     Abstract available


  299. MCANDREW T, Cambeiro J, Besiroglu T
    Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00200.
    PubMed     Abstract available


  300. LAU YL, Fan Leung T, Sirvan Cetin B, Cagri Dinleyici E, et al
    Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00218.
    PubMed     Abstract available


  301. SALIOU P, Duteil Q, Plotkin SA, Gentilini M, et al
    The scourge of vaccine falsification.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00119.
    PubMed     Abstract available


  302. SCHAFER W, Reinders T, Schink T
    Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00222.
    PubMed     Abstract available


  303. DANIELS V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, et al
    Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00220.
    PubMed     Abstract available


  304. KAGEYAMA T, Tanaka S, Etori K, Hattori K, et al
    Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00192.
    PubMed     Abstract available


  305. MULLER KE, Dohos D, Sipos Z, Kiss S, et al
    Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00163.
    PubMed     Abstract available


  306. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    Vaccine. 2022;40:1223-1230.
    PubMed     Abstract available


  307. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    Vaccine. 2022;40:1215-1222.
    PubMed     Abstract available


  308. DIXON MG, Tapia MD, Wannemuehler K, Luce R, et al
    Measles susceptibility in maternal-infant dyads-Bamako, Mali.
    Vaccine. 2022;40:1316-1322.
    PubMed     Abstract available


  309. HAO F, Shao W
    Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00219.
    PubMed     Abstract available


  310. NIE J, Sun Y, Feng K, Huang L, et al
    The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00159.
    PubMed     Abstract available


  311. EL-HENEIDY A, Grimwood K, Lambert SB, Sarna M, et al
    Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00198.
    PubMed     Abstract available


  312. ABBATECOLA AM, Incalzi RA, Malara A, Palmieri A, et al
    Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00217.
    PubMed     Abstract available


  313. CHOOI WH, Ng PW, Hussain Z, Ming LC, et al
    Vaccine contamination: Causes and control.
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00169.
    PubMed    


  314. TAWINPRAI K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, et al
    Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00143.
    PubMed     Abstract available


  315. ISMAIL ALHOSANI F, Eduardo Stanciole A, Aden B, Timoshkin A, et al
    Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00174.
    PubMed     Abstract available


  316. FILIA A, Rota MC, Grossi A, Martinelli D, et al
    Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination.
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00187.
    PubMed     Abstract available


  317. WINTER T, Riordan BC, Scarf D, Jose PE, et al
    Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00074.
    PubMed     Abstract available


  318. STANDAERT B, Strens D, Raes M, Benninghoff B, et al
    Explaining the formation of a plateau in rotavirus vaccine impact on rotavirus hospitalisations in Belgium.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00199.
    PubMed     Abstract available


  319. LEE GY, Inthasorn P, Laowahutanont P, Lawpoolsri S, et al
    Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00188.
    PubMed     Abstract available


  320. SCHMALING KB
    Couples and COVID-19 vaccination: Frequency and reasons for discordance.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00202.
    PubMed     Abstract available


  321. TRUMP BD, Golan MS, Keisler JM, Cegan JC, et al
    Vaccine supply chain: Resilience-by-design and resilience-by-intervention.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00172.
    PubMed    


  322. HENSCHKE N, Bergman H, Hungerford D, Cunliffe NA, et al
    The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00125.
    PubMed     Abstract available


  323. KASSTAN B, Mounier-Jack S, Letley L, Gaskell KM, et al
    Localising vaccination services: Qualitative insights on public health and minority group collaborations to co-deliver coronavirus vaccines.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00201.
    PubMed     Abstract available


  324. MERKLEY E, Loewen PJ
    The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00168.
    PubMed     Abstract available


  325. LAZO L, Bequet-Romero M, Lemos G, Musacchio A, et al
    A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Vaccine. 2022;40:1162-1169.
    PubMed     Abstract available


  326. JOG P, Memon IA, Thisyakorn U, Hozbor D, et al
    Pertussis in Asia: Recent country-specific data and recommendations.
    Vaccine. 2022;40:1170-1179.
    PubMed     Abstract available


  327. STEFANIZZI P, Larocca AMV, Martinelli A, Soldano S, et al
    Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00124.
    PubMed     Abstract available


  328. KALASKA B, Miklosz J, Swieton J, Jakimczuk A, et al
    The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00173.
    PubMed     Abstract available


  329. BUCKLEY A, Lager K
    Efficacy of an inactivated Senecavirus A vaccine in weaned pigs and mature sows.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00142.
    PubMed     Abstract available


  330. ANUGULRUENGKITT S, Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, et al
    Seroprevalence of mumps among children and adolescents in Thailand, 2020.
    Vaccine. 2022;40:1061-1064.
    PubMed     Abstract available


  331. HUSKA B, Kubinec C, Sadarangani M, Ulanova M, et al
    Seroprevalence of IgG and IgM antibodies to Haemophilus influenzae type a in Canadian children.
    Vaccine. 2022;40:1128-1134.
    PubMed     Abstract available


  332. ARAKELIAN T, Oosterhuis K, Tondini E, Los M, et al
    Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00162.
    PubMed     Abstract available


  333. SALEH OA, Halperin O
    Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00160.
    PubMed     Abstract available


  334. HIDLE A, Brennan T, Garon J, An Q, et al
    Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00047.
    PubMed     Abstract available


  335. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    PubMed     Abstract available


  336. TANI N, Chong Y, Kurata Y, Gondo K, et al
    Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00158.
    PubMed     Abstract available


  337. AMMETER T, Lang P, Czock A
    Overview of the influenza vaccination activities and legal frameworks in 26 Swiss cantons during the influenza season 2019/20.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00132.
    PubMed     Abstract available


  338. MUCHIRI SK, Muthee R, Kiarie H, Sitienei J, et al
    Unmet need for COVID-19 vaccination coverage in Kenya.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00167.
    PubMed     Abstract available


  339. GAFFNEY KK, Jana Broadhurst M, Brett-Major DM
    Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00193.
    PubMed     Abstract available


  340. YAMAMOTO S, Fukunaga A, Tanaka A, Takeuchi JS, et al
    Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00196.
    PubMed     Abstract available


  341. UWAMINO Y, Yokoyama T, Shimura T, Nishimura T, et al
    The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00191.
    PubMed     Abstract available


  342. GAO F, An C, Bian L, Wang Y, et al
    Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00194.
    PubMed     Abstract available


  343. CHAN IL, Mowson R, Alonso JP, Roberti J, et al
    Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00197.
    PubMed     Abstract available


  344. CHRYSI P, Stella M, Marios K, Despo C, et al
    Exploring vaccination coverage and attitudes of health care workers towards influenza vaccine in Cyprus.
    Vaccine. 2022 Feb 12. pii: S0264-410X(22)00141.
    PubMed     Abstract available


  345. HELLER O, Chun Y, Shlomo Y, Gewirtz-Meydan A, et al
    Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00165.
    PubMed     Abstract available


  346. KOCHHAR S, Barreira D, Beattie P, Cavaleri M, et al
    Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
    Vaccine. 2022 Feb 11. pii: S0264-410X(21)01395.
    PubMed     Abstract available


  347. DIETRICH LG, Luthy A, Lucas Ramanathan P, Baldesberger N, et al
    Healthcare professional and professional stakeholders' perspectives on vaccine mandates in Switzerland: A mixed-methods study.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00007.
    PubMed     Abstract available


  348. TIBBELS NJ, Dosso A, Fordham C, Benie W, et al
    "On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00166.
    PubMed     Abstract available


  349. KAPLONEK P, Yao L, Reppe K, Voss F, et al
    A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae.
    Vaccine. 2022;40:1038-1046.
    PubMed     Abstract available


  350. ABHILASH KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, et al
    Impact of prior vaccination with Covishield(TM) and Covaxin(R) on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00157.
    PubMed     Abstract available


  351. DEBELLUT F, Mkisi R, Masoo V, Chisema M, et al
    Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00139.
    PubMed     Abstract available


  352. COLE JW, M H Chen A, McGuire K, Berman S, et al
    Motivational interviewing and vaccine acceptance in children: The MOTIVE study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00114.
    PubMed     Abstract available


  353. PAOLINO KM, Regules JA, Moon JE, Ruck RC, et al
    Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00093.
    PubMed     Abstract available


  354. BERGMANN ESTEVES S, Moreira Santos C, Ferreira Salgado F, Paldes Goncales A, et al
    Efficacy of commercially available vaccines against canine leptospirosis: A systematic review and meta-analysis.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00144.
    PubMed     Abstract available


  355. DREYER N, Reynolds MW, Albert L, Brinkley E, et al
    How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00103.
    PubMed     Abstract available


  356. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    PubMed     Abstract available


  357. DE LUCA C, Schachner A, Heidl S, Hess M, et al
    Vaccination with a fowl adenovirus chimeric fiber protein (crecFib-4/11) simultaneously protects chickens against hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH).
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00116.
    PubMed     Abstract available


  358. SCHALTZ-BUCHHOLZER F, Toldi G
    The association between parental and neonatal BCG vaccination and neonatal T helper 17 cell expansion.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00128.
    PubMed     Abstract available


  359. CARLOW DA, Lai JCY, Kollmann TR, Sadarangani M, et al
    Cutaneous CpG adjuvant conditioning to enhance vaccine responses.
    Vaccine. 2022 Feb 8. pii: S0264-410X(21)01668.
    PubMed     Abstract available


  360. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00164.
    PubMed     Abstract available


  361. PEREZ-RODRIGUEZ S, de la Caridad Rodriguez-Gonzalez M, Ochoa-Azze R, Climent-Ruiz Y, et al
    A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00161.
    PubMed     Abstract available


  362. LADHANI SN, Campbell H, Amin-Chowdhury Z, Lucidarme J, et al
    Timing of meningococcal vaccination with 4CMenB (Bexsero(R)) in children with invasive meningococcal group B (MenB) disease in England.
    Vaccine. 2022 Feb 8. pii: S0264-410X(21)01618.
    PubMed     Abstract available


  363. CORNISH MJ, Hedrick JA, Gabrielsen AA, Johnson AD, et al
    Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00096.
    PubMed     Abstract available


  364. DENG JZ, Lancaster C, Winters MA, Phillips KM, et al
    Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00076.
    PubMed     Abstract available


  365. WALKER B, Anderson A, Stoecker C, Shao Y, et al
    COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid.
    Vaccine. 2022;40:837-840.
    PubMed     Abstract available


  366. CRUVINEL E, P Richter K, S Scheuermann T, M Machado N, et al
    The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00120.
    PubMed     Abstract available


  367. MEWHIRTER J, Sagir M, Sanders R
    Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00134.
    PubMed     Abstract available


  368. DOMNICH A, Orsi A, Sticchi L, Panatto D, et al
    Effect of the 2020/21 season influenza vaccine on SARS-CoV-2 infection in a cohort of Italian healthcare workers.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00137.
    PubMed     Abstract available


  369. BELLOS I, Karageorgiou V, Viskin D
    Myocarditis following mRNA Covid-19 vaccination: A pooled analysis.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00140.
    PubMed     Abstract available


  370. SPRENGHOLZ P, Korn L, Eitze S, Felgendreff L, et al
    Attitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00130.
    PubMed     Abstract available


  371. WONODI C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, et al
    Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00126.
    PubMed     Abstract available


  372. WALKER J, Paul P, Dooling K, Oliver S, et al
    Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00136.
    PubMed     Abstract available


  373. HU S, Logan N, Puenpa J, Wanlapakorn N, et al
    Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants.
    Vaccine. 2022 Feb 5. pii: S0264-410X(22)00095.
    PubMed     Abstract available


  374. AKGUN O, Kayaalp GK, Demirkan FG, Cakmak F, et al
    Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00117.
    PubMed     Abstract available


  375. NONVIGNON J, Owusu R, Asare B, Adjagba A, et al
    Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00070.
    PubMed     Abstract available


  376. OLIANI F, Savoia A, Gallo G, Tiwana N, et al
    Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00115.
    PubMed     Abstract available


  377. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00059.
    PubMed     Abstract available


  378. IRVING SA, Groom HC, Dandamudi P, Daley MF, et al
    A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00091.
    PubMed     Abstract available


  379. TAKESHITA K, Ishiwada N, Takeuchi N, Ohkusu M, et al
    Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00102.
    PubMed     Abstract available


  380. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00058.
    PubMed     Abstract available


  381. ELLITHORPE ME, Alade F, Adams RB, Nowak GJ, et al
    Looking ahead: Caregivers' COVID-19 vaccination intention for children 5 years old and younger using the health belief model.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00097.
    PubMed     Abstract available


  382. HEYERDAHL LW, Vray M, Lana B, Tvardik N, et al
    Conditionality of COVID-19 vaccine acceptance in European countries.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00099.
    PubMed     Abstract available


  383. SHAW J, Anderson KB, Fabi RE, Thompson CA, et al
    COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00100.
    PubMed     Abstract available


  384. YOUSAF M, Hassan Raza S, Mahmood N, Core R, et al
    Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00101.
    PubMed     Abstract available


    January 2022
  385. YANG YL, Kim J, Jeong Y, Jang YS, et al
    Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection.
    Vaccine. 2022;40:714-725.
    PubMed     Abstract available


  386. JANSSEN YF, Feitsma EA, Boersma HH, Alleva DG, et al
    Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00077.
    PubMed     Abstract available


  387. PANWAR K, Godi A, Cocuzza CE, Andrews N, et al
    Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix(R) or Gardasil(R) vaccine.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00075.
    PubMed     Abstract available


  388. SANDMANN FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, et al
    Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00039.
    PubMed     Abstract available


  389. PITTET LF, Cox L, Freyne B, Germano S, et al
    Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
    Vaccine. 2022 Jan 29. pii: S0264-410X(22)00020.
    PubMed     Abstract available


  390. MORGAN C, Giattas MR, Holroyd T, Pfitzer A, et al
    Integration of other services with human papillomavirus vaccination; lessons from earlier in the life course highlight the need for new policy and implementation evidence.
    Vaccine. 2022 Jan 29. pii: S0264-410X(21)01674.
    PubMed     Abstract available


  391. SHERIDAN S, McIntyre P, Liu B, Fathima P, et al
    Pertussis burden and acellular pertussis vaccine effectiveness in high risk children.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01322.
    PubMed     Abstract available


  392. MSUSA KP, Rogalski-Salter T, Mandi H, Clemens R, et al
    Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00072.
    PubMed     Abstract available


  393. KANTELE A, Rombo L, Vene S, Kundi M, et al
    Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50 years or older: A single-centre, open-label, randomized controlled trial.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00048.
    PubMed     Abstract available


  394. KALNIN KV, Plitnik T, Kishko M, Huang D, et al
    Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00045.
    PubMed     Abstract available


  395. WHITE AA, Neelon B, Martin RH, Cartmell KB, et al
    Spatial patterns of HPV and Tdap vaccine dose administration and the association of health department clinic access in Georgia counties.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01647.
    PubMed     Abstract available


  396. DING H, Huang J, Ngai CH, Sun Q, et al
    The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00057.
    PubMed     Abstract available


  397. STEPPERT P, Mosor M, Stanek L, Burgstaller D, et al
    A scalable, integrated downstream process for production of a recombinant measles virus-vectored vaccine.
    Vaccine. 2022 Jan 27. pii: S0264-410X(22)00019.
    PubMed     Abstract available


  398. HE Q, Xiao J, Liu M, Li Z, et al
    Immunogenicity of meningococcal polysaccharide conjugate vaccine as a replacement for meningococcal polysaccharide vaccine in children in Guangzhou, China.
    Vaccine. 2022 Jan 27. pii: S0264-410X(21)01200.
    PubMed     Abstract available


  399. JAFFE AE, Graupensperger S, Blayney JA, Duckworth JC, et al
    The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies.
    Vaccine. 2022 Jan 26. pii: S0264-410X(22)00073.
    PubMed     Abstract available


  400. KARAFILLAKIS E, Peretti-Watel P, Verger P, Chantler T, et al
    'I trust them because my mum trusts them': Exploring the role of trust in HPV vaccination decision-making among adolescent girls and their mothers in France.
    Vaccine. 2022 Jan 25. pii: S0264-410X(22)00046.
    PubMed     Abstract available


  401. IANNINO F, Uriza PJ, Duarte CM, Pepe MV, et al
    Development of a Salmonella-based oral vaccine to control intestinal colonization of Shiga-toxin-producing Escherichia coli (STEC) in animals.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00056.
    PubMed     Abstract available


  402. OGUTI B, Ali A, Andrews N, Barug D, et al
    The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.
    Vaccine. 2022;40:450-458.
    PubMed     Abstract available


  403. ZINTGRAFF J, Gagetti P, Napoli D, Sanchez Eluchans N, et al
    Invasive Streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006-2019. Temporal progression of serotypes distribution and antibiotic resistance.
    Vaccine. 2022;40:459-470.
    PubMed     Abstract available


  404. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Vaccine. 2022;40:536-543.
    PubMed     Abstract available


  405. KIMOTO T
    Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant.
    Vaccine. 2022;40:544-553.
    PubMed     Abstract available


  406. TANGUAY M, Boutin M, Laumaea A, Salaciak M, et al
    B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00071.
    PubMed     Abstract available


  407. TRICOU V, Gottardo R, Egan MA, Clement F, et al
    Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00040.
    PubMed     Abstract available


  408. HIDALGO-RUIZ M, Mejia-Lopez S, Perez-Serrano RM, Zaldivar-Lelo de Larrea G, et al
    Babesia bovis AMA-1, MSA-2c and RAP-1 contain conserved B and T-cell epitopes, which generate neutralizing antibodies and a long-lasting Th1 immune response in vaccinated cattle.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00049.
    PubMed     Abstract available


  409. GHASWALLA PK, Bengtson LGS, Marshall GS, Buikema AR, et al
    Corrigendum to 'Meningococcal vaccination in patients with newly diagnosed asplenia in the United States' [Vaccine 39 (2021) 272-281].
    Vaccine. 2022 Jan 22. pii: S0264-410X(21)00994.
    PubMed    


  410. TRENT MJ, Salmon DA, MacIntyre CR
    Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00026.
    PubMed     Abstract available


  411. STEBBINGS R, Armour G, Pettis V, Goodman J, et al
    AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice.
    Vaccine. 2022;40:192-195.
    PubMed     Abstract available


  412. DRAZAN D, Czajka H, Maguire JD, Pregaldien JL, et al
    A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Vaccine. 2022;40:351-358.
    PubMed     Abstract available


  413. RUSTANDI RR, Xu Q
    Reactivity characterization of bromoacetyl derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB(R) by NMR spectroscopy.
    Vaccine. 2022;40:187-191.
    PubMed     Abstract available


  414. TUN ZM, Ring Z, Tam CC
    Factors associated with maternal tetanus vaccination in Myanmar: An analysis of demographic and health survey data.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00042.
    PubMed     Abstract available


  415. LIU F, Feng C, Xu S, Wu Q, et al
    An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00054.
    PubMed     Abstract available


  416. LIAO Q, Cowling BJ, Xiao J, Yuan J, et al
    Priming with social benefit information of vaccination to increase acceptance of COVID-19 vaccines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00055.
    PubMed     Abstract available


  417. LI LL, Zheng C, La J, Do NV, et al
    Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00051.
    PubMed     Abstract available


  418. PITCOVSKI J, Gruzdev N, Abzach A, Katz C, et al
    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00050.
    PubMed     Abstract available


  419. ZHU D, Lv M, Bai Y, Wu J, et al
    Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00024.
    PubMed     Abstract available


  420. PASSARETTI CL, Priem JS, Agner TG, McCurdy L, et al
    Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00044.
    PubMed     Abstract available


  421. TUSE D, Malm M, Tamminen K, Diessner A, et al
    Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants.
    Vaccine. 2022 Jan 18. pii: S0264-410X(22)00022.
    PubMed     Abstract available


  422. ROLFES L, Harmark L, Kant A, van Balveren L, et al
    COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00028.
    PubMed     Abstract available


  423. OHFUJI S, Tanaka T, Nakano T, Kase T, et al
    Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00023.
    PubMed     Abstract available


  424. BEDSTON S, Akbari A, Jarvis CI, Lowthian E, et al
    COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
    Vaccine. 2022 Jan 15. pii: S0264-410X(21)01535.
    PubMed     Abstract available


  425. TANAKA M, Okubo R, Hoshi SL, Ishikawa N, et al
    Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Vaccine. 2022 Jan 13. pii: S0264-410X(22)00003.
    PubMed     Abstract available


  426. SIMON JK, Staerke NB, Hemming-Harlo M, Layle S, et al
    Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged >/=50 years: A randomized phase 3 trial (PNEU-TRUE).
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01675.
    PubMed     Abstract available


  427. MALTER KB, Tugel ME, Gil-Rodriguez M, Guardia G, et al
    Variability in non-core vaccination rates of dogs and cats in veterinary clinics across the United States.
    Vaccine. 2022 Jan 13. pii: S0264-410X(22)00006.
    PubMed     Abstract available


  428. WARNER EL, Barbati JL, Duncan KL, Yan K, et al
    Vaccine misinformation types and properties in Russian troll tweets.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01648.
    PubMed     Abstract available


  429. MOYO P, Bosco E, Bardenheier BH, Rivera-Hernandez M, et al
    Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01688.
    PubMed     Abstract available


  430. WONG WHS, Leung D, Chua GT, Duque JSR, et al
    Adolescents' attitudes to the COVID-19 vaccination.
    Vaccine. 2022 Jan 12. pii: S0264-410X(22)00025.
    PubMed     Abstract available


  431. WOO EJ, Moro PL
    Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Vaccine. 2022 Jan 11. pii: S0264-410X(22)00001.
    PubMed     Abstract available


  432. SHIMIZU S, Tanaka R, Itoh E, Maekawa-Matsuura M, et al
    Performance and usability evaluation of novel intradermal injection device Immucise and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01669.
    PubMed     Abstract available


  433. BLYTH DM, Liang Z, Williams M, Murray CK, et al
    Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01637.
    PubMed     Abstract available


  434. DANIEL CL, Williams J, Legg R, McGowen C, et al
    Factors associated with COVID-19 vaccination intentions among adults in the deep South.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01667.
    PubMed     Abstract available


  435. PENG KW, Carey T, Lech P, Vandergaast R, et al
    Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01671.
    PubMed     Abstract available


  436. OMER I, Rosenberg A, Sefty H, Pando R, et al
    Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Vaccine. 2022 Jan 8. pii: S0264-410X(21)01664.
    PubMed     Abstract available


  437. VADLAMUDI NK, Patrick DM, Rose C, Sadatsafavi M, et al
    A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01673.
    PubMed     Abstract available


  438. FOO D, Sarna M, Pereira G, Moore HC, et al
    Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhood.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01556.
    PubMed     Abstract available


  439. UWAMINO Y, Kurafuji T, Sato Y, Tomita Y, et al
    Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and universit
    Vaccine. 2022 Jan 7. pii: S0264-410X(22)00002.
    PubMed     Abstract available


  440. HSIAO A, Hansen J, Nunley KV, Lewis N, et al
    Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
    Vaccine. 2022 Jan 6. pii: S0264-410X(21)01641.
    PubMed     Abstract available


  441. EUSER S, Kroese FM, Derks M, de Bruin M, et al
    Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands.
    Vaccine. 2022 Jan 5. pii: S0264-410X(21)01670.
    PubMed     Abstract available


  442. HUANG Z, Ji M, Ren J, Sun X, et al
    Effect of the framing of HPV vaccination on parents' willingness to accept an HPV vaccine.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01659.
    PubMed     Abstract available


  443. GLADSTONE RA, Siira L, Brynildsrud OB, Vestrheim DF, et al
    International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01377.
    PubMed     Abstract available


  444. LEDLIE S, Ricci C, Pan C, Rojas A, et al
    Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01655.
    PubMed     Abstract available


  445. VILLENA R, Valenzuela MT, Bastias M, Santolaya ME, et al
    Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01549.
    PubMed     Abstract available


  446. PENLINGTON M, Goulet P, Metcalfe B
    Improving knowledge and trust in vaccines: A survey-based assessment of the potential of the European Union Clinical Trial Regulation No 536/2014 plain language summary to increase health literacy.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01653.
    PubMed     Abstract available


  447. ZHANG J, Ji Y, Wang Z, Jia Y, et al
    Effective improvements to the live-attenuated Newcastle disease virus vaccine by polyethylenimine-based biomimetic silicification.
    Vaccine. 2022 Jan 3. pii: S0264-410X(21)01662.
    PubMed     Abstract available


  448. KUZNETSOVA A, Ceregido MA, Jourquin A, Campora L, et al
    Fourteen years of the Pregnancy Registry on maternal immunisation with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine.
    Vaccine. 2022 Jan 3. pii: S0264-410X(21)01658.
    PubMed     Abstract available


  449. OHM M, Knol MJ, Vos ERA, Bogaard MJM, et al
    Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020.
    Vaccine. 2022;40:59-66.
    PubMed     Abstract available


  450. KUJAWSKI SA, Yao L, Wang HE, Carias C, et al
    Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis.
    Vaccine. 2022 Jan 1. pii: S0264-410X(21)01672.
    PubMed     Abstract available


    December 2021
  451. PASCHALL AV, Ozdilek A, Briner SL, Brindley MA, et al
    Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01666.
    PubMed     Abstract available


  452. GROOM HC, Crane B, Naleway AL, Weintraub E, et al
    Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01656.
    PubMed     Abstract available


  453. LUBLIN A, Katz C, Gruzdev N, Yadid I, et al
    Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins.
    Vaccine. 2021 Dec 30. pii: S0264-410X(21)01661.
    PubMed     Abstract available


  454. SAELAND E, van der Fits L, Bolder R, Heemskerk-van der Meer M, et al
    Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01651.
    PubMed     Abstract available


  455. FAINGELERNT Y, Dagan R, Givon-Lavi N, van der Beek BA, et al
    The impact of the pneumococcal conjugate vaccines on the incidence of community-acquired alveolar pneumonia in premature compared with in term-born infants.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01636.
    PubMed     Abstract available


  456. ASOGWA OA, de Hoog MLA, Bruijning-Verhagen PCJI
    Impact of 7-valent versus 10-valent pneumococcal conjugate vaccines on primary care consultations across various age groups in the Netherlands, 5 years after the switch: A time-series analysis.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01533.
    PubMed     Abstract available


  457. REIS LR, Costa-Rocha IAD, Campi-Azevedo AC, Peruhype-Magalhaes V, et al
    Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01638.
    PubMed     Abstract available


  458. KUSI KA, Ofori EA, Akyea-Mensah K, Kyei-Baafour E, et al
    Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01650.
    PubMed     Abstract available


  459. CHOWDHURY F, Akter A, Bhuiyan TR, Tauheed I, et al
    A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01623.
    PubMed     Abstract available


  460. SHUKLA S, Fressin F, Un M, Coetzer H, et al
    Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01657.
    PubMed     Abstract available


  461. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    PubMed     Abstract available


  462. DE KOFF EM, van Houten MA, de Heij F, Berbers GAM, et al
    Salivary antibody responses to ten-valent pneumococcal conjugate vaccination following two different immunization schedules in a healthy birth cohort.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01622.
    PubMed     Abstract available


  463. FREEMAN RE, Thaker J, Daley MF, Glanz JM, et al
    Vaccine timeliness and prevalence of undervaccination patterns in children ages 0-19 months, U.S., National immunization Survey-Child 2017.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01645.
    PubMed     Abstract available


  464. JUNE CHOE Y, Yi S, Hwang I, Kim J, et al
    Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01654.
    PubMed     Abstract available


  465. THOMAS SJ, Perez JL, Lockhart SP, Hariharan S, et al
    Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01652.
    PubMed     Abstract available


  466. LACY J, Tessier E, Andrews N, White J, et al
    Impact of an accelerated measles-mumps-rubella (MMR) vaccine schedule on vaccine coverage: An ecological study among London children, 2012-2018.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01619.
    PubMed     Abstract available


  467. BRENNAN T, Hidle A, Doshi RH, An Q, et al
    Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01531.
    PubMed     Abstract available


  468. RAHIM S, Ahmad Z, Abdul-Ghafar J
    The polio vaccination story of Pakistan.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01595.
    PubMed     Abstract available


  469. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01544.
    PubMed     Abstract available


  470. KIM HJ, Yun HJ, Kim J, Kym S, et al
    Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01620.
    PubMed     Abstract available


  471. ROMAIN-SCELLE N, Elias C, Vanhems P
    COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhone-Alpes region (France): An ecological study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01644.
    PubMed     Abstract available


  472. MANOMAIPIBOON A, Phumisantiphong U, Maneerit J, Chalearmchai Y, et al
    Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01632.
    PubMed     Abstract available


  473. KENNEDY RB, Ovsyannikova IG, Haralambieva IH, Grill DE, et al
    Proteomic assessment of humoral immune responses in smallpox vaccine recipients.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01642.
    PubMed     Abstract available


  474. PORTH JM, Wagner AL, Treleaven E, Fleischer NL, et al
    Childhood vaccination timeliness following maternal migration to an informal urban settlement in Kenya.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01625.
    PubMed     Abstract available


  475. TADAKUMA K, Maruyama T, Mori K, Fujiki N, et al
    Effectiveness of seasonal influenza vaccine in adult Japanese workers, 2017-2020.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01624.
    PubMed     Abstract available


  476. ERBER W, Khan F, Zavadska D, Freimane Z, et al
    Effectiveness of TBE vaccination in southern Germany and Latvia.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01639.
    PubMed     Abstract available


  477. PETERSEN MB, Jorgensen F, Lindholt MF
    Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01631.
    PubMed     Abstract available


  478. WILLIAMS KV, Zhai B, Alcorn JF, Patricia Nowalk M, et al
    A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01643.
    PubMed     Abstract available


  479. SHAPIRO GK, Gottfredson N, Leask J, Wiley K, et al
    COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01649.
    PubMed     Abstract available


  480. BLANCO S, Salome Konigheim B, Diaz A, Spinsanti L, et al
    Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Vaccine. 2021 Dec 20. pii: S0264-410X(21)01634.
    PubMed     Abstract available


  481. NASREEN S, Wang J, Kwong JC, Crowcroft NS, et al
    Population-based incidence of invasive pneumococcal disease in children and adults in Ontario and British Columbia, 2002-2018: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2021;39:7545-7553.
    PubMed     Abstract available


  482. IVANOVA-MARKOVA Y, Gonzalez-Dominguez A, Hidalgo A, Sanchez R, et al
    Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
    Vaccine. 2021;39:7646-7654.
    PubMed     Abstract available


  483. RANADE D, Jena R, Sancheti S, Deore V, et al
    Rapid, high throughput protein estimation method for saponin and alhydrogel adjuvanted R21 VLP Malaria vaccine based on intrinsic fluorescence.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01627.
    PubMed     Abstract available


  484. HERRING WL, Zhang Y, Shinde V, Stoddard J, et al
    Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01609.
    PubMed     Abstract available


  485. POUKKA E, Baum U, Palmu AA, Lehtonen TO, et al
    Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01640.
    PubMed     Abstract available


  486. WIDGREN K, Tomba GS, Leung KY, Giesecke J, et al
    Modelling varicella vaccination - What does a lack of surge in herpes zoster incidence tell us about exogenous boosting?
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01537.
    PubMed     Abstract available


  487. CHUNG NH, Chen YC, Yang SJ, Lin YC, et al
    Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein.
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01635.
    PubMed     Abstract available


  488. CARLSON SJ, McKenzie L, Roberts L, Blyth CC, et al
    Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
    Vaccine. 2021 Dec 16. pii: S0264-410X(21)01629.
    PubMed     Abstract available


  489. GOLDBLATT D, Fiore-Gartland A, Johnson M, Hunt A, et al
    Towards a population-based threshold of protection for COVID-19 vaccines.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01615.
    PubMed     Abstract available


  490. YU Y, Jia W, Lau MMC, Lau JTF, et al
    Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01628.
    PubMed     Abstract available


  491. CHEN X, Wang H
    On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine.
    Vaccine. 2021 Dec 14. pii: S0264-410X(21)01596.
    PubMed     Abstract available


  492. ALMOHAYA AM, Alsubie H, Alqarni B, Alzayad B, et al
    Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01610.
    PubMed     Abstract available


  493. KURANI S, MacLaughlin KL, Jacobson RM, St Sauver JL, et al
    Socioeconomic disadvantage and human papillomavirus (HPV) vaccination uptake.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01611.
    PubMed     Abstract available


  494. BOTTON J, Dray-Spira R, Baricault B, Drouin J, et al
    Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01617.
    PubMed     Abstract available


  495. COSSU D, Ruberto S, Yokoyama K, Hattori N, et al
    Efficacy of BCG vaccine in animal models of neurological disorders.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01613.
    PubMed     Abstract available


  496. LUTRICK K, Groom H, Fowlkes AL, Groover KD, et al
    COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01593.
    PubMed     Abstract available


  497. HSIEH YL, Rak S, SteelFisher GK, Bauhoff S, et al
    Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01559.
    PubMed     Abstract available


  498. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01621.
    PubMed     Abstract available


  499. ZHAO AR, Bishai DM
    Public health spending, primary care, and perceived risk promoted vaccination against H1N1.
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01538.
    PubMed     Abstract available


  500. KATZ MA, Harlev EB, Chazan B, Chowers M, et al
    Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01580.
    PubMed     Abstract available


  501. AVILA-AGUERO ML, Camacho-Badilla K, Ulloa-Gutierrez R, Espinal-Tejada C, et al
    Epidemiology of pertussis in Costa Rica and the impact of vaccination: A 58-year experience (1961-2018).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01552.
    PubMed     Abstract available


  502. KADKHODA K
    Post RNA-based COVID vaccines myocarditis: Proposed mechanisms.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01594.
    PubMed    


  503. ZHAO H, Li Y, Wang Z
    Adverse event of Sinovac Coronavirus vaccine: Deafness.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01576.
    PubMed     Abstract available


  504. HOOK SA, Hansen AP, Niesobecki SA, Meek JI, et al
    Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States.
    Vaccine. 2021 Dec 8. pii: S0264-410X(21)01540.
    PubMed     Abstract available


  505. PEPIN J, Labbe AC, Carignan A, Parent ME, et al
    Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
    Vaccine. 2021;39:7300-7307.
    PubMed     Abstract available


  506. VON REYN CF
    BCG versus rBCG: What is the way forward?
    Vaccine. 2021;39:7319-7320.
    PubMed    


  507. VAN HOOIJ A, van den Eeden SJF, Khatun M, Soren S, et al
    BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease.
    Vaccine. 2021;39:7230-7237.
    PubMed     Abstract available


  508. HEIJMENBERG I, Husain A, Sathkumara HD, Muruganandah V, et al
    ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence.
    Vaccine. 2021;39:7265-7276.
    PubMed     Abstract available


  509. KOWALEWICZ-KULBAT M, Locht C
    BCG for the prevention and treatment of allergic asthma.
    Vaccine. 2021;39:7341-7352.
    PubMed     Abstract available


  510. LENNON RP, Block R Jr, Schneider EC, Zephrin L, et al
    Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01597.
    PubMed     Abstract available


  511. MA J, Casadei E, Bruce TJ, Sepahi A, et al
    Long-term efficacy of nasal vaccination against enteric red mouth (ERM) disease and infectious hematopoietic necrosis (IHN) in juvenile rainbow trout (Oncorhynchus mykiss).
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01551.
    PubMed     Abstract available


  512. MARGOLIS MA, Brewer NT, Boynton MH, Lafata JE, et al
    Provider response and follow-up to parental declination of HPV vaccination.
    Vaccine. 2021 Dec 6. pii: S0264-410X(21)01529.
    PubMed     Abstract available


  513. PEREZ-VILAR S, Dores GM, Marquez PL, Ng CS, et al
    Safety surveillance of meningococcal group B vaccine (Bexsero(R)), Vaccine Adverse Event Reporting System, 2015-2018.
    Vaccine. 2021 Dec 6. pii: S0264-410X(21)01545.
    PubMed     Abstract available


  514. SULIS G, Basta NE, Wolfson C, Kirkland SA, et al
    Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01579.
    PubMed     Abstract available


  515. RAW RK, Rees J, Kelly CA, Wroe C, et al
    Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01577.
    PubMed     Abstract available


  516. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01553.
    PubMed     Abstract available


  517. FACK C, Wood R, Hatherill M, Cobelens F, et al
    The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01488.
    PubMed     Abstract available


  518. NGUYEN AT, Arnold BF, Kennedy CJ, Mishra K, et al
    Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01547.
    PubMed     Abstract available


  519. IZAK M, Stoyanov E, Dezuraev K, Shinar E, et al
    Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01557.
    PubMed     Abstract available


  520. HERZBERG J, Vollmer T, Fischer B, Becher H, et al
    SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01555.
    PubMed     Abstract available


  521. YORSAENG R, Suntronwong N, Phowatthanasathian H, Assawakosri S, et al
    Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01560.
    PubMed     Abstract available


  522. HELLE F, Moyet J, Demey B, Francois C, et al
    Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01558.
    PubMed     Abstract available


  523. LI S, Chen W, Shen Y, Xia J, et al
    Molecular characterization of infectious bronchitis virus in Southwestern China for the protective efficacy evaluation of four live vaccine strains.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01546.
    PubMed     Abstract available


  524. DUONG CH, Mueller JE, Tubert-Bitter P, Escolano S, et al
    Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01502.
    PubMed     Abstract available


  525. WANG CH, Kung WJ, Lee CH, Lee CF, et al
    High rates of colonization and antimicrobial resistance of group B streptococcus highlight the need for vaccination even after implementation of guidelines for intrapartum antibiotic prophylaxis.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01543.
    PubMed     Abstract available


  526. MUNOZ-QUILES C, Lopez-Lacort M, Diez-Domingo J, Rodrigo-Casares V, et al
    Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01536.
    PubMed     Abstract available


  527. NEWALL AT, Beutels P, Tuffaha HW, Hall PS, et al
    How can early stage economic evaluation help guide research for future vaccines?
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01462.
    PubMed    


  528. PRICE J, Mooney J, Bain C, Bawa JT, et al
    National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01443.
    PubMed     Abstract available


  529. VALCKX S, Crevecoeur J, Verelst F, Vranckx M, et al
    Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01414.
    PubMed     Abstract available


  530. EZE P, Aniebo CL, Agu UJ, Agu SA, et al
    Validity of maternal recall for estimating childhood vaccination coverage - Evidence from Nigeria.
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01534.
    PubMed     Abstract available


  531. WIRTZ C, Mohamed Y, Engel D, Sidibe A, et al
    Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01447.
    PubMed     Abstract available


    November 2021
  532. ATTWELL K, Rizzi M, McKenzie L, Carlson SJ, et al
    COVID-19 vaccine Mandates: An Australian attitudinal study.
    Vaccine. 2021 Nov 30. pii: S0264-410X(21)01530.
    PubMed     Abstract available


  533. SUGISHITA Y, Sugawara T
    Effectiveness and cost-effectiveness of influenza vaccination for elderly people.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01257.
    PubMed     Abstract available


  534. PORRAS C, Sampson JN, Herrero R, Gail MH, et al
    Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01486.
    PubMed     Abstract available


  535. ZOU X, He J, Zheng J, Liang M, et al
    Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01532.
    PubMed     Abstract available


  536. LAURENZ M, von Eiff C, Borchert K, Jacob C, et al
    Vaccination rates and adherence in premature infants before and after pneumococcal conjugate vaccine schedule change for term infants - A claims database analysis in Germany.
    Vaccine. 2021 Nov 28. pii: S0264-410X(21)01437.
    PubMed     Abstract available


  537. LI H, Monslow MA, Freed DC, Chang D, et al
    Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates.
    Vaccine. 2021 Nov 28. pii: S0264-410X(21)01416.
    PubMed     Abstract available


  538. MALTEZOU HC, Anastassopoulou C, Hatziantoniou S, Poland GA, et al
    Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01539.
    PubMed     Abstract available


  539. CASTRO F, Pascale JM, Slocum Hewitt I, Calvo A, et al
    Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01504.
    PubMed    


  540. SCHMITZ M, Luminet O, Klein O, Morbee S, et al
    Predicting vaccine uptake during COVID-19 crisis: A motivational approach.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01542.
    PubMed     Abstract available


  541. JIN P, Sun F, Liu Q, Wang Q, et al
    An oral vaccine based on chitosan/aluminum adjuvant induces both local and systemic immune responses in turbot (Scophthalmus maximus).
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01396.
    PubMed     Abstract available


  542. GULPINAR G, Uzun MB
    Examining community pharmacists' intention to provide pharmacist-driven vaccination services: A structural equation modelling.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01499.
    PubMed     Abstract available


  543. ROBERTSON JS, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, et al
    International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01528.
    PubMed     Abstract available


  544. ENGEL D, Afeli ADJ, Morgan C, Zeck W, et al
    Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01466.
    PubMed     Abstract available


  545. AHMED S, Dorin F, Satter SM, Sarker AR, et al
    The economic burden of rotavirus hospitalization among children < 5 years of age in selected hospitals in Bangladesh.
    Vaccine. 2021;39:7082-7090.
    PubMed     Abstract available


  546. CANNON K, Elder C, Young M, Scott DA, et al
    A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults >/=65 years of age with different prior pneumococcal vaccination.
    Vaccine. 2021 Nov 25. pii: S0264-410X(21)01352.
    PubMed     Abstract available


  547. KLEINWAKS G, Schmit V, Morrison J
    Considering human challenge trials for tuberculosis vaccine development.
    Vaccine. 2021 Nov 25. pii: S0264-410X(21)01469.
    PubMed     Abstract available


  548. URUENA A, Badano MN, Bare P, Gonzalez J, et al
    Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children.
    Vaccine. 2021 Nov 24. pii: S0264-410X(21)01482.
    PubMed     Abstract available


  549. BUCHMAN TG, Simpson SQ, Sciarretta KL, Finne KP, et al
    Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries().
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01461.
    PubMed     Abstract available


  550. BETTENCOURT PJG, Joosten SA, Lindestam Arlehamn CS, Behr MA, et al
    100 years of the Bacillus Calmette-Guerin vaccine.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01483.
    PubMed    


  551. SUN P, Jani V, Johnson A, Cheng Y, et al
    T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01325.
    PubMed     Abstract available


  552. DINC HO, Saltoglu N, Can G, Balkan II, et al
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01507.
    PubMed     Abstract available


  553. LENTZEN MP, Huebenthal V, Kaiser R, Kreppel M, et al
    A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01526.
    PubMed     Abstract available


  554. AREGA SM, Knobel DL, Toka FN, Conan A, et al
    Non-specific effects of veterinary vaccines: a systematic review.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01479.
    PubMed     Abstract available


  555. HARA M, Koshida R, Nakano T
    Parents' views on mumps, mumps vaccine, and the factors associated with vaccination in Japan.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01449.
    PubMed     Abstract available


  556. YE K, Shi D, Zhang Z, Bian L, et al
    A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01393.
    PubMed     Abstract available


  557. LIN C, Tu P, Terry TC
    Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01444.
    PubMed     Abstract available


  558. CHEN T, Dai M, Xia S
    Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01484.
    PubMed     Abstract available


  559. CAMBON L, Schwarzinger M, Alla F
    Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01467.
    PubMed     Abstract available


  560. MUSCATELLO DJ, Nazareno AL, Turner RM, Newall AT, et al
    Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01464.
    PubMed     Abstract available


  561. BELLIZZI S, Aidyralieva C, Al-Shaikh A, Muthu N, et al
    Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01468.
    PubMed    


  562. ORTEGA-SANCHEZ IR, Mott JA, Kittikraisak W, Khanthamaly V, et al
    Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01445.
    PubMed     Abstract available


  563. IRVING SA, Ball SW, Booth SM, Regan AK, et al
    A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01463.
    PubMed     Abstract available


  564. HAFNER-GIESSAUF H, Horn S, Schwantzer G, Sprenger-Mahr H, et al
    Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01474.
    PubMed     Abstract available


  565. BLAIN AE, Reese HE, Marjuki H, Topaz N, et al
    Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01480.
    PubMed     Abstract available


  566. WANG W, Wang Y, Wang Y, Yan F, et al
    Vaccine bidding, procurement and distribution management practices in mainland China: A nationwide study.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01465.
    PubMed     Abstract available


  567. NGUYEN KH, Anneser E, Toppo A, Allen JD, et al
    Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults >/= 18 years, United States.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01485.
    PubMed     Abstract available


  568. KITRO A, Sirikul W, Piankusol C, Rirermsoonthorn P, et al
    Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand.
    Vaccine. 2021 Nov 17. pii: S0264-410X(21)01476.
    PubMed     Abstract available


  569. JEAN BAPTISTE AE, Bawa S, Oteri AJ, Dieng B, et al
    Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria.
    Vaccine. 2021;39 Suppl 3:C1-C2.
    PubMed    


  570. KORAVE J, Bawa S, Ageda B, Ucho A, et al
    Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State.
    Vaccine. 2021;39 Suppl 3:C76-C81.
    PubMed     Abstract available


  571. HOFF NA, Bratcher A, Mukadi P, Ahuka S, et al
    Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01404.
    PubMed     Abstract available


  572. VOSS G, Jacquet JM, Tornieporth N, Kampmann B, et al
    Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01382.
    PubMed     Abstract available


  573. VOHRA P, Chintoan-Uta C, Bremner A, Mauri M, et al
    Evaluation of a Campylobacter jejuni N-glycan-ExoA glycoconjugate vaccine to reduce C. jejuni colonisation in chickens.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01434.
    PubMed     Abstract available


  574. LIANG Q, Li H, Chang X, Zhang H, et al
    A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.
    Vaccine. 2021;39:6947-6955.
    PubMed     Abstract available


  575. BRAKEL KA, Binjawadagi B, French-Kim K, Watts M, et al
    Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Vaccine. 2021;39:6817-6828.
    PubMed     Abstract available


  576. BOBO FT, Asante A, Woldie M, Dawson A, et al
    Child vaccination in sub-Saharan Africa: Increasing coverage addresses inequalities.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01439.
    PubMed     Abstract available


  577. ESPARZA J, Damaso CR
    Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01441.
    PubMed    


  578. AMEND KL, Turnbull B, Zhou L, Marks MA, et al
    Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01403.
    PubMed     Abstract available


  579. SILAS J, Jones A, Weiss-Cohen L, Ayton P, et al
    The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01472.
    PubMed     Abstract available


  580. MURPHY RP, Taaffe C, Ahern E, McMahon G, et al
    A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01470.
    PubMed     Abstract available


  581. ROGERS JH, Cox SN, Hughes JP, Link AC, et al
    Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01471.
    PubMed     Abstract available


  582. CHOKEPHAIBULKIT K, Puthanakit T, Bhat N, Mansouri S, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
    Vaccine. 2021 Nov 14. pii: S0264-410X(21)01425.
    PubMed     Abstract available


  583. BURKE RM, Shih S, Hsiung CA, Yen C, et al
    Impact of rotavirus vaccination on rotavirus hospitalizations in Taiwanese children.
    Vaccine. 2021 Nov 14. pii: S0264-410X(21)01397.
    PubMed     Abstract available


  584. REESE HE, McNamara LA, Vianzon V, Blain A, et al
    Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01438.
    PubMed     Abstract available


  585. ROSENTHAL S, Cummings CL
    Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01448.
    PubMed     Abstract available


  586. HARMON SHE, Faour DE, MacDonald NE
    Mandatory immunization and vaccine injury support programs: A survey of 28 GNN countries.
    Vaccine. 2021 Nov 12. pii: S0264-410X(21)01390.
    PubMed     Abstract available


  587. CHHABRIA S, Stanford FC
    A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01442.
    PubMed    


  588. VIZCARRA P, Haemmerle J, Velasco H, Velasco T, et al
    BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01417.
    PubMed     Abstract available


  589. AW R, Ashik MR, Islam AAZM, Khan I, et al
    Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01432.
    PubMed     Abstract available


  590. COLOMBATTI OLIVIERI MA, Moyano RD, Mon ML, Gravisaco MJ, et al
    Evaluation of a virulent strain of Mycobacterium avium subsp. Paratuberculosis used as a heat-killed vaccine.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01433.
    PubMed     Abstract available


  591. MCLEAN HQ, Levine MZ, King JP, Flannery B, et al
    Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01415.
    PubMed     Abstract available


  592. BABUADZE GG, Echanove J, Lamarre C, deLaVega MA, et al
    A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01315.
    PubMed     Abstract available


  593. RODRIGUES CMC, Plotkin SA
    The influence of interval between doses on response to vaccines.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01381.
    PubMed    


  594. RADWAN NF, Abu-Sheasha GA, Bedwani RN, Yassine OG, et al
    Vaccine wastage and cost saving after multi-dose vial policy implementation in Egypt: A success story.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01400.
    PubMed     Abstract available


  595. SHAH SFA, Ginossar T, Bentley JM, Zimet G, et al
    Using the Theory of Planned behavior to identify correlates of HPV vaccination uptake among college students attending a rural university in Alabama.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01431.
    PubMed     Abstract available


  596. SVENNERHOLM AM, Qadri F, Lundgren A, Kaim J, et al
    Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01389.
    PubMed     Abstract available


  597. THULUVA S, Matur R, Tsa K, Gv SR, et al
    A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV(TM)) in 1-15 years-old healthy hepatitis A vaccine-naive children.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01326.
    PubMed     Abstract available


  598. HOSANGADI D, Martin EK, Watson M, Bruns R, et al
    Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01398.
    PubMed    


  599. MCKINNON B, Quach C, Dube E, Tuong Nguyen C, et al
    Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01426.
    PubMed     Abstract available


  600. WU K, Choi A, Koch M, Elbashir S, et al
    Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01435.
    PubMed     Abstract available


  601. VILLANUEVA-UY MET, Lam HY, Aldaba JG, Uy TMZ, et al
    Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01290.
    PubMed     Abstract available


  602. CUEVAS-JUAREZ E, Pando-Robles V, Palomares LA
    Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01383.
    PubMed     Abstract available


  603. SHARUN K, Tiwari R, Saied AA, Dhama K, et al
    SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01386.
    PubMed     Abstract available


  604. GOODE JR, Cook P, Cuttino S, Gatewood SBS, et al
    Early experience with COVID-19 vaccine in a Federally-Qualified Healthcare Center for the homeless.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01388.
    PubMed    


  605. DE HAAS TDJ, Yeung KHT, Hutubessy R, van der Putten IM, et al
    Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong.
    Vaccine. 2021;39:6762-6780.
    PubMed     Abstract available


  606. LAU CL, Mayfield HJ, Sinclair JE, Brown SJ, et al
    Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
    Vaccine. 2021 Nov 4. pii: S0264-410X(21)01428.
    PubMed     Abstract available


  607. SANZ-ROJO S, Jimenez-Garcia R, Lopez-de-Andres A, de Miguel-Diez J, et al
    Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01392.
    PubMed     Abstract available


  608. VASUDEVAN L, Ostermann J, Wang Y, Harrison SE, et al
    Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01356.
    PubMed     Abstract available


  609. RIBERA-CANO A, Dupont M, Houze-Cerfon CH, Houze-Cerfon V, et al
    Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01429.
    PubMed     Abstract available


  610. MIYA TV, Groome MJ, de Assis Rosa D
    TLR genetic variation is associated with Rotavirus-specific IgA seroconversion in South African Black infants after two doses of Rotarix vaccine.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01384.
    PubMed     Abstract available


  611. PIERRON A, Bozon F, Berceanu A, Fontan J, et al
    Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01369.
    PubMed     Abstract available


  612. MALTEZOU HC
    Vaccination of healthcare personnel in the COVID-19 era: A call for actions.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01427.
    PubMed    


  613. CASSONE A, Cauda R
    Multicomponent vaccines to fight SARS-CoV-2 variants of concern.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01402.
    PubMed    


  614. WAGNER A, Jasinska J, Tomosel E, Zielinski CC, et al
    Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01401.
    PubMed     Abstract available


    October 2021
  615. LIU H, Zhou C, An J, Song Y, et al
    Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01399.
    PubMed     Abstract available


  616. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    PubMed     Abstract available


  617. KHOURY J, Najjar-Debbiny R, Hanna A, Jabbour A, et al
    COVID-19 vaccine - Long term immune decline and breakthrough infections.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01370.
    PubMed     Abstract available


  618. GORDON SF, Clothier HJ, Morgan H, Buttery JP, et al
    Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01350.
    PubMed     Abstract available


  619. GARCIA-GRIMSHAW M, Ceballos-Liceaga SE, Michel-Chavez A, Garcia-Alanis M, et al
    Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01391.
    PubMed     Abstract available


  620. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.
    PubMed    


  621. MARTIN S, Vanderslott S
    "Any idea how fast 'It's just a mask!' can turn into 'It's just a vaccine!'": From mask mandates to vaccine mandates during the COVID-19 pandemic.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01351.
    PubMed     Abstract available


  622. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    PubMed     Abstract available


  623. JEON S, Kelly M, Yun J, Lee B, et al
    Scalable production and immunogenicity of a cholera conjugate vaccine.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01312.
    PubMed     Abstract available


  624. CAPPOZZO F, Dal Zotto A, Scollo M, Bernardini D, et al
    dTap vaccination uptake during pregnancy: Pregnant women-focused and health professionals-focused predictors in the Veneto Region (Italy).
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01321.
    PubMed     Abstract available


  625. HUANG J, Bai Y, Ding H, Wang B, et al
    Acceptance of pneumococcal vaccination in older adults: A general population-based survey.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01344.
    PubMed     Abstract available


  626. CHANTHAVANICH P, Versage E, Van Twuijver E, Hohenboken M, et al
    Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01317.
    PubMed     Abstract available


  627. OLANIPEKUN T, Abe T, Effoe V, Westney G, et al
    Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01324.
    PubMed     Abstract available


  628. OPRIESSNIG T, Rawal G, McKeen L, Filippsen Favaro P, et al
    Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination.
    Vaccine. 2021 Oct 24. pii: S0264-410X(21)01353.
    PubMed     Abstract available


  629. LOEB M, Russell ML, Kelly-Stradiotto C, Fuller N, et al
    Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01355.
    PubMed     Abstract available


  630. MYAT TW, Thu HM, Tate JE, Burnett E, et al
    Rotavirus infection among children under five years of age hospitalized with acute gastroenteritis in Myanmar during 2018-2020 - Multicentre surveillance before rotavirus vaccine introduction.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01323.
    PubMed     Abstract available


  631. FAN X, Li X, Wan K, Zhao X, et al
    Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01354.
    PubMed     Abstract available


  632. SHACHOR-MEYOUHAS Y, Hussein K, Szwarcwort-Cohen M, Weissman A, et al
    Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01327.
    PubMed     Abstract available


  633. TRAN VN, Nguyen HA, Le TTA, Truong TT, et al
    Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Vaccine. 2021;39:6485-6491.
    PubMed     Abstract available


  634. ANDRADE G
    Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01371.
    PubMed     Abstract available


  635. SHUBITZ LF, Robb EJ, Powell DA, Bowen RA, et al
    Deltacps1 vaccine protects dogs against experimentally induced coccidioidomycosis.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01349.
    PubMed     Abstract available


  636. VAN BEEK LF, Langereis JD, van den Berg van Saparoea HB, Gillard J, et al
    Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01313.
    PubMed     Abstract available


  637. DAR SA, Kole S, Shin SM, Jeong HJ, et al
    Comparative study on antigen persistence and immunoprotective efficacy of intramuscular and intraperitoneal injections of squalene - aluminium hydroxide (Sq + Al) adjuvanted viral hemorrhagic septicaemia virus vaccine in olive flounder (Paralichthys o
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01345.
    PubMed     Abstract available


  638. ABU-RAYA B, Maertens K, Munoz FM, Zimmermann P, et al
    Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis.
    Vaccine. 2021;39:6545-6552.
    PubMed     Abstract available


  639. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    PubMed     Abstract available


  640. MAKOVITZKI A, Lerer E, Kafri Y, Adar Y, et al
    Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01376.
    PubMed     Abstract available


  641. WANG J, Wagner AL, Chen Y, Jaime E, et al
    Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01340.
    PubMed     Abstract available


  642. JAMES EK, Bokemper SE, Gerber AS, Omer SB, et al
    Persuasive messaging to increase COVID-19 vaccine uptake intentions.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01368.
    PubMed     Abstract available


  643. NETANEL C, Ben-Aharon O, Ben-Ari Z, Chodick G, et al
    Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016.
    Vaccine. 2021 Oct 20. pii: S0264-410X(21)01287.
    PubMed     Abstract available


  644. DANKWA EA, Donnelly CA, Brouwer AF, Zhao R, et al
    Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United states.
    Vaccine. 2021 Oct 19. pii: S0264-410X(21)01308.
    PubMed     Abstract available


  645. KIM D, Pekgun P, Yildirim I, Keskinocak P, et al
    Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01346.
    PubMed     Abstract available


  646. DANG TKNS, Rivero Cabrera R, Yeung KHT, van der Putten IM, et al
    Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months - 2 years and pregnant women.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01291.
    PubMed     Abstract available


  647. CHEN AT, Stacey HD, Marzok A, Singh P, et al
    Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01341.
    PubMed     Abstract available


  648. MAKI Y, Kashiwagi S, Kimizuka Y
    Laser vaccine adjuvants: Light-augmented immune responses.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01233.
    PubMed     Abstract available


  649. CHAPIN-BARDALES J, Myers T, Gee J, Shay DK, et al
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01339.
    PubMed     Abstract available


  650. ALI SAHRAIAN M, Ghadiri F, Azimi A, Naser Moghadasi A, et al
    Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Vaccine. 2021;39:6347-6350.
    PubMed     Abstract available


  651. AYAZ S, Dibben O, Chapman D
    Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness.
    Vaccine. 2021 Oct 15. pii: S0264-410X(21)01320.
    PubMed     Abstract available


  652. SILVER MC, Neumann PJ, Ma S, Kim DD, et al
    Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01285.
    PubMed     Abstract available


  653. MOGHNIEH R, Mekdashi R, El-Hassan S, Abdallah D, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01314.
    PubMed     Abstract available


  654. LALWANI SK, Ramanan PV, Sapru A, Sundaram B, et al
    Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01208.
    PubMed     Abstract available


  655. BUUS M, da Silva I, Nielsen S, Thysen SM, et al
    Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau.
    Vaccine. 2021 Oct 12. pii: S0264-410X(21)01150.
    PubMed     Abstract available


  656. PARK WJ, Yoon YK, Kim Y, Park JS, et al
    Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to DeltaVP8* protein from rotavirus.
    Vaccine. 2021 Oct 9. pii: S0264-410X(21)01282.
    PubMed     Abstract available


  657. MCNAY LA, Arnoczy G, Martell M, Mock P, et al
    Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies.
    Vaccine. 2021;39:6183-6185.
    PubMed     Abstract available


  658. HART P, Farrar J
    The influenza vaccines roadmap - A better future through improved influenza vaccines.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01286.
    PubMed    


  659. VERBERK JDM, van Dongen JAP, van de Kassteele J, Andrews NJ, et al
    Impact analysis of rotavirus vaccination in various geographic regions in Western Europe.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01262.
    PubMed     Abstract available


  660. BRYDEN GM, Rockloff M, Browne M, Unsworth C, et al
    Effect of contamination and purity priming on attitudes to vaccination and other health interventions: A randomised controlled experiment.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01278.
    PubMed     Abstract available


  661. VANDERMEULEN C, Leroux-Roels I, Vandeleur J, Staniscia T, et al
    A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01283.
    PubMed     Abstract available


  662. FU LY, Torres R, Caleb S, Cheng YI, et al
    Vaccination coverage among young homeless children compared to US national immunization survey data.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01288.
    PubMed     Abstract available


  663. MOTTELSON A, Vandeweerdt C, Atchapero M, Luong T, et al
    A self-administered virtual reality intervention increases COVID-19 vaccination intention.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01311.
    PubMed     Abstract available


  664. HUMBLE RM, Sell H, Dube E, MacDonald NE, et al
    Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01309.
    PubMed     Abstract available


  665. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    PubMed     Abstract available


  666. MULLER-PEBODY B, Sinnathamby MA, Warburton F, Rooney G, et al
    Impact of the childhood influenza vaccine programme on antibiotic prescribing rates in primary care in England.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01284.
    PubMed     Abstract available


  667. GIERSING B, Shah N, Kristensen D, Amorij JP, et al
    Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)00996.
    PubMed     Abstract available


  668. REIDENBERG BE, Hirsch K, Costello CM, Russo M, et al
    Drive through COVID19 vaccination for developmentally disabled persons.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01279.
    PubMed    


  669. MUKHERJEE N, Julian E, Torrelles JB, Svatek RS, et al
    Effects of Mycobacterium bovis Calmette et Guerin (BCG) in oncotherapy: Bladder cancer and beyond.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01256.
    PubMed     Abstract available


  670. ALLEVA DG, Delpero AR, Scully MM, Murikipudi S, et al
    Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01294.
    PubMed     Abstract available


  671. LAZAROS G, Anastassopoulou C, Hatziantoniou S, Kalos T, et al
    A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01295.
    PubMed     Abstract available


  672. DRAPER M, Stergiopoulos S
    Shingles vaccination uptake in Massachusetts adults aged 50 years and older.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01223.
    PubMed     Abstract available


  673. BRUCE YU Y, Taraban MB, Briggs KT
    All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01280.
    PubMed    


  674. VADREVU KM, Raju D, Rani S, Reddy S, et al
    Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV(R)) vaccine up to 7years following primary vaccination of children<2years of age with, or without, a booster vaccination.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)00966.
    PubMed     Abstract available


  675. CORCORAN KE, Scheitle CP, DiGregorio BD
    Christian nationalism and COVID-19 vaccine hesitancy and uptake.
    Vaccine. 2021 Oct 2. pii: S0264-410X(21)01289.
    PubMed     Abstract available


  676. SRICHAN P, Thohinung U, Kodyee S, Apidechkul T, et al
    Vaccine serocoverage under the expanded program on immunization among hill tribe children in Thailand: A cross-sectional study.
    Vaccine. 2021 Oct 1. pii: S0264-410X(21)01264.
    PubMed     Abstract available


    September 2021
  677. NIEUWENHUIZEN NE, Zyla J, Zedler U, Bandermann S, et al
    Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females.
    Vaccine. 2021 Sep 30. pii: S0264-410X(21)01230.
    PubMed     Abstract available


  678. LEWIS G, Lazzaro T, Crawford NW
    Recurrent lipoatrophy following multiple vaccinations: A case study.
    Vaccine. 2021 Sep 30. pii: S0264-410X(21)01237.
    PubMed    


  679. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    PubMed     Abstract available


  680. FRANCIS-OLIVIERO F, Bozoki S, Micsik A, Kieny MP, et al
    Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01224.
    PubMed     Abstract available


  681. YACOUB MR, Cucca V, Asperti C, Ramirez GA, et al
    Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01239.
    PubMed     Abstract available


  682. ROMANO CJ, Hall C, Khodr ZG, Bukowinski AT, et al
    History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01171.
    PubMed     Abstract available


  683. HOFMEISTER MG, Weng MK, Thoroughman D, Thomasson ED, et al
    Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016-2019.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01254.
    PubMed     Abstract available


  684. MOON JE, Greenleaf ME, Regules JA, Debois M, et al
    A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01203.
    PubMed     Abstract available


  685. CASEY RM, Adrien N, Badiane O, Diallo A, et al
    National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01075.
    PubMed     Abstract available


  686. SINGH AK, Srikrishna G, Bivalacqua TJ, Bishai WR, et al
    Recombinant BCGs for tuberculosis and bladder cancer.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01231.
    PubMed     Abstract available


  687. VIEIRA REZENDE RP, Braz AS, Guimaraes MFB, Ribeiro SLE, et al
    Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01260.
    PubMed     Abstract available


  688. BLEICHER I, Kadour-Peero E, Sagi-Dain L, Sagi S, et al
    Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01234.
    PubMed     Abstract available


  689. SHEVZOV-ZEBRUN N, Caplan A
    Parental consent for vaccination of minors against COVID-19.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01250.
    PubMed    


  690. FISHER KA, Nguyen N, Crawford S, Fouayzi H, et al
    Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01261.
    PubMed     Abstract available


  691. MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
    Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
    PubMed     Abstract available


  692. ZENG W, Cui Y, Jarawan E, Avila C, et al
    Optimizing immunization schedules in endemic cholera regions: cost-effectiveness assessment of vaccination strategies for cholera control in Bangladesh.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01235.
    PubMed     Abstract available


  693. AKSNES BN, Walldorf JA, Nkwenkeu SF, Zoma RL, et al
    Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01229.
    PubMed     Abstract available


  694. FADLYANA E, Rusmil K, Tarigan R, Rahmadi AR, et al
    A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01255.
    PubMed     Abstract available


  695. SINGH AK, Phatak SR, Singh R, Bhattacharjee K, et al
    Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)(R)) and BBV-152 (Covaxin(TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01258.
    PubMed     Abstract available


  696. YAMAZAKI Y, Ikeda M, Imada T, Furuno K, et al
    A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased ris
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01168.
    PubMed     Abstract available


  697. MOORE KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, et al
    A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future.
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01028.
    PubMed     Abstract available


  698. CHOWDHURY F, Akter A, Rahman Bhuiyan T, Tauheed I, et al
    A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01222.
    PubMed     Abstract available


  699. MELGAARD A, Krogsgaard LW, Randrup T, Plana-Ripoll O, et al
    Pre-vaccination vulnerability and suspected adverse events following HPV vaccination. A case-control study nested in the Danish national birth cohort.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01232.
    PubMed     Abstract available


  700. LIU CH, Huang WT, Chie WC, Arnold Chan K, et al
    Safety surveillance of varicella vaccine using tree-temporal scan analysis.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01226.
    PubMed     Abstract available


  701. GIESE H, Neth H, Gaissmaier W
    Determinants of information diffusion in online communication on vaccination: The benefits of visual displays.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01195.
    PubMed     Abstract available


  702. MAHAPATRA SR, Dey J, Kaur T, Sarangi R, et al
    Immunoinformatics and molecular docking studies reveal a novel Multi-Epitope peptide vaccine against pneumonia infection.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01204.
    PubMed     Abstract available


  703. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01207.
    PubMed     Abstract available


  704. ANGSUWATCHARAKON P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, et al
    High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01127.
    PubMed     Abstract available


  705. SCHNEIDER JC, Chen HC, Bautista E, Retallack D, et al
    Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01123.
    PubMed     Abstract available


  706. WILEY KE, Levy D, Shapiro GK, Dube E, et al
    A user-centered approach to developing a new tool measuring the behavioural and social drivers of vaccination.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01186.
    PubMed     Abstract available


  707. ELBASHA EH, Choi Y, Daniels V, Goveia MG, et al
    Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01147.
    PubMed     Abstract available


  708. MANSUY JM, Sagna AS, Laurent M, Izopet J, et al
    COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination?
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01227.
    PubMed    


  709. RAINA MACINTYRE C, Costantino V, Chanmugam A
    The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01164.
    PubMed     Abstract available


  710. WANG J, Wu QS, Lu J, Ni YH, et al
    Low vaccination coverage of pneumococcal conjugate vaccines (PCVs) in Shanghai, China: A database analysis based on birth cohorts from 2012 to 2020.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01190.
    PubMed     Abstract available


  711. OZAWA S, Chen HH, Rao GG, Eguale T, et al
    Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)00471.
    PubMed     Abstract available


  712. CHARD AN, Martinez M, Matanock A, Kassem AM, et al
    Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01199.
    PubMed     Abstract available


  713. MOSINA L, Kulper-Schiek W, Jacques-Carroll L, Earnshaw A, et al
    Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01225.
    PubMed     Abstract available


  714. AUGUSTO HERNANDES ROCHA T, Grapiuna de Almeida D, Shankar Kozhumam A, Cristina da Silva N, et al
    Microplanning for designing vaccination campaigns in low-resource settings: A geospatial artificial intelligence-based framework.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01197.
    PubMed     Abstract available


  715. ABAYNEH T, Getachew B, Gelaye E, Traxler R, et al
    Viability evaluation of freeze dried and suspension anthrax spore vaccine formulations stored at different temperatures.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01202.
    PubMed     Abstract available


  716. LEE SI, Jeong CG, Ul Salam Mattoo S, Nazki S, et al
    Protective immunity induced by concurrent intradermal injection of porcine circovirus type 2 and Mycoplasma hyopneumoniae inactivated vaccines in pigs.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)00921.
    PubMed     Abstract available


  717. SULIMAN S, Pelzer PT, Shaku M, Rozot V, et al
    Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01154.
    PubMed     Abstract available


  718. KOSHAL SS, Ray A, Mehra R, Kaur A, et al
    Partnering for rotavirus vaccine introduction in India: A retrospective analysis.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01193.
    PubMed     Abstract available


  719. KIM DY, Kang YM, Cho HK, Park SJ, et al
    Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01149.
    PubMed     Abstract available


  720. VAN HOOSTE WLC
    Influenza vaccination at the workplace.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01188.
    PubMed    


  721. BENJAMIN-CHUNG J, Arnold BF, Mishra K, Kennedy CJ, et al
    City-wide school-located influenza vaccination: A retrospective cohort study.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01161.
    PubMed     Abstract available


  722. KNUF M, Haas H, Garcia-Corbeira P, Turriani E, et al
    Hexavalent vaccines: What can we learn from head-to-head studies?
    Vaccine. 2021 Sep 13. pii: S0264-410X(21)01146.
    PubMed     Abstract available


  723. MKOPI A, Mtenga S, Festo C, Mhalu G, et al
    Factors affecting non-coverage of measles-rubella vaccination among children aged 9-59 months in Tanzania.
    Vaccine. 2021 Sep 13. pii: S0264-410X(21)01196.
    PubMed     Abstract available


  724. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    PubMed     Abstract available


  725. YOSHIKAWA T
    Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01169.
    PubMed     Abstract available


  726. PARADOWSKA-STANKIEWICZ I, Rumik A, Bogusz J, Zbrzezniak J, et al
    Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents.
    Vaccine. 2021 Sep 9. pii: S0264-410X(21)01167.
    PubMed     Abstract available


  727. FUJISAWA S, Murata S, Takehara M, Aoyama J, et al
    In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickens.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01166.
    PubMed     Abstract available


  728. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    PubMed     Abstract available


  729. PERRY M, Akbari A, Cottrell S, Gravenor MB, et al
    Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01198.
    PubMed     Abstract available


  730. PLATT HL, Cardona JF, Haranaka M, Schwartz HI, et al
    A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01097.
    PubMed     Abstract available


  731. ABREU E SILVA HB, Correa HP, Ribeiro IA, Nascimento VAM, et al
    Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01009.
    PubMed     Abstract available


  732. KUNITOKI K, Funato M, Mitsunami M, Kinoshita T, et al
    Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01145.
    PubMed     Abstract available


  733. MOLL K, Wong HL, Fingar K, Ke Zhou C, et al
    Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016-2018.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01151.
    PubMed     Abstract available


  734. VAN DONGEN JAP, Rouers EDM, Bonten MJM, Bruijning-Verhagen PCJ, et al
    Evaluation of non-specific effects of human rotavirus vaccination in medical risk infants.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01115.
    PubMed     Abstract available


  735. JACOBI CJ, Vaidyanathan B
    Racial differences in anticipated COVID-19 vaccine acceptance among religious populations in the US.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01184.
    PubMed     Abstract available


  736. MOORE DCBC, Nehab MF, Camacho KG, Reis AT, et al
    Low COVID-19 vaccine hesitancy in Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01192.
    PubMed     Abstract available


  737. EBERHARDT J, Ling J
    Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01189.
    PubMed     Abstract available


  738. WAINSTOCK T, Yoles I, Sergienko R, Sheiner E, et al
    Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01191.
    PubMed     Abstract available


  739. SULIMAN DM, Nawaz FA, Mohanan P, Modber MAKA, et al
    UAE efforts in promoting COVID-19 vaccination and building vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01194.
    PubMed     Abstract available


  740. BHAT S, Caldera F, Farraye FA
    Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01121.
    PubMed    


  741. RANE MS, Rohani P, Halloran ME
    Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01118.
    PubMed     Abstract available


  742. SISNOWSKI J, Vujovich-Dunn C, Gidding H, Brotherton J, et al
    Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01124.
    PubMed     Abstract available


  743. LEVIN D, Shimon G, Fadlon-Derai M, Gershovitz L, et al
    Myocarditis following COVID-19 vaccination - A case series.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01172.
    PubMed     Abstract available


  744. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01036.
    PubMed     Abstract available


  745. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01066.
    PubMed     Abstract available


  746. SONG JY, Chang CJ, Andrews C, Diez-Domingo J, et al
    Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged>/=50years: A randomized phase III trial (PNEU-PATH).
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01071.
    PubMed     Abstract available


  747. LAWRENCE J, Kitchin N, Anderson AS, Pride MW, et al
    Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)00592.
    PubMed     Abstract available


  748. ZHOU Z, Zhang X, Li Q, Fu L, et al
    Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01165.
    PubMed     Abstract available


  749. VOORMAN A, O'Reilly K, Lyons H, Goel AK, et al
    Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01112.
    PubMed     Abstract available


  750. KARAFILLAKIS E, Peretti-Watel P, Verger P, Chantler T, et al
    The role of maturity in adolescent decision-making around HPV vaccination in France.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01156.
    PubMed     Abstract available


  751. ALI A, Dwyer D, Wu Q, Wang Q, et al
    Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01126.
    PubMed     Abstract available


  752. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    PubMed     Abstract available


  753. DRUEDAHL LC, Minssen T, Price WN
    Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01163.
    PubMed     Abstract available


  754. ZAMAN K, Kovacs SD, Vanderende K, Aziz A, et al
    Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01113.
    PubMed     Abstract available


  755. BARRY M, Temsah MH, Aljamaan F, Saddik B, et al
    COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01131.
    PubMed     Abstract available


  756. KOTLER L, Greenberg D, Givon-Lavi N, van der Beek BA, et al
    Decline in pneumococcal nasopharyngeal carriage in children 6-23 months with respiratory illnesses following pneumococcal conjugate vaccine implementation.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01130.
    PubMed     Abstract available


  757. CLAYTON K, Finley C, Flynn DJ, Graves M, et al
    Evaluating the effects of vaccine messaging on immunization intentions and behavior: Evidence from two randomized controlled trials in Vermont.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01095.
    PubMed     Abstract available


  758. AZAM JM, Saitta B, Bonner K, Ferrari MJ, et al
    Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01101.
    PubMed     Abstract available


    August 2021
  759. PRIVOR-DUMM LA, Poland GA, Barratt J, Durrheim DN, et al
    A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
    Vaccine. 2021;39:5240-5250.
    PubMed     Abstract available


  760. TROGSTAD L, Robertson AH, Mjaaland S, Magnus P, et al
    Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01103.
    PubMed     Abstract available


  761. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    PubMed     Abstract available


  762. ALBANI VVL, Loria J, Massad E, Zubelli JP, et al
    The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01158.
    PubMed     Abstract available


  763. FOWLER A, Sampson M, Remaley AT, Chackerian B, et al
    A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01125.
    PubMed     Abstract available


  764. BROSH-NISSIMOV T, Sorek N, Yeshayahu M, Zherebovich I, et al
    Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01148.
    PubMed     Abstract available


  765. BATOOL R, Tahir Yousafzai M, Qureshi S, Ali M, et al
    Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
    Vaccine. 2021 Aug 28. pii: S0264-410X(21)01099.
    PubMed     Abstract available


  766. CAMPBELL JD, Pasetti MF, Oot L, Adam Z, et al
    Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach.
    Vaccine. 2021 Aug 28. pii: S0264-410X(21)01119.
    PubMed     Abstract available


  767. BAQUI AH, Koffi AK, McCollum ED, Roy AD, et al
    Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies.
    Vaccine. 2021 Aug 28. pii: S0264-410X(21)01116.
    PubMed     Abstract available


  768. PRELOG M, Almanzar G, Stern R, Robrade K, et al
    Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)01049.
    PubMed     Abstract available


  769. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    PubMed     Abstract available


  770. MALTEZOU HC, Effraimidou E, Cassimos DC, Medic S, et al
    Vaccination programs for pregnant women in Europe, 2021.
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)01122.
    PubMed     Abstract available


  771. GORANDER S, Honda-Okubo Y, Backstrom M, Baldwin J, et al
    A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01098.
    PubMed     Abstract available


  772. SILCOCK R, Moghimi A, Perrett K, Crawford N, et al
    Subcutaneous nodule at the vaccine injection site - A case of mistaken identity.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01069.
    PubMed    


  773. NOWAK SA, Gidengil CA, Parker AM, Matthews LJ, et al
    Association among trust in health care providers, friends, and family, and vaccine hesitancy.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01068.
    PubMed     Abstract available


  774. HARPAZ R
    COVID-19 vaccine safety monitoring: Might differential healthcare seeking introduce detection bias into rates of medical events and cause false safety signals?
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)00712.
    PubMed    


  775. AZIZ AB, Zaman K, Kim DR, Park JY, et al
    Re-evaluation of population-level protection conferred by a rotavirus vaccine using the 'fried-egg' approach in a rural setting in Bangladesh.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01096.
    PubMed     Abstract available


  776. DECKER MD, Garman PM, Hughes H, Yacovone MA, et al
    Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01074.
    PubMed     Abstract available


  777. KUROKAWA N, Robinson MK, Bernard C, Kawaguchi Y, et al
    Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01100.
    PubMed     Abstract available


  778. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    PubMed     Abstract available


  779. XU X, Rodgers MD, Guo WG
    A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01117.
    PubMed     Abstract available


  780. ODUWOLE EO, Mahomed H, Laurenzi CA, Larson HJ, et al
    Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01102.
    PubMed     Abstract available


  781. ROTENBERG S, Downer MB, Cooper J
    Making COVID-19 vaccinations accessible for people with disabilities.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01110.
    PubMed    


  782. MORAIS E, El Mouaddin N, Schuurman S, De A, et al
    Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01076.
    PubMed     Abstract available


  783. MORIKAWA Y, Sakakibara H, Kimiya T, Obonai T, et al
    Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01011.
    PubMed     Abstract available


  784. SUZUKI H, Noguchi T, Ogawa K, Miyazato P, et al
    Fusion of parvovirus B19 receptor-binding domain and pneumococcal surface protein A induces protective immunity against parvovirus B19 and Streptococcus pneumoniae.
    Vaccine. 2021;39:5146-5152.
    PubMed     Abstract available


  785. AHMED D, VanderEnde K, Harvey P, Bhatnagar P, et al
    Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019.
    Vaccine. 2021 Aug 21. pii: S0264-410X(21)00901.
    PubMed     Abstract available


  786. HAUSI H, Nicks P, Mzengeza T, Tsega A, et al
    The challenge of identifying eligible girls for HPV vaccination: HPV mapping data verification in Malawi.
    Vaccine. 2021 Aug 20. pii: S0264-410X(21)00902.
    PubMed     Abstract available


  787. NIKOLAY B, Ribeiro Dos Santos G, Lipsitch M, Rahman M, et al
    Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh.
    Vaccine. 2021 Aug 20. pii: S0264-410X(21)01047.
    PubMed     Abstract available


  788. DUDLEY MZ, Bernier R, Brewer J, Salmon DA, et al
    Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01070.
    PubMed     Abstract available


  789. JUNG Y, Min JY, Kim HJ, Min KB, et al
    Disparities in infant mortality from all-infectious, vaccine-preventable, and non-vaccine preventable diseases in relation to parental education.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01012.
    PubMed     Abstract available


  790. VENEGAS-VARGAS C, Taylor LP, Foss DL, Godbee TK, et al
    Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01033.
    PubMed     Abstract available


  791. ZHANG N, Zheng T, Chen Y, Zhu H, et al
    Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01007.
    PubMed     Abstract available


  792. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    Dementia risk following influenza vaccination in a large veteran cohort running head: Influenza vaccination and dementia.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01079.
    PubMed     Abstract available


  793. BRAEYE T, Cornelissen L, Catteau L, Haarhuis F, et al
    Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01108.
    PubMed     Abstract available


  794. LEE T, Gutierrez RL, Maciel M, Poole S, et al
    Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01065.
    PubMed     Abstract available


  795. HUANG XX, Bose AS, Gupta BP, Rai P, et al
    Vaccine preventable diseases surveillance in Nepal: How much does it cost?
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)00915.
    PubMed     Abstract available


  796. KARAFILLAKIS E, Paterson P, Larson HJ
    'My primary purpose is to protect the unborn child': Understanding pregnant women's perceptions of maternal vaccination and vaccine trials in Europe.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01014.
    PubMed     Abstract available


  797. BEDFORD H, Firman N, Waller J, Marlow L, et al
    Which young women are not being vaccinated against HPV? Cross-sectional analysis of a UK national cohort study.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01005.
    PubMed     Abstract available


  798. KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
    Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01037.
    PubMed     Abstract available


  799. NACIUTE M, Kiwitt T, Kemp RA, Hook S, et al
    Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01048.
    PubMed     Abstract available


  800. LIU S, Liu J
    Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01106.
    PubMed     Abstract available


  801. LAMM DL, Morales A
    A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01046.
    PubMed     Abstract available


  802. MVUNDURA M, Frivold C, Janik Osborne A, Soni P, et al
    Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01044.
    PubMed     Abstract available


  803. JIANG Y, Li X, Yu L, Tong W, et al
    Immune efficacy of a candidate porcine reproductive and respiratory syndrome vaccine rHN-NP49 administered by a Needle-free intradermal delivery system in comparison with intramuscular injection.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01043.
    PubMed     Abstract available


  804. HASSAN AS, Perera DJ, Ward BJ, Ndao M, et al
    Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01051.
    PubMed     Abstract available


  805. LAIGLE V, Postma MJ, Pavlovic M, Cadeddu C, et al
    Vaccine market access pathways in the EU27 and the United Kingdom-analysis and recommendations for improvements.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)00918.
    PubMed     Abstract available


  806. JANSSEN RS, Bruxvoort K, Jacobsen SJ, Slezak J, et al
    Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01015.
    PubMed     Abstract available


  807. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    PubMed     Abstract available


  808. PRESTON KB, Wong TAS, To A, Tashiro TE, et al
    Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01002.
    PubMed     Abstract available


  809. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01035.
    PubMed     Abstract available


  810. RODRIGUES DE OLIVEIRA N, Jorge S, Andrade Colares Maia M, Thurow Bunde T, et al
    Protective efficacy of whole-cell inactivated Leptospira vaccines made using virulent or avirulent strains in a hamster model.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01034.
    PubMed     Abstract available


  811. CIAPPONI A, Bardach A, Mazzoni A, Alconada T, et al
    Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01067.
    PubMed     Abstract available


  812. SCHLEISS MR, John CC, Permar SR
    Children are the key to the Endgame: A case for routine pediatric COVID vaccination.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01004.
    PubMed    


  813. ROBERTSON RC, Church JA, Edens TJ, Mutasa K, et al
    The fecal microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)00981.
    PubMed     Abstract available


  814. WEBSTER H, Valencia S, Kumar A, Chan C, et al
    Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01029.
    PubMed     Abstract available


  815. IWAMOTO M, Hickman CJ, Colley H, Arciuolo RJ, et al
    Measles infection in persons with secondary vaccine failure, New York City, 2018-19.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)00983.
    PubMed     Abstract available


  816. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    PubMed     Abstract available


  817. GRUPEL D, Gazit S, Schreiber L, Nadler V, et al
    Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01045.
    PubMed     Abstract available


  818. STINSON JA, Boopathy AV, Cieslewicz BM, Zhang Y, et al
    Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)00957.
    PubMed     Abstract available


  819. OKAMURA S, Ebina H
    Could live attenuated vaccines better control COVID-19?
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01038.
    PubMed     Abstract available


  820. KANJI JN, Bailey A, Fenton J, Ling SH, et al
    Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01042.
    PubMed     Abstract available


  821. RIZK JG, Barr CE, Rizk Y, Lewin JC, et al
    The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action.
    Vaccine. 2021 Aug 10. pii: S0264-410X(21)01006.
    PubMed    


  822. GALOR I, Hartal M, Perry Markovich M, Avramovich E, et al
    Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule: Response letter, to letter to the editor.
    Vaccine. 2021;39:4777.
    PubMed    


  823. HERZOG C
    Immune memory persistence is well documented for hepatitis A vaccines.
    Vaccine. 2021;39:4775-4776.
    PubMed    


  824. STAPLES JN, Nelamangala SL, Morris S, Wells K, et al
    Exploring socio-demographic and geospatial variation in human papillomavirus vaccination uptake in Virginia.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00984.
    PubMed     Abstract available


  825. GOUD R, Thompson D, Welsh K, Lu M, et al
    ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)01003.
    PubMed     Abstract available


  826. PETRIE JG, Fligiel H, Lamerato L, Martin ET, et al
    Agreement between state registry, health record, and self-report of influenza vaccination.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00995.
    PubMed     Abstract available


  827. KRISTINSDOTTIR I, Haraldsson A, Love A, Asgeirsdottir TL, et al
    Burden of rotavirus disease in young children in Iceland - Time to vaccinate?
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00944.
    PubMed     Abstract available


  828. BRITTON KJ, Pickering JL, Pomat WS, de Gier C, et al
    Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00990.
    PubMed     Abstract available


  829. ILLOUZ T, Madar R, Hirsh T, Biragyn A, et al
    Induction of an effective anti-Amyloid-beta humoral response in aged mice.
    Vaccine. 2021;39:4817-4829.
    PubMed     Abstract available


  830. PHILLIPS A, Carlson S, Danchin M, Beard F, et al
    From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00950.
    PubMed     Abstract available


  831. LYTLE KL, Collins SP, Feldstein LR, Baughman AH, et al
    Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00948.
    PubMed     Abstract available


  832. YLADE M, Agrupis KA, Daag JV, Crisostomo MV, et al
    Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: A case-control study.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00920.
    PubMed     Abstract available


  833. YOSHIKAWA T
    Implementing vaccination policies based upon scientific evidence in Japan.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00968.
    PubMed     Abstract available


  834. ELDRIDGE JH, Egan MA, Matassov D, Hamm S, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00907.
    PubMed     Abstract available


  835. BORGHI L, Riva E
    Was Aldo Castellani the inventor of combined and polyvalent vaccines?
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00955.
    PubMed     Abstract available


  836. FENG J, Li Q
    How to ensure vaccine safety: An evaluation of China's vaccine regulation system.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00986.
    PubMed     Abstract available


  837. MILLER CN, Kemp TJ, Abrahamsen M, Isaacs-Soriano K, et al
    Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00962.
    PubMed     Abstract available


  838. TAYLOR SC, Hurst B, Martiszus I, Hausman MS, et al
    Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)01013.
    PubMed     Abstract available


  839. JOHM P, Nkoum N, Ceesay A, Mbaye EH, et al
    Erratum to 'Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal' [Vaccine 39 (2021) 3926-3934].
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00991.
    PubMed    


  840. WILSON R
    HPV vaccine acceptance in West Africa: A systematic literature review.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00835.
    PubMed     Abstract available


  841. CHHATWAL J, Sapru A, Sundaram B, Shenoy B, et al
    A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00946.
    PubMed     Abstract available


  842. DODD RH, Pickles K, Cvejic E, Cornell S, et al
    Perceived public health threat a key factor for willingness to get the COVID-19 vaccine in Australia.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01008.
    PubMed     Abstract available


  843. FRIEDENSOHN L, Zur M, Timofeyev M, Burshtein S, et al
    Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01010.
    PubMed     Abstract available


  844. HVASS AMF, Norredam M, Sodemann M, Thomsen MK, et al
    Corrigendum to 'Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study' [Vaccine 38 (2020) 2788-2794].
    Vaccine. 2021 Aug 4. pii: S0264-410X(21)00993.
    PubMed    


  845. HAYMAN B, Dennehy M
    Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00922.
    PubMed     Abstract available


  846. SAKALA IG, Honda-Okubo Y, Li L, Baldwin J, et al
    A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00914.
    PubMed     Abstract available


  847. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    PubMed     Abstract available


  848. SUN J, Zheng Z, Li M, Liu Z, et al
    Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+ T cell epitopes identified through comprehensive epitope mapping in Zika virus infected mice.
    Vaccine. 2021 Aug 2. pii: S0264-410X(21)00913.
    PubMed     Abstract available


  849. LEIDNER AJ, Tang Z, Guo A, Anderson TC, et al
    Insurance reimbursements for recombinant zoster vaccine in the private sector.
    Vaccine. 2021 Aug 2. pii: S0264-410X(21)00928.
    PubMed     Abstract available


    July 2021
  850. LITWIN C, Smith L, Donken R, Krajden M, et al
    High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia, Canada.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00868.
    PubMed     Abstract available


  851. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Corrigendum to "Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations" [Vaccine 38(51) (2020) 8206-8215].
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00963.
    PubMed    


  852. REDONDO E, Drago G, Lopez-Belmonte JL, Guillen JM, et al
    Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00926.
    PubMed     Abstract available


  853. KONTOPOULOU K, Ainatzoglou A, Nakas CT, Ifantidou A, et al
    Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00958.
    PubMed     Abstract available


  854. SIDDIQUI A, Ahmed A, Tanveer M, Saqlain M, et al
    An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00965.
    PubMed    


  855. MAHAJAN A, Kaur J, Sidana C, Shivam S, et al
    Geo-prioritization framework for COVID-19 vaccine allocation in India.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00989.
    PubMed     Abstract available


  856. LUCINDE RK, Ong'ayo G, Houlihan C, Bottomley C, et al
    Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00910.
    PubMed     Abstract available


  857. JONES A, Kawesa-Newell N
    Using branded behaviour change communication to create demand for the HPV vaccine among girls in Malawi: An evaluation of Girl Effect's Zathu mini magazine.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00870.
    PubMed     Abstract available


  858. DOI H, Kanto T
    Factors influencing the durability of hepatitis B vaccine responses.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00876.
    PubMed     Abstract available


  859. RAGHUNANDAN R, Higgins D, Hosken N
    RSV neutralization assays - Use in immune response assessment.
    Vaccine. 2021;39:4591-4597.
    PubMed     Abstract available


  860. VELANDIA-GONZALEZ M, Vilajeliu A, Contreras M, Trumbo SP, et al
    Monitoring progress of maternal and neonatal immunization in Latin America and the Caribbean.
    Vaccine. 2021;39 Suppl 2:B55-B63.
    PubMed     Abstract available


  861. KOBAYASHI M, Abdul-Karim A, Milucky JL, Zakariah A, et al
    Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction.
    Vaccine. 2021;39:4685-4699.
    PubMed     Abstract available


  862. LIM H, In HJ, Kim YJ, Jang S, et al
    Development of an attenuated smallpox vaccine candidate: The KVAC103 strain.
    Vaccine. 2021 Jul 29. pii: S0264-410X(21)00810.
    PubMed     Abstract available


  863. CARRICO J, Talbird SE, La EM, Poston S, et al
    Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population.
    Vaccine. 2021 Jul 29. pii: S0264-410X(21)00906.
    PubMed     Abstract available


  864. DALON F, Majed L, Belhassen M, Jacoud F, et al
    Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study.
    Vaccine. 2021 Jul 29. pii: S0264-410X(21)00945.
    PubMed     Abstract available


  865. DIACO M, Yin K, Seet B, Samson S, et al
    Author response to a Letter to the Editor on "Introductory paper: High dose influenza vaccine".
    Vaccine. 2021 Jul 28. pii: S0264-410X(21)00917.
    PubMed    


  866. GARLASCO J, Bordino V, Marengo N, Rainero E, et al
    Pertussis immunisation during pregnancy: Antibody levels and the impact of booster vaccine.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00930.
    PubMed     Abstract available


  867. YU VG, Lasco G, David CC
    Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00929.
    PubMed     Abstract available


  868. GEORGIADIS GP, Georgiadis MC
    Optimal planning of the COVID-19 vaccine supply chain.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00961.
    PubMed     Abstract available


  869. VINK M, Upadhaya N, Amin HA, Liwal MG, et al
    Does support to Private Health Practitioners increase childhood vaccination coverage? Findings from a comparative study in Afghanistan.
    Vaccine. 2021 Jul 26. pii: S0264-410X(21)00877.
    PubMed     Abstract available


  870. KHAN SA, Choudhury P, Kakati S, Doley R, et al
    Effectiveness of a single dose of Japanese encephalitis vaccine among adults, Assam, India, 2012-2018.
    Vaccine. 2021 Jul 26. pii: S0264-410X(21)00919.
    PubMed     Abstract available


  871. KUROKAWA N, Lavoie PO, D'Aoust MA, Couture MM, et al
    Development and characterization of a plant-derived rotavirus-like particle vaccine.
    Vaccine. 2021 Jul 26. pii: S0264-410X(21)00916.
    PubMed     Abstract available


  872. KLEIN NP, Peyrani P, Yacisin K, Caldwell N, et al
    A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00863.
    PubMed     Abstract available


  873. RAJAN S, Akhtar N, Sharma S, Chakrabarti D, et al
    COVID-19 vaccination for cancer patients: Evidence, priority, and practice.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00956.
    PubMed    


  874. MICHOS A, Tatsi EB, Filippatos F, Dellis C, et al
    Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00960.
    PubMed     Abstract available


  875. ALVES MLF, Ferreira MRA, Donassolo RA, Rodrigues RR, et al
    Clostridium septicum: A review in the light of alpha-toxin and development of vaccines.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00878.
    PubMed     Abstract available


  876. BURKE PF, Masters D, Massey G
    Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00947.
    PubMed     Abstract available


  877. TEASDALE CA, Borrell LN, Shen Y, Kimball S, et al
    Parental plans to vaccinate children for COVID-19 in New York city.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00949.
    PubMed     Abstract available


  878. SUNDARAM M, Nasreen S, Calzavara A, He S, et al
    Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00951.
    PubMed     Abstract available


  879. CALLAHAN AG, Coleman-Cowger VH, Schulkin J, Power ML, et al
    Racial disparities in influenza immunization during pregnancy in the United States: A narrative review of the evidence for disparities and potential interventions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00905.
    PubMed     Abstract available


  880. SCHEIBLHOFER S, Drothler S, Braun W, Braun R, et al
    Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
    Vaccine. 2021;39:4399-4403.
    PubMed     Abstract available


  881. TISSOT N, Brunel AS, Bozon F, Rosolen B, et al
    Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00925.
    PubMed     Abstract available


  882. MATHIVATHANAN K
    Will COVID-19 vaccine equity be possible in India?
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00927.
    PubMed    


  883. HERVE PL, Dhelft V, Zuniga A, Ghasparian A, et al
    Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Vaccine. 2021;39:4555-4563.
    PubMed     Abstract available


  884. VODICKA E, Nonvignon J, Antwi-Agyei KO, Bawa J, et al
    The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana.
    Vaccine. 2021 Jul 21. pii: S0264-410X(21)00904.
    PubMed     Abstract available


  885. JACKSON B, Harvey Y, Perez-Martin E, Wilsden G, et al
    The selection of naturally stable candidate foot-and-mouth disease virus vaccine strains for East Africa.
    Vaccine. 2021 Jul 21. pii: S0264-410X(21)00860.
    PubMed     Abstract available


  886. PAUL E, Brown GW, Kalk A, Ridde V, et al
    Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00923.
    PubMed    


  887. CHUA H, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010-2020.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00873.
    PubMed     Abstract available


  888. HECHT J, Suliman S, Wegiel B
    Bacillus Calmette-Guerin (BCG) vaccination to treat endometriosis.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00879.
    PubMed     Abstract available


  889. INGROLE RSJ, Tao W, Joshi G, Gill HS, et al
    M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00909.
    PubMed     Abstract available


  890. CORCORAN M, Mereckiene J, Cotter S, Murchan S, et al
    Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00741.
    PubMed     Abstract available


  891. COLTON H, Greenfield DM, Snowden JA, Miller PDE, et al
    Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant.
    Vaccine. 2021 Jul 19. pii: S0264-410X(21)00881.
    PubMed     Abstract available


  892. MADHIVANAN P, Krupp K, Coudray M, Colbert B, et al
    Longitudinal assessment of nonavalent vaccine HPV types in a sample of sexually active African American women from ten U.S. Cities.
    Vaccine. 2021 Jul 19. pii: S0264-410X(21)00903.
    PubMed     Abstract available


  893. HANLY M, Churches T, Fitzgerald O, MacIntyre CR, et al
    Vaccinating Australia: How long will it take?
    Vaccine. 2021 Jul 17. pii: S0264-410X(21)00865.
    PubMed     Abstract available


  894. SHILLING H, Garland SM, Atchison S, Cornall AM, et al
    Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00864.
    PubMed     Abstract available


  895. FLUCKIGER AC, Ontsouka B, Bozic J, Diress A, et al
    An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00911.
    PubMed     Abstract available


  896. INSERRA F, Tajer C, Antonietti L, Mariani J, et al
    Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00908.
    PubMed    


  897. PATHIRANA J, Kwatra G, Maposa I, Groome MJ, et al
    Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00661.
    PubMed     Abstract available


  898. LAMONTAGNE DS, Manangazira P, Marembo J, Chigodo C, et al
    HPV vaccination coverage in three districts in ZIMBABWE following national introduction of 0,12 month schedule among 10 to 14 year old girls.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00871.
    PubMed     Abstract available


  899. ELAS M, Villatoro N, Pezzoli L
    Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00869.
    PubMed     Abstract available


  900. MOGAJI E
    Marketing the COVID-19 vaccine and the implications for public health.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00874.
    PubMed     Abstract available


  901. O'DELL FJ, Williams AN, Poland A
    The contributions of William Money MRCS to smallpox vaccination and control - A little-known story.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00844.
    PubMed     Abstract available


  902. HAYMAN B, Suri R, Prasad SD
    COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00866.
    PubMed     Abstract available


  903. LAZAROS G, Klein AL, Hatziantoniou S, Tsioufis C, et al
    The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00875.
    PubMed    


  904. WANG X, Xia A, Wang C, Tian H, et al
    Clinical and molecular characterization of the first culture-confirmed pediatric fulminant meningococcemia case caused by a serogroup Y clonal complex 23 strain in China.
    Vaccine. 2021;39:4261-4265.
    PubMed     Abstract available


  905. TONG L, Jia Q, Li B, Li Z, et al
    Investigation of the baseline tetanus antibody level and its persistence in a military unit.
    Vaccine. 2021;39:4328-4334.
    PubMed     Abstract available


  906. CLARKE M, Goodchild LM, Evans S, Giles LC, et al
    Body mass index and vaccine responses following influenza vaccination during pregnancy.
    Vaccine. 2021 Jul 12. pii: S0264-410X(21)00826.
    PubMed     Abstract available


  907. GOMEZ M, McCollum J, Wang H, Bachchhav S, et al
    Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00861.
    PubMed     Abstract available


  908. MACINTYRE CR, Veness B, Berger D, Hamad N, et al
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00872.
    PubMed     Abstract available


  909. GUKTUR RE, Nep EI, Asala O, Olorunfemi PO, et al
    Carboxymethylated and acetylated xerogel derivatives of Plectranthus esculentus starch protect Newcastle disease vaccines against cold chain failure.
    Vaccine. 2021 Jul 9. pii: S0264-410X(21)00812.
    PubMed     Abstract available


  910. ZHANG T, Zhang J, Shao X, Feng S, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
    Vaccine. 2021 Jul 9. pii: S0264-410X(21)00836.
    PubMed     Abstract available


  911. FONGWEN N, Delrieu I, Ham LH, Gubler DJ, et al
    Implementation strategies for the first licensed dengue vaccine: A meeting report.
    Vaccine. 2021 Jul 9. pii: S0264-410X(21)00845.
    PubMed     Abstract available


  912. TERNA RICHARD M, Taiwo L, Jean Baptiste AE, Bawa S, et al
    Planning for supplemental immunization activities using the readiness assessment dashboard: Experience from 2017/2018 Measles vaccination campaign, Nigeria.
    Vaccine. 2021 Jul 8. pii: S0264-410X(21)00831.
    PubMed     Abstract available


  913. MATEO-URDIALES A, Del Manso M, Andrianou X, Spuri M, et al
    Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00862.
    PubMed     Abstract available


  914. DING Y, Luo L, Luo Y, Zhao D, et al
    A novel combined vaccine against classical swine fever and porcine epidemic diarrhea viruses elicits a significant Th2-favored humoral response in mice.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00846.
    PubMed     Abstract available


  915. AT THOBARI J, Damayanti W, Haposan JH, Nirwati H, et al
    Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.
    Vaccine. 2021 Jul 6. pii: S0264-410X(21)00832.
    PubMed     Abstract available


  916. GESSNER BD, Theilacker C, Mendez C, Jodar L, et al
    Comment on "Vila-Corcoles et al., Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016."
    Vaccine. 2021;39:4032-4033.
    PubMed    


  917. BELLIER L, Petitjean A, Sarazu T, Tresierra J, et al
    Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Vaccine. 2021;39:4144-4152.
    PubMed     Abstract available


  918. OZAWA S, Yemeke TT, Mitgang E, Wedlock PT, et al
    Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations.
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00581.
    PubMed     Abstract available


  919. GENTILE A, Pacchiotti AC, Giglio N, Nolte MF, et al
    Vaccine hesitancy in Argentina: Validation of WHO scale for parents.
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00842.
    PubMed     Abstract available


  920. MARTIN C, Marinova D, Aguilo N, Gonzalo-Asensio J, et al
    MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG.
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00799.
    PubMed     Abstract available


  921. GOSSET A, Diallo MY, Betsem E, Schaeffer L, et al
    Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NeoVac Study).
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00809.
    PubMed     Abstract available


  922. KURITA J, Uematsu T, Sakurai N, Sugawara T, et al
    Attenuation of antibody titer of measles and rubella virus among university students of department of healthcare providers during 2015-2018 in Japan.
    Vaccine. 2021;39:4203-4209.
    PubMed     Abstract available


  923. LUO J, Huo C, Qin H, Hu J, et al
    Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection.
    Vaccine. 2021;39:4135-4143.
    PubMed     Abstract available


  924. SIMAS C, Paterson P, Lees S, J Larson H, et al
    "From my phone, I could rule the world": Critical engagement with maternal vaccine information, vaccine confidence builders and post-Zika outbreak rumours in Brazil.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00775.
    PubMed     Abstract available


  925. LI AJ, Manzi F, Kyesi F, Makame Y, et al
    Tanzania's human papillomavirus (HPV) vaccination program: Community awareness, feasibility, and acceptability of a national HPV vaccination program, 2019.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00797.
    PubMed     Abstract available


  926. HUANG Y, Seaton KE, Casapia M, Polakowski L, et al
    AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00827.
    PubMed     Abstract available


  927. SCHALTZ-BUCHHOLZER F, Roth A, de Bree LCJ, Biering-Sorensen S, et al
    Neonatal Bacille Calmette-Guerin vaccination and tuberculin skin test reactions at 2- and 6-months: Effects on mortality up to 1 year of age.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00839.
    PubMed     Abstract available


  928. LO CY, Misplon JA, Li X, Price GE, et al
    Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00833.
    PubMed     Abstract available


  929. RAHAMIMOV N, Baturov V, Shani A, Ben Zoor I, et al
    Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00843.
    PubMed     Abstract available


  930. THIEM VD, Anh DD, Ha VH, Hien ND, et al
    Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants.
    Vaccine. 2021 Jul 1. pii: S0264-410X(21)00806.
    PubMed     Abstract available


  931. CHOWDHURY F, Ali Syed K, Akter A, Rahman Bhuiyan T, et al
    A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol(R), an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.
    Vaccine. 2021 Jul 1. pii: S0264-410X(21)00830.
    PubMed     Abstract available


  932. YEMEKE TT, Mitgang E, Wedlock PT, Higgins C, et al
    Promoting, seeking, and reaching vaccination services: A systematic review of costs to immunization programs, beneficiaries, and caregivers.
    Vaccine. 2021 Jul 1. pii: S0264-410X(21)00670.
    PubMed     Abstract available


    June 2021
  933. MWABA J, Chisenga CC, Xiao S, Ng'ombe H, et al
    Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00770.
    PubMed     Abstract available


  934. SORENSEN MK, Schaltz-Buchholzer F, Jensen AM, Nielsen S, et al
    Retesting the hypothesis that early Diphtheria-Tetanus-Pertussis vaccination increases female mortality: An observational study within a randomised trial.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00720.
    PubMed     Abstract available


  935. HINES AM, Murphy N, Mullin C, Barillas J, et al
    Henoch-Schonlein purpura presenting post COVID-19 vaccination.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00841.
    PubMed    


  936. FISCHER P, Pawlowski A, Cao D, Bell D, et al
    Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00796.
    PubMed     Abstract available


  937. OSTERGAARD L, Vesikari T, Senders SD, Flodmark CE, et al
    Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00717.
    PubMed     Abstract available


  938. PLUTZER E, Warner SB
    A potential new front in health communication to encourage vaccination: Health education teachers.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00800.
    PubMed     Abstract available


  939. KAUR R, Pham M, Pichichero M
    Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.
    Vaccine. 2021;39:3900-3906.
    PubMed     Abstract available


  940. KELLY SM, Larsen KR, Darling R, Petersen AC, et al
    Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.
    Vaccine. 2021;39:3862-3870.
    PubMed     Abstract available


  941. AL-SHAIKH A, Muthu N, Aidyralieva C, Profili MC, et al
    COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00840.
    PubMed    


  942. BANKS C, Portnoy A, Moi F, Boonstoppel L, et al
    Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00838.
    PubMed     Abstract available


  943. VERGER P, Duale C, Lenzi N, Scronias D, et al
    Vaccine hesitancy among hospital staff physicians: A cross-sectional survey in France in 2019.
    Vaccine. 2021 Jun 28. pii: S0264-410X(21)00803.
    PubMed     Abstract available


  944. BURNETT E, Juin S, Esona MD, Desormeaux AM, et al
    Effectiveness of monovalent rotavirus vaccine against hospitalizations due to all rotavirus and equine-like G3P[8] genotypes in Haiti 2014-2019.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00805.
    PubMed     Abstract available


  945. SARHAN AT, Bahey-El-Din M, Zaghloul TI
    Recombinant Ax21 protein is a promising subunit vaccine candidate against Stenotrophomonas maltophilia in a murine infection model.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00801.
    PubMed     Abstract available


  946. FUJIMOTO AB, Keskinocak P, Yildirim I
    Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00828.
    PubMed     Abstract available


  947. FELIX S, Handem S, Nunes S, Paulo AC, et al
    Impact of private use of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage among Portuguese children living in urban and rural regions.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00771.
    PubMed     Abstract available


  948. CARNALLA M, Torres-Ibarra L, Barrientos-Gutierrez T, Cruz-Valdez A, et al
    Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00776.
    PubMed     Abstract available


  949. MYLES IA, Vinciguerra JS, Premus RT
    Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00811.
    PubMed     Abstract available


  950. TUO W, Feng X, Cao L, Vinyard B, et al
    Vaccination with Neospora caninum-cyclophilin and -profilin confers partial protection against experimental neosporosis-induced abortion in sheep.
    Vaccine. 2021 Jun 24. pii: S0264-410X(21)00768.
    PubMed     Abstract available


  951. DESAI AP, Desai AP, Loomis GJ
    Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00808.
    PubMed     Abstract available


  952. BALDOLLI A, Michon J, Appia F, Galimard C, et al
    Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00804.
    PubMed     Abstract available


  953. FURUYA-KANAMORI L, Xu C, Doi SAR, Clark J, et al
    Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00759.
    PubMed     Abstract available


  954. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    PubMed     Abstract available


  955. MARTIN-MERINO E, Castillo-Cano B, Martin-Perez M, Llorente-Garcia A, et al
    Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00765.
    PubMed     Abstract available


  956. KRISTENSEN D, Giersing B, Hickling J, Kazi F, et al
    A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00711.
    PubMed    


  957. PHILLIP K, Nair N, Samanta K, Azevedo JF, et al
    Maternal transfer of neutralizing antibodies to B. burgdorferi OspA after oral vaccination of the rodent reservoir.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00761.
    PubMed     Abstract available


  958. OOSTDIJK C, Van Zoonen K, Ruijs WLM, Mollema L, et al
    Household decision-making for the MenACWY vaccination: How parents and adolescents deal with an adolescent vaccination decision.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00772.
    PubMed     Abstract available


  959. TRENT M, Seale H, Chughtai AA, Salmon D, et al
    Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00798.
    PubMed     Abstract available


  960. JAYARAMAN Y, Veeraraghavan B, Girish Kumar CP, Sukumar B, et al
    Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in India.
    Vaccine. 2021;39:3737-3744.
    PubMed     Abstract available


  961. MBAEYI C, Moran T, Wadood Z, Ather F, et al
    Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Vaccine. 2021;39:3717-3723.
    PubMed     Abstract available


  962. GOOCH KE, Smith TRF, Salguero FJ, Fotheringham SA, et al
    One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00807.
    PubMed     Abstract available


  963. LUNDBERG L, Bygdell M, Stukat von Feilitzen G, Woxenius S, et al
    Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00795.
    PubMed     Abstract available


  964. CHEN IH, Ahorsu DK, Ko NY, Yen CF, et al
    Adapting the Motors of Influenza Vaccination Acceptance Scale into the Motors of COVID-19 Vaccination Acceptance Scale: Psychometric evaluation among mainland Chinese university students.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00794.
    PubMed     Abstract available


  965. WANG Z, Zhou C, Gao F, Zhu Q, et al
    Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): Immunogenicity, efficacy and toxicology.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00767.
    PubMed     Abstract available


  966. RADHAKRISHNAN L, Stein Z, DeVies J, Smith A, et al
    Syndromic surveillance of vaccine-associated adverse events in U.S. emergency departments.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00766.
    PubMed     Abstract available


  967. SMITH KJ, Wateska AR, Nowalk MP, Lin CJ, et al
    Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00773.
    PubMed     Abstract available


  968. WEDLOCK PT, Cox SN, Bartsch SM, Randall SL, et al
    Should countries switch to using five- or ten-dose rotavirus vaccines now that they are available?
    Vaccine. 2021 Jun 19. pii: S0264-410X(21)00757.
    PubMed     Abstract available


  969. FOGEL B, Schaefer EW, Hicks SD
    Early influenza vaccination rates decline in children during the COVID-19 pandemic.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00777.
    PubMed     Abstract available


  970. BROWN CC, Young SG, Pro GC
    COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00774.
    PubMed     Abstract available


  971. LILES E, Irving SA, Dandamudi P, Belongia EA, et al
    Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination.
    Vaccine. 2021;39:3614-3620.
    PubMed     Abstract available


  972. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    PubMed     Abstract available


  973. VAILLANT L, Oster P, McMillan B, Velin D, et al
    Gastric eosinophils are detrimental for Helicobacter pylori vaccine efficacy.
    Vaccine. 2021;39:3590-3601.
    PubMed     Abstract available


  974. JETHWA H, Wong R, Abraham S
    Covid-19 vaccine trials: Ethnic diversity and immunogenicity.
    Vaccine. 2021;39:3541-3543.
    PubMed    


  975. PRASAD N, Read JM, Jewell C, Waite B, et al
    Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00708.
    PubMed     Abstract available


  976. FRADICO JRB, Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JGA, et al
    CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00709.
    PubMed     Abstract available


  977. YITBAREK K, Tilahun T, Debela T, Abdena D, et al
    Measles epidemiology and vaccination coverage in Oromia Region, Ethiopia: Evidence from surveillance, 2011-2018.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00739.
    PubMed     Abstract available


  978. MOSS WJ, Shendale S, Lindstrand A, O'Brien KL, et al
    Feasibility assessment of measles and rubella eradication.
    Vaccine. 2021;39:3544-3559.
    PubMed     Abstract available


  979. ANDRE GO, Borges MT, Assoni L, Ferraz LFC, et al
    Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis.
    Vaccine. 2021;39:3626-3632.
    PubMed     Abstract available


  980. GARON JR, Mukavhi A, Rupfutse M, Bright S, et al
    Multiple cohort HPV vaccination in Zimbabwe: 2018-2019 program feasibility, awareness, and acceptability among health, education, and community stakeholders.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00669.
    PubMed     Abstract available


  981. ZIMMERMAN RK
    Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00763.
    PubMed     Abstract available


  982. SMITH LE, Hodson A, Rubin GJ
    Parental attitudes towards mandatory vaccination; a systematic review.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00742.
    PubMed     Abstract available


  983. IVANOV V, Oomens AGP, Papin JF, Staats R, et al
    Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00737.
    PubMed     Abstract available


  984. KOCHHAR GS, Desai A, Caldera DO F, El Hachem S, et al
    Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00615.
    PubMed     Abstract available


  985. POLAND GA, Ovsyannikova IG, Kennedy RB
    The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00764.
    PubMed    


  986. SCHALTZ-BUCHHOLZER F, Kjaer Sorensen M, Benn CS, Aaby P, et al
    The introduction of BCG vaccination to neonates in Northern Sweden, 1927-31: Re-analysis of historical data to understand the lower mortality among BCG-vaccinated children.
    Vaccine. 2021 Jun 13. pii: S0264-410X(21)00718.
    PubMed     Abstract available


  987. LIPSITCH M, Kahn R
    Interpreting vaccine efficacy trial results for infection and transmission.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00735.
    PubMed     Abstract available


  988. FERRARI D, Di Resta C, Tomaiuolo R, Sabetta E, et al
    Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00756.
    PubMed     Abstract available


  989. MCFADDEN K, Heywood A, Dyda A, Kaufman J, et al
    Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?
    Vaccine. 2021;39:3467-3472.
    PubMed     Abstract available


  990. DAVIES C, Stoney T, Hutton H, Parrella A, et al
    School-based HPV vaccination positively impacts parents' attitudes toward adolescent vaccination.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00637.
    PubMed     Abstract available


  991. BEAU RENEER Z, Abreu RB, Jamal US, Corn MR, et al
    Seasonal influenza vaccination does not effectively expand H2 cross-reactive antibodies in humans.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00659.
    PubMed     Abstract available


  992. MESHER D, Thomas SL, Linley E, Edmundson C, et al
    Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00580.
    PubMed     Abstract available


  993. OH SH, Kim SH, Jeon JH, Kim EB, et al
    Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00734.
    PubMed     Abstract available


  994. HSIA J, Zhao G, Lu PJ, Town M, et al
    Estimating bias from internet non-use for a hybrid web vaccination survey - 2013-2017 Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00675.
    PubMed     Abstract available


  995. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    PubMed     Abstract available


  996. CHEN Y, Wang Y, Robertson ID, Hu C, et al
    Key issues affecting the current status of infectious diseases in Chinese cattle farms and their control through vaccination.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00673.
    PubMed     Abstract available


  997. RAHMAN T, de Gier C, Orami T, Seppanen EJ, et al
    PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life.
    Vaccine. 2021;39:3486-3492.
    PubMed     Abstract available


  998. SORG AL, Obermeier V, Liese JG, von Kries R, et al
    Incidence trends of parapneumonic pleural effusions/empyema in children 2009 to 2018 from health insurance data: Only temporal reduction after the introduction of PCV13.
    Vaccine. 2021;39:3516-3519.
    PubMed     Abstract available


  999. CHAUHAN AS, Kapoor I, Rana SK, Kumar D, et al
    Cost effectiveness of typhoid vaccination in India.
    Vaccine. 2021 Jun 10. pii: S0264-410X(21)00713.
    PubMed     Abstract available


  1000. VANDERSLOTT S, Marks T
    Charting mandatory childhood vaccination policies worldwide.
    Vaccine. 2021 Jun 10. pii: S0264-410X(21)00547.
    PubMed     Abstract available


  1001. LUTZ CS, Biggerstaff M, Rolfes MA, Lafond KE, et al
    Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00557.
    PubMed     Abstract available


  1002. MUHI S, Stinear TP
    Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00700.
    PubMed     Abstract available


  1003. GUNTUKU SC, Buttenheim AM, Sherman G, Merchant RM, et al
    Twitter discourse reveals geographical and temporal variation in concerns about COVID-19 vaccines in the United States.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00738.
    PubMed     Abstract available


  1004. HOEHL S, Ciesek S, Graf J, Wicker S, et al
    A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00736.
    PubMed    


  1005. DE VRIES LM, Kellerborg KM, Brouwer WBF, van Baal PHM, et al
    Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00699.
    PubMed     Abstract available


  1006. STOECKEL F, Carter C, Lyons BA, Reifler J, et al
    Association of vaccine hesitancy and immunization coverage rates in the European Union.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00657.
    PubMed     Abstract available


  1007. SUN Y, Jackson K, Dalmon CA, Shapiro BL, et al
    Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00642.
    PubMed     Abstract available


  1008. DIAZ-MITOMA F, Popovic V, Spaans JN
    Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac(R), compared with Engerix-B(R) in healthy Asian adults: A phase 3 randomized clinical trial.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00662.
    PubMed     Abstract available


  1009. ANDAYI F, Emukule GO, Osoro E, Ndegwa LK, et al
    Knowledge and attitude of Kenyan healthcare workers towards pandemic influenza disease and vaccination: 9 years after the last influenza pandemic.
    Vaccine. 2021 Jun 7. pii: S0264-410X(21)00643.
    PubMed     Abstract available


  1010. RAZ A, Keshet Y, Popper-Giveon A, Karkabi MS, et al
    One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy.
    Vaccine. 2021 Jun 5. pii: S0264-410X(21)00714.
    PubMed    


  1011. CHUA JV, Davis C, Husson JS, Nelson A, et al
    Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00685.
    PubMed     Abstract available


  1012. NOGUERA M, Vela A, Kraft C, Chevalier M, et al
    Effects of three commercial vaccines against porcine parvovirus 1 in pregnant gilts.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00614.
    PubMed     Abstract available


  1013. KARAFILLAKIS E, Francis MR, Paterson P, Larson HJ, et al
    Trust, emotions and risks: Pregnant women's perceptions, confidence and decision-making practices around maternal vaccination in France.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00704.
    PubMed     Abstract available


  1014. WOLFE LS, Smedley JG 3rd, Bubna N, Hussain A, et al
    Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00668.
    PubMed     Abstract available


  1015. DAL-RE R, Launay O
    Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00703.
    PubMed    


  1016. ITO N, Okamoto T, Sasaki M, Miyamoto S, et al
    Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00553.
    PubMed     Abstract available


  1017. CHANDRA D, Vipin B
    On the vaccine supply chain coordination under subsidy contract.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00676.
    PubMed     Abstract available


  1018. STUURMAN AL, Biccler J, Carmona A, Descamps A, et al
    Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00654.
    PubMed     Abstract available


  1019. UWINS C, Cyriac S, Bhandoria G
    HPV vaccine: Expanding indications and global disparity.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00677.
    PubMed    


  1020. GATES A, Rahman S, Sim S, Pillay J, et al
    Health inequities related to vaccination: An evidence map of potentially influential factors and systematic review of interventions.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00640.
    PubMed     Abstract available


  1021. FERDINANDS JM, Thompson MG, Blanton L, Spencer S, et al
    Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00562.
    PubMed     Abstract available


  1022. LASKY T, McMahon AW, Hua W, Forshee R, et al
    Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00666.
    PubMed     Abstract available


  1023. SHINGAI M, Nomura N, Sekiya T, Ohno M, et al
    Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00660.
    PubMed     Abstract available


  1024. YANG T, Liu B, Yue L, Xie T, et al
    Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00653.
    PubMed     Abstract available


  1025. JOHM P, Nkoum N, Ceesay A, Mbaye EH, et al
    Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00663.
    PubMed     Abstract available


  1026. SHI M, Chen X, Sun Y, Kim HK, et al
    A protein A based Staphylococcus aureus vaccine with improved safety.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00667.
    PubMed     Abstract available


  1027. CHYDERIOTIS S, Sicsic J, Raude J, Bonmarin I, et al
    Optimising HPV vaccination communication to adolescents: A discrete choice experiment.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00656.
    PubMed     Abstract available


  1028. WANG Y, Zhang Y, Wu H, Huang L, et al
    Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00665.
    PubMed     Abstract available


  1029. DEY A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, et al
    Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00706.
    PubMed     Abstract available


  1030. PATEL MK, Bergeri I, Bresee JS, Cowling BJ, et al
    Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00707.
    PubMed     Abstract available


    May 2021
  1031. BREWER NT, Mitchell CG, Alton Dailey S, Hora L, et al
    HPV vaccine communication training in healthcare systems: Evaluating a train-the-trainer model.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00610.
    PubMed     Abstract available


  1032. ZIPFEL CM, Colizza V, Bansal S
    The missing season: The impacts of the COVID-19 pandemic on influenza.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00635.
    PubMed     Abstract available


  1033. LEWIS NS, Banyard AC, Essen S, Whittard E, et al
    Antigenic evolution of contemporary clade 2.3.4.4 HPAI H5 influenza A viruses and impact on vaccine use for mitigation and control.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00655.
    PubMed     Abstract available


  1034. GREWAL R, Deeks SL, Hart TA, Cox J, et al
    Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00603.
    PubMed     Abstract available


  1035. MCGUINNESS D, Kaufhold RM, McHugh PM, Winters MA, et al
    Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00549.
    PubMed     Abstract available


  1036. BARDENHEIER BH, Gravenstein S, Blackman C, Gutman R, et al
    Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00683.
    PubMed     Abstract available


  1037. ABU MOUCH S, Roguin A, Hellou E, Ishai A, et al
    Myocarditis following COVID-19 mRNA vaccination.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00682.
    PubMed     Abstract available


  1038. WAGNER NM, Dempsey AF, Narwaney KJ, Gleason KS, et al
    Addressing logistical barriers to childhood vaccination using an automated reminder system and online resource intervention: A randomized controlled trial.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00639.
    PubMed     Abstract available


  1039. SULLIVAN E, Lecollinet S, Kerviel A, Hue E, et al
    Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.
    Vaccine. 2021;39:3161-3168.
    PubMed     Abstract available


  1040. BRANDILEONE MC, Almeida SCG, Bokermann S, Minamisava R, et al
    Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019.
    Vaccine. 2021;39:3207-3215.
    PubMed     Abstract available


  1041. GURWITZ D
    COVID-19 vaccine hesitancy: Lessons from Israel.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00680.
    PubMed    


  1042. CHU H, Ko LK, Ibrahim A, Bille Mohamed F, et al
    The impact of an educational forum intervention on East African mothers' HPV vaccine-related knowledge, attitudes, and intentions to vaccinate their adolescent children.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00593.
    PubMed     Abstract available


  1043. VUJOVICH-DUNN C, Kaufman J, King C, Skinner SR, et al
    A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00583.
    PubMed     Abstract available


  1044. KESSELS R, Luyten J, Tubeuf S
    Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00664.
    PubMed     Abstract available


  1045. SATTLER C, Hoffmann P, Herzberg PY, Weber D, et al
    Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - A single center retrospective efficacy analysis.
    Vaccine. 2021 May 25. pii: S0264-410X(21)00511.
    PubMed     Abstract available


  1046. WATESKA AR, Nowalk MP, Jalal H, Lin CJ, et al
    Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Alpha value of information analysis.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00609.
    PubMed     Abstract available


  1047. COX SN, Wedlock PT, Pallas SW, Mitgang EA, et al
    A systems map of the economic considerations for vaccination: Application to hard-to-reach populations.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00605.
    PubMed     Abstract available


  1048. VANHEMS P
    A breath of humanity in the era of Covid-19 vaccine.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00638.
    PubMed    


  1049. EARLE KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, et al
    Evidence for antibody as a protective correlate for COVID-19 vaccines.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00658.
    PubMed     Abstract available


  1050. GIDENGIL C, Goetz MB, Newberry S, Maglione M, et al
    Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis.
    Vaccine. 2021 May 23. pii: S0264-410X(21)00385.
    PubMed     Abstract available


  1051. NADARZYNSKI T, Frost M, Miller D, Wheldon CW, et al
    Vaccine acceptability, uptake and completion amongst men who have sex with men: A systematic review, meta-analysis and theoretical framework.
    Vaccine. 2021 May 22. pii: S0264-410X(21)00564.
    PubMed     Abstract available


  1052. HIRST A, Hyer RN, Janssen RS
    Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00582.
    PubMed     Abstract available


  1053. TUFAIL S, Shah MA, Zafar M, Asif TA, et al
    Identification of potent epitopes on hexon capsid protein and their evaluation as vaccine candidates against infections caused by members of Adenoviridae family.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00585.
    PubMed     Abstract available


  1054. ARDURA-GARCIA C, Kreis C, Rakic M, Jaboyedoff M, et al
    Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis.
    Vaccine. 2021;39:2917-2928.
    PubMed     Abstract available


  1055. BIANCHI FP, Larocca AMV, Bozzi A, Spinelli G, et al
    Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study.
    Vaccine. 2021;39:2989-2994.
    PubMed     Abstract available


  1056. VOGEL TP, Top KA, Karatzios C, Hilmers DC, et al
    Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3037-3049.
    PubMed     Abstract available


  1057. SERAZIN NA, Edem B, Williams SR, Ortiz JR, et al
    Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3028-3036.
    PubMed     Abstract available


  1058. AIZAWA Y, Katsuta T, Sakiyama H, Tanaka-Taya K, et al
    Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00636.
    PubMed     Abstract available


  1059. OKORONKWO C, Taiwo LA, Asolo JA, Baptiste AEJ, et al
    Leveraging on the 2017/2018 measles vaccination campaign to improve health workers knowledge and practice on injection safety: A case study of north-central states, Nigeria.
    Vaccine. 2021 May 20. pii: S0264-410X(21)00565.
    PubMed     Abstract available


  1060. SON HJ, Lee E, Park SY, Lee S, et al
    Promotion of healthcare personnel vaccinations among newly employed doctors and nurses: Evidence-guided strategy.
    Vaccine. 2021 May 20. pii: S0264-410X(21)00589.
    PubMed     Abstract available


  1061. BLANCHARD-ROHNER G, Enriquez N, Lemaitre B, Cadau G, et al
    Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients.
    Vaccine. 2021 May 20. pii: S0264-410X(21)00594.
    PubMed     Abstract available


  1062. NICHOLLS LAB, Gallant AJ, Cogan N, Rasmussen S, et al
    Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00544.
    PubMed     Abstract available


  1063. DANG JHT, Stewart SL, Blumberg DA, Rodriguez HP, et al
    Patient and clinician factors associated with uptake of the human papillomavirus (HPV) vaccine among adolescent patients of a primary care network.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00525.
    PubMed     Abstract available


  1064. KIM S, Williams TC, Viboud C, Campbell H, et al
    RSV genomic diversity and the development of a globally effective RSV intervention.
    Vaccine. 2021;39:2811-2820.
    PubMed     Abstract available


  1065. NAG K, Chandra Baray J, Rahman Khan M, Mahmud A, et al
    An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00607.
    PubMed     Abstract available


  1066. LUK TT, Zhao S, Wu Y, Wong JY, et al
    Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00608.
    PubMed     Abstract available


  1067. MENKIR TF, Jbaily A, Verguet S
    Incorporating equity in infectious disease modeling: Case study of a distributional impact framework for measles transmission.
    Vaccine. 2021;39:2894-2900.
    PubMed     Abstract available


  1068. GULLA K, Cibelli N, Cooper JW, Fuller HC, et al
    A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00545.
    PubMed     Abstract available


  1069. FUKUDA M, Nakamura J, Ito S, Kawazoe K, et al
    Vaccination inhibits the human adenoviral transduction in a mouse keratoconjunctivitis model.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00561.
    PubMed     Abstract available


  1070. NAKAHASHI-OUCHIDA R, Uchida Y, Yuki Y, Katakai Y, et al
    A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00552.
    PubMed     Abstract available


  1071. CHAN YW, Wong ML, Kwok FY, Au AK, et al
    The effect of seasonal influenza vaccine on medically-attended influenza and non-influenza respiratory viruses infections at primary care level, Hong Kong SAR, 2017/18 to 2019/20.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00541.
    PubMed     Abstract available


  1072. MCGIRR A, Bourgoin T, Wortzman M, Millson B, et al
    An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00523.
    PubMed     Abstract available


  1073. AWAD AM, Ntoso A, Connaire JJ, Hernandez GT, et al
    An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) in adults receiving hemodialysis.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00554.
    PubMed     Abstract available


  1074. WOOD RM, Murch BJ, Moss SJ, Tyler JMB, et al
    Operational research for the safe and effective design of COVID-19 mass vaccination centres.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00588.
    PubMed    


  1075. GUBERNOT D, Jazwa A, Niu M, Baumblatt J, et al
    U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00578.
    PubMed     Abstract available


  1076. CHUNG JR, Flannery B, Kim SS, Gaglani M, et al
    Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00555.
    PubMed     Abstract available


  1077. WANG J, Jiang L, Zhang C, He W, et al
    The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00560.
    PubMed     Abstract available


  1078. LIU Y, Xiong Y, Liang Y, Deng X, et al
    Waning immunity and potential asymptomatic infection in 3-7 years old children who received one dose of measles-mumps-rubella vaccine: A 4-year prospective study.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00559.
    PubMed     Abstract available


  1079. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00543.
    PubMed     Abstract available


  1080. BANNISTER S, Sudbury E, Villanueva P, Perrett K, et al
    The safety of BCG revaccination: A systematic review.
    Vaccine. 2021;39:2736-2745.
    PubMed     Abstract available


  1081. LONGCHAMPS C, Ducarroz S, Crouzet L, Vignier N, et al
    COVID-19 vaccine hesitancy among persons living in homeless shelters in France.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00563.
    PubMed     Abstract available


  1082. GROENEWEG L, Loeffen YGT, Versluys AB, Wolfs TFW, et al
    Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00508.
    PubMed     Abstract available


  1083. HAN B, Liu W, Du J, Liu H, et al
    Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00540.
    PubMed     Abstract available


  1084. KIM TH, Choi JH, Park SH, Yoo JH, et al
    Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged >/= 65 years.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00551.
    PubMed     Abstract available


  1085. UWABOR E, Chau V, Romanin C, Loh LC, et al
    Digital tools for vaccine reporting: A perspective from the province of Ontario.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00558.
    PubMed    


  1086. ARREDONDO JL, Villagomez Martinez SM, Concepcion Morales M, Meyer S, et al
    Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00546.
    PubMed     Abstract available


  1087. KRAIGSLEY AM, Moore KA, Bolster A, Peters M, et al
    Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00502.
    PubMed     Abstract available


  1088. CHILENGI R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, et al
    Immunogenicity and safety of two monovalent rotavirus vaccine, ROTAVAC(R) and ROTAVAC 5D(R) in Zambian infants.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00542.
    PubMed     Abstract available


  1089. GLENN BA, Nonzee NJ, Tieu L, Pedone B, et al
    Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00454.
    PubMed     Abstract available


  1090. AFIFI TO, Salmon S, Taillieu T, Stewart-Tufescu A, et al
    Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00590.
    PubMed     Abstract available


  1091. LEUNG VKY, Fox A, Carolan LA, Aban M, et al
    Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00483.
    PubMed     Abstract available


  1092. POWELL H, Liu H, Pekosz A
    Changes in sialic acid binding associated with egg adaptation decrease live attenuated influenza virus replication in human nasal epithelial cell cultures.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00535.
    PubMed     Abstract available


  1093. DU QQ, Zeng HL, Yuan L, Tang P, et al
    One cross-sectional investigation revealed that non-vaccine serotypes of Streptococcus pneumoniae could be identified more frequently in elderly Chinese people.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00233.
    PubMed     Abstract available


  1094. PASTORINO R, Villani L, La Milia DI, Ieraci R, et al
    Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00566.
    PubMed     Abstract available


  1095. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    PubMed     Abstract available


  1096. STABEL JR, Bannantine JP
    Reduced tissue colonization of Mycobacterium avium subsp. paratuberculosis in neonatal calves vaccinated with a cocktail of recombinant proteins.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00510.
    PubMed     Abstract available


  1097. TANG XY, Yan XX, Wei X, Qin QL, et al
    Timeliness, completeness, and timeliness-and-completeness of serial routine vaccinations among rural children in Southwest China: A multi-stage stratified cluster sampling survey.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00507.
    PubMed     Abstract available


  1098. KHALIL I, Walker R, Porter CK, Muhib F, et al
    Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00453.
    PubMed     Abstract available


  1099. SOMIYA M, Mine S, Yasukawa K, Ikeda S, et al
    Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00548.
    PubMed    


  1100. SATOH C, Toizumi M, Nguyen HAT, Hara M, et al
    Prevalence and characteristics of children with otitis media with effusion in Vietnam.
    Vaccine. 2021;39:2613-2619.
    PubMed     Abstract available


  1101. MANCA TA, Graham JE, MacDonald NE, Top KA, et al
    Healthcare providers' interpretations of product labelling information developed through a consensus stakeholder approach.
    Vaccine. 2021;39:2652-2659.
    PubMed     Abstract available


  1102. CORREIA R, Meneses L, Richheimer C, Alves PM, et al
    Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00480.
    PubMed     Abstract available


  1103. FAIRMAN J, Agarwal P, Barbanel S, Behrens C, et al
    Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
    Vaccine. 2021 May 5. pii: S0264-410X(21)00374.
    PubMed     Abstract available


  1104. JO CL, Burchett H, Bastias M, Campbell P, et al
    Using existing systematic reviews for developing vaccination recommendations: Results of an international expert workshop.
    Vaccine. 2021 May 5. pii: S0264-410X(21)00504.
    PubMed     Abstract available


  1105. WANG J, Bai S, Zhou S, Zhao W, et al
    Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2-5 years in China.
    Vaccine. 2021 May 5. pii: S0264-410X(21)00484.
    PubMed     Abstract available


  1106. BITENCOURT J, Sarno A, Oliveira C, Souza RA, et al
    Comparing cytokine production and clinical response following vaccination with BCG Moreau and BCG Russia strains in a Brazilian infant population.
    Vaccine. 2021 May 5. pii: S0264-410X(21)00475.
    PubMed     Abstract available


  1107. MILLAR EV, Bennett JW, Barin B, Carey PM, et al
    Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00478.
    PubMed     Abstract available


  1108. HALL GC, Douglas I, Heath PT, Prabhakar P, et al
    Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00256.
    PubMed     Abstract available


  1109. MPHURU A, Li AJ, Kyesi F, Mwengee W, et al
    National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00472.
    PubMed     Abstract available


  1110. OTERI AJ, Adamu U, Dieng B, Bawa S, et al
    Nigeria experience on the use of polio assets for the 2017/18 measles vaccination campaign follow-up.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00497.
    PubMed     Abstract available


  1111. LAURENZ M, von Eiff C, Borchert K, Jacob C, et al
    Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change - A claims database analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00476.
    PubMed     Abstract available


  1112. TAMANDJOU TCHUEM CR, Andersson MI, Wiysonge CS, Mufenda J, et al
    Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00498.
    PubMed     Abstract available


  1113. MANDOMANDO I, Mumba M, Nsiari-Muzeyi Biey J, Kipese Paluku G, et al
    Implementation of the World Health Organization recommendation on the use of rotavirus vaccine without age restriction by African countries.
    Vaccine. 2021 May 3. pii: S0264-410X(21)00289.
    PubMed     Abstract available


  1114. YOSHIMURA M, Shinmura Y, Shishido T, Takagi S, et al
    Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys.
    Vaccine. 2021 May 1. pii: S0264-410X(21)00477.
    PubMed     Abstract available


    April 2021
  1115. WELSH KJ, Baumblatt J, Chege W, Goud R, et al
    Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00524.
    PubMed     Abstract available


  1116. EYAL N, Gerhard T, Strom BL
    Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00526.
    PubMed    


  1117. ITO S, Nakamura J, Fukuta M, Ura T, et al
    Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles.
    Vaccine. 2021 Apr 29. pii: S0264-410X(21)00482.
    PubMed     Abstract available


  1118. WILKINSON K, Righolt CH, Elliott LJ, Fanella S, et al
    Pertussis vaccine effectiveness and duration of protection - A systematic review and meta-analysis.
    Vaccine. 2021 Apr 29. pii: S0264-410X(21)00479.
    PubMed     Abstract available


  1119. POLKOWSKA A, Rinta-Kokko H, Toropainen M, Palmu AA, et al
    Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland.
    Vaccine. 2021 Apr 29. pii: S0264-410X(21)00186.
    PubMed     Abstract available


  1120. KINI A, Morgan R, Kuo H, Shea P, et al
    Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00448.
    PubMed     Abstract available


  1121. DIAS HF, Kuhtreiber WM, Nelson KJ, Ng NC, et al
    Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00446.
    PubMed     Abstract available


  1122. VEKEMANS J, Schellenberg D, Benns S, O'Brien K, et al
    Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00409.
    PubMed     Abstract available


  1123. SAITOH A, Okabe N
    Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00460.
    PubMed     Abstract available


  1124. XU J, Doyon-Plourde P, Tunis M, Quach C, et al
    Effect of early measles vaccination on long-term protection: A systematic review.
    Vaccine. 2021 Apr 26. pii: S0264-410X(21)00447.
    PubMed     Abstract available


  1125. KWON JH, Criado MF, Killmaster L, Ali MZ, et al
    Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh.
    Vaccine. 2021 Apr 25. pii: S0264-410X(21)00459.
    PubMed     Abstract available


  1126. MACINTYRE CR, Costantino V, Trent M
    Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00501.
    PubMed     Abstract available


  1127. KREPS SE, Kriner DL
    Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00503.
    PubMed     Abstract available


  1128. PARK MA, Jenkins SM, Smith CY, Pyle RC, et al
    Pneumococcal serotype-specific cut-offs based on antibody responses to pneumococcal polysaccharide vaccination in healthy adults.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00450.
    PubMed     Abstract available


  1129. XIRIDOU M, Visser M, Urbanus A, Matser A, et al
    Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00433.
    PubMed     Abstract available


  1130. OLATUNJI EA, Ogunsola AS, Khodakarami N, Callaghan T, et al
    Who receives influenza vaccinations at the Pharmacy? An analysis of the Texas Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00451.
    PubMed     Abstract available


  1131. SOLANS L, Debrie AS, Coutte L, Locht C, et al
    Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00449.
    PubMed     Abstract available


  1132. ROY CHOUDHURY A, Polachek SW
    The impact of paid family leave on the timely vaccination of infants.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00403.
    PubMed     Abstract available


  1133. KAWAMURA Y, Hattori F, Higashimoto Y, Kozawa K, et al
    Evaluation of varicella vaccine effectiveness during outbreaks in schools or nurseries by cross-sectional study.
    Vaccine. 2021 Apr 21. pii: S0264-410X(21)00434.
    PubMed     Abstract available


  1134. STEVENS NE, van Wolfswinkel M, Bao W, Ryan FJ, et al
    Immunisation with the BCG and DTPw vaccines induces different programs of trained immunity in mice.
    Vaccine. 2021 Apr 21. pii: S0264-410X(21)00400.
    PubMed     Abstract available


  1135. HAMISU M, Dieng B, Taiwo L, Jean Baptiste AE, et al
    Microplanning verification and 2017/2018 measles vaccination campaign in Nigeria: Lessons learnt.
    Vaccine. 2021 Apr 20. pii: S0264-410X(21)00432.
    PubMed     Abstract available


  1136. PIERSON BC, Cardile AP, Okwesili AC, Downs IL, et al
    Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine.
    Vaccine. 2021 Apr 19. pii: S0264-410X(21)00309.
    PubMed     Abstract available


  1137. JEAN BAPTISTE AE, Masresha B, Wagai J, Luce R, et al
    Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018.
    Vaccine. 2021 Apr 17. pii: S0264-410X(21)00424.
    PubMed     Abstract available


  1138. SAVAGE RD, Bell CA, Righolt CH, Wilkinson K, et al
    A multisite study of pertussis vaccine effectiveness by time since last vaccine dose from three Canadian provinces: A Canadian Immunization Research Network study.
    Vaccine. 2021 Apr 16. pii: S0264-410X(21)00310.
    PubMed     Abstract available


  1139. OSTOLIN TLVDP, Gusmao MR, Mathias FAS, Cardoso JMO, et al
    A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
    Vaccine. 2021 Apr 16. pii: S0264-410X(21)00429.
    PubMed     Abstract available


  1140. MARTIN JC, Petrecz ML, Stek JE, Simon JK, et al
    Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA).
    Vaccine. 2021 Apr 15. pii: S0264-410X(21)00345.
    PubMed     Abstract available


  1141. GUZMAN-HOLST A, Luna-Casas G, Cervantes-Apolinar MY, Huerta-Garcia GC, et al
    Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: An ecological database study with time-series analysis.
    Vaccine. 2021;39:2311-2318.
    PubMed     Abstract available


  1142. YAMADA M, Li M, Iino T
    Pneumococcal vaccine coverage in Japan among patients with a history of splenectomy: Results of a retrospective administrative database study.
    Vaccine. 2021 Apr 14. pii: S0264-410X(21)00338.
    PubMed     Abstract available


  1143. DANIEL M, Liang B, Luo M
    Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00372.
    PubMed     Abstract available


  1144. BROOK B, Schaltz-Buchholzer F, Ben-Othman R, Kollmann T, et al
    A place for neutrophils in the beneficial pathogen-agnostic effects of the BCG vaccine.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00408.
    PubMed     Abstract available


  1145. LEVIN Y, Balakirski NM, Caraco Y, Ben-Ami E, et al
    Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00452.
    PubMed    


  1146. WANG C, Han B, Zhao T, Liu H, et al
    Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00455.
    PubMed     Abstract available


  1147. YU Q, Li X, Fan M, Qiu H, et al
    The impact of childhood pneumococcal conjugate vaccine immunisation on all-cause pneumonia admissions in Hong Kong: A 14-year population-based interrupted time series analysis.
    Vaccine. 2021 Apr 12. pii: S0264-410X(21)00406.
    PubMed     Abstract available


  1148. PRYMULA R, Povey M, Brzostek J, Cabrnochova H, et al
    Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Vaccine. 2021 Apr 12. pii: S0264-410X(21)00401.
    PubMed     Abstract available


  1149. CHOI SK, Baik YO, Kim CW, Kim SK, et al
    An open-label, comparative, single dose, clinical Phase study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
    Vaccine. 2021 Apr 10. pii: S0264-410X(21)00405.
    PubMed     Abstract available


  1150. LA EM, Garbinsky D, Hunter S, Poston S, et al
    Meningococcal B vaccination coverage among older adolescents in the United States.
    Vaccine. 2021 Apr 10. pii: S0264-410X(21)00375.
    PubMed     Abstract available


  1151. HAMILTON RA, Krockow EM, Vekria P
    Attitudes towards influenza and uptake of the flu vaccine: A survey of pharmacy staff working in English hospitals.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00407.
    PubMed     Abstract available


  1152. JENSEN KJ, Tolstrup LK, Knobel DL, Aaby P, et al
    Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00399.
    PubMed     Abstract available


  1153. PU J, Yu Q, Yin Z, Zhang Y, et al
    The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00431.
    PubMed     Abstract available


  1154. DE SL, May S, Shah K, Slawinski M, et al
    Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00376.
    PubMed     Abstract available


  1155. HOGAN AB, Winskill P, Watson OJ, Walker PGT, et al
    Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00427.
    PubMed     Abstract available


  1156. CEYHAN M, Karadag-Oncel E, Hascelik G, Ustundag G, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children aged less than five years.
    Vaccine. 2021;39:2041-2047.
    PubMed     Abstract available


  1157. PAGLIUSI S, Hayman B, Jarrett S
    Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Vaccine. 2021 Apr 7. pii: S0264-410X(21)00293.
    PubMed     Abstract available


  1158. GRAMACHO WG, Turgeon M
    When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00396.
    PubMed     Abstract available


  1159. HATZIANTONIOU S, Maltezou HC, Tsakris A, Poland GA, et al
    Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00377.
    PubMed    


  1160. DANIELS V, Saxena K, Roberts C, Kothari S, et al
    Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00428.
    PubMed     Abstract available


  1161. SMITH TG, Fooks AR, Moore SM, Freuling CM, et al
    Negligible risk of rabies importation in dogs thirty days after demonstration of adequate serum antibody titer.
    Vaccine. 2021 Apr 4. pii: S0264-410X(21)00368.
    PubMed    


  1162. DION SB, Major M, Gabriela Grajales A, Nepal RM, et al
    Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Vaccine. 2021 Apr 3. pii: S0264-410X(21)00260.
    PubMed     Abstract available


  1163. DONG TQ, Wakefield J
    Modeling and presentation of vaccination coverage estimates using data from household surveys.
    Vaccine. 2021 Apr 3. pii: S0264-410X(21)00275.
    PubMed     Abstract available


  1164. STALPERS CAL, Retmana IA, Pennings JLA, Vandebriel RJ, et al
    Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines.
    Vaccine. 2021 Apr 3. pii: S0264-410X(21)00384.
    PubMed     Abstract available


  1165. YAO T, Shao Z, Wu L, Dong S, et al
    Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China.
    Vaccine. 2021 Apr 2. pii: S0264-410X(21)00378.
    PubMed     Abstract available


  1166. BEZERRA FSB, Silva MTO, Rezende AFS, Lopes AS, et al
    Saponin-adjuvanted recombinant vaccines containing rCP00660, rCP09720 or rCP01850 proteins against Corynebacterium pseudotuberculosis infection in mice.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00366.
    PubMed     Abstract available


  1167. DE MIRANDA LOPES KA, Baptista PN, de Medeiros Nascimento R, Pimentel A, et al
    Clinical repercussions in pertussis infants post-Tdpa vaccination of pregnant woman: An immunization success?
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00373.
    PubMed     Abstract available


  1168. SUH J, Lee T, Choi JK, Lee J, et al
    The impact of two-dose varicella vaccination on varicella and herpes zoster incidence in South Korea using a mathematical model with changing population demographics.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00349.
    PubMed     Abstract available


  1169. CARR DJJ, Berube AN, Filiberti A, Gmyrek GB, et al
    Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0DeltaNLS vaccine against ocular HSV-1 challenge.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00379.
    PubMed     Abstract available


  1170. HOFFMAN BL, Colditz JB, Shensa A, Wolynn R, et al
    #DoctorsSpeakUp: Lessons learned from a pro-vaccine Twitter event.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00365.
    PubMed     Abstract available


  1171. CROWCROFT NS, Bolotin S, Li Y, Campbell H, et al
    Infant pertussis and maternal immunity: The curious case of Canada.
    Vaccine. 2021;39:1977-1981.
    PubMed     Abstract available


  1172. AMIN-CHOWDHURY Z, Groves N, Sheppard CL, Litt D, et al
    Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Vaccine. 2021;39:1997-2004.
    PubMed     Abstract available


  1173. QUAN DH, Counoupas C, Nagalingam G, Pinto R, et al
    Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity.
    Vaccine. 2021;39:1990-1996.
    PubMed     Abstract available


    March 2021
  1174. ERIKSSON M, Kayhty H, Lahdenkari M, Makisalo H, et al
    A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.
    Vaccine. 2021 Mar 31. pii: S0264-410X(21)00367.
    PubMed     Abstract available


  1175. KLOUWENS MJ, Salverda MLM, Trentelman JJ, Ersoz JI, et al
    Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
    Vaccine. 2021 Mar 31. pii: S0264-410X(21)00363.
    PubMed     Abstract available


  1176. AZZI L, Focosi D, Dentali F, Baj A, et al
    Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00402.
    PubMed    


  1177. CHEN H, Gao Z, Bai S, Liu X, et al
    Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00264.
    PubMed     Abstract available


  1178. PELTON SI, Divino V, Postma MJ, Shah D, et al
    A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00347.
    PubMed     Abstract available


  1179. GUR-ARIE R, Katz MA, Hirsch A, Greenberg D, et al
    "You Have to Die Not to Come to Work": A Mixed Methods Study of Attitudes and Behaviors regarding Presenteeism, Absenteeism and Influenza Vaccination among Healthcare Personnel with Respiratory Illness in Israel, 2016-2019.
    Vaccine. 2021 Mar 29. pii: S0264-410X(21)00361.
    PubMed     Abstract available


  1180. YAMAWAKI RA, Rubio MDS, Alves LBR, de Almeida AM, et al
    Evaluation of transfer of maternal immunity to the offspring of broiler breeders vaccinated with a candidate recombinant vaccine against Salmonella Enteritidis.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00343.
    PubMed     Abstract available


  1181. BAVANANTHASIVAM J, Alizadeh M, Astill J, Alqazlan N, et al
    Effects of administration of probiotic lactobacilli on immunity conferred by the herpesvirus of turkeys vaccine against challenge with a very virulent Marek's disease virus in chickens.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00339.
    PubMed     Abstract available


  1182. WIJAYANTI KE, Schutze H, MacPhail C, Braunack-Mayer A, et al
    Parents' knowledge, beliefs, acceptance and uptake of the HPV vaccine in members of The Association of Southeast Asian Nations (ASEAN): A systematic review of quantitative and qualitative studies.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00342.
    PubMed     Abstract available


  1183. KUTER BJ, Offit PA, Poland GA
    The development of COVID-19 vaccines in the United States: Why and how so fast?
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00383.
    PubMed    


  1184. RUSSO AG, Decarli A, Valsecchi MG
    Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00382.
    PubMed     Abstract available


  1185. LAMPONEN T, Hetemaki I, Niemi HJ, Jarva H, et al
    Heterologous boosting of nonrelated toxoid immunity during acute Puumala hantavirus infection.
    Vaccine. 2021;39:1818-1825.
    PubMed     Abstract available


  1186. VREMAN S, Rebel JMJ, McCaffrey J, Ledl K, et al
    Early immune responses in skin and lymph node after skin delivery of Toll-like receptor agonists in neonatal and adult pigs.
    Vaccine. 2021;39:1857-1869.
    PubMed     Abstract available


  1187. WAN C, Gao C, Xie Q, Wang Y, et al
    Flagella hook protein FlgE is a novel vaccine candidate of Pseudomonas aeruginosa identified by a genomic approach.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00344.
    PubMed     Abstract available


  1188. NGUYEN KH, Santibanez TA, Stokley S, Lindley MC, et al
    Parental vaccine hesitancy and its association with adolescent HPV vaccination.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00341.
    PubMed    


  1189. GKENTZI D, Aggelopoulos K, Karatza A, Sinopidis X, et al
    Influenza vaccination among caregivers and household contacts of children with asthma.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00325.
    PubMed     Abstract available


  1190. MPHAHLELE MJ, Groome MJ, Page NA, Bhagwandin N, et al
    A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12(th) African Rotavirus Symposium.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00282.
    PubMed     Abstract available


  1191. SALMON DA, Dudley MZ, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00315.
    PubMed     Abstract available


  1192. MURRAY SM, McKay PF
    Chlamydia trachomatis: Cell biology, immunology and vaccination.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00326.
    PubMed     Abstract available


  1193. BEISSBARTH J, Wilson N, Arrowsmith B, Binks MJ, et al
    Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00311.
    PubMed     Abstract available


  1194. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    PubMed     Abstract available


  1195. HAEDER SF
    Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00348.
    PubMed     Abstract available


  1196. ANGELIS A, Darrow J
    Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00346.
    PubMed    


  1197. KOCHHAR S, Dube E, Graham J, Jee Y, et al
    COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00364.
    PubMed    


  1198. ZHANG Y, Li D, Zhao H, Wang L, et al
    The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00371.
    PubMed    


  1199. ANTONELLI INCALZI R, Trevisan C, Del Signore S, Volpato S, et al
    Are vaccines against COVID-19 tailored to the most vulnerable people?
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00370.
    PubMed    


  1200. KENDAL A
    Safety monitoring of COVID-19 vaccines - Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00283.
    PubMed    


  1201. CHEN D, Ye Z, Pi Z, Mizukami S, et al
    Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00324.
    PubMed     Abstract available


  1202. VILCHES TN, Zhang K, Van Exan R, Langley JM, et al
    Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00362.
    PubMed     Abstract available


  1203. ARTENSTEIN AW
    A half-century of meningococcal vaccines.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00292.
    PubMed     Abstract available


  1204. EL BARA A, Pivert A, Veillon P, Ng Wing Sang C, et al
    From national HBV and HDV screenings to vaccination and treatment in healthcare workers: The Mauritanian pilot study.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00279.
    PubMed     Abstract available


  1205. ZHANG Z, Pan J, Chen M, Zhang T, et al
    Seroepidemiology of pertussis in China: A population-based, cross-sectional study.
    Vaccine. 2021;39:1687-1692.
    PubMed     Abstract available


  1206. RANE MS, Page LC, McVeigh E, Miller K, et al
    Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns.
    Vaccine. 2021;39:1765-1772.
    PubMed     Abstract available


  1207. KHANNA M, Rady H, Dai G, Ramsay AJ, et al
    Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
    Vaccine. 2021;39:1780-1787.
    PubMed     Abstract available


  1208. TEMPLE B, Nation ML, Dai VTT, Beissbarth J, et al
    Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam.
    Vaccine. 2021 Mar 18. pii: S0264-410X(21)00223.
    PubMed     Abstract available


  1209. NWOGU IB, Jones M, Langley T
    Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
    Vaccine. 2021 Mar 18. pii: S0264-410X(21)00229.
    PubMed     Abstract available


  1210. BROWN DR, Joura EA, Yen GP, Kothari S, et al
    Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence.
    Vaccine. 2021 Mar 17. pii: S0264-410X(20)31564.
    PubMed     Abstract available


  1211. PHUA LC, Choi HCW, Wu J, Jit M, et al
    Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00321.
    PubMed     Abstract available


  1212. AGOCS M, Ismail A, Kamande K, Tabu C, et al
    Reasons why children miss vaccinations in Western Kenya; A step in a five-point plan to improve routine immunization.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00262.
    PubMed     Abstract available


  1213. CAMBOU MC, Copeland TP, Nielsen-Saines K, Macinko J, et al
    Insurance status predicts self-reported influenza vaccine coverage among pregnant women in the United States: A cross-sectional analysis of the National Health Interview Study Data from 2012 to 2018.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00294.
    PubMed     Abstract available


  1214. HAMIDI A, Hoeksema F, Velthof P, Lemckert A, et al
    Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00312.
    PubMed     Abstract available


  1215. UEKI S, Matsunaka E, Takao K, Kitao M, et al
    The effectiveness of vibratory stimulation in reducing pain in children receiving vaccine injection: A randomized controlled trial.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00281.
    PubMed     Abstract available


  1216. SZIGETI R, Kellermayer R
    Natural unblinding of BCG vaccination trials.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00320.
    PubMed     Abstract available


  1217. GRAUPENSPERGER S PHD, Abdallah DA, Lee CM
    Social norms and vaccine uptake: College students' COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00286.
    PubMed     Abstract available


  1218. STEIMLE LN, Havumaki J, Eisenberg MC, Eisenberg JNS, et al
    Cost-effectiveness of pediatric norovirus vaccination in daycare settings.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00257.
    PubMed     Abstract available


  1219. SUSARLA SK, Palkar S, Sv PS, Diwan A, et al
    Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00280.
    PubMed     Abstract available


  1220. DEERIN JF, Clifton R, Elmi A, Lewis PE, et al
    Hepatitis B birth dose vaccination patterns in the military health System, 2014-2018.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00278.
    PubMed     Abstract available


  1221. ALLINGTON D, McAndrew S, Moxham-Hall VL, Duffy B, et al
    Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00234.
    PubMed     Abstract available


  1222. CHOI UY, Kim KH, Lee KY, Kim JH, et al
    Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00273.
    PubMed     Abstract available


  1223. HARRISON GBL, Heath DD, Robinson CM, Lawrence SB, et al
    Combined use of two separate but protective vaccine antigens provides protection against Taenia ovis infection in lambs in the presence of protective maternal antibody.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00308.
    PubMed     Abstract available


  1224. MOLODECKY NA, Usman A, Javaid A, Wahdan A, et al
    Quantifying movement patterns and vaccination status of high risk mobile populations in Pakistan and Afghanistan to inform poliovirus risk and vaccination strategy.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00269.
    PubMed     Abstract available


  1225. HABIB MA, Prymula R, Carryn S, Esposito S, et al
    Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00265.
    PubMed     Abstract available


  1226. NET P, Colrat F, Nascimento Costa M, Bianic F, et al
    Estimating public health and economic benefits along 10 years of Fluzone(R) High Dose in the United States.
    Vaccine. 2021;39 Suppl 1:A56-A69.
    PubMed     Abstract available


  1227. FERREIRA MN, Netto EM, Nascimento-Carvalho CM
    The impact of 10-valent pneumococcal conjugate vaccine upon hospitalization rate of children with pneumonia in different Brazilian administrative regions.
    Vaccine. 2021 Mar 14. pii: S0264-410X(21)00231.
    PubMed     Abstract available


  1228. WILLIAMSON JD, Gould KG, Brown K
    Richard Pfeiffer's typhoid vaccine and Almroth Wright's claim to priority.
    Vaccine. 2021 Mar 13. pii: S0264-410X(21)00285.
    PubMed     Abstract available


  1229. RIGHOLT CH, Pabla G, Donelle J, Brna P, et al
    Vaccine coverage among children with epilepsy in two Canadian provinces: A Canadian immunization research network study.
    Vaccine. 2021 Mar 13. pii: S0264-410X(21)00277.
    PubMed     Abstract available


  1230. BUTTERY JP
    Developing standard safety outcomes for COVID-19 vaccines.
    Vaccine. 2021 Mar 12. pii: S0264-410X(21)00272.
    PubMed    


  1231. THANAWASTIEN A, Joyce KE, Cartee RT, Haines LA, et al
    Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid.
    Vaccine. 2021;39:1652-1660.
    PubMed     Abstract available


  1232. LEE J, Li Y, Li Y, Cino-Ozuna AG, et al
    Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00268.
    PubMed     Abstract available


  1233. BERTRAN K, Kassa A, Criado MF, Nunez IA, et al
    Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00266.
    PubMed     Abstract available


  1234. EBAMA MS, Chu SY, Azziz-Baumgartner E, Lafond KE, et al
    Ancillary benefits of seasonal influenza vaccination in middle-income countries.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00228.
    PubMed     Abstract available


  1235. GBENEWEI E, Nomhwange T, Taiwo L, Ayodeji I, et al
    Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00258.
    PubMed     Abstract available


  1236. MOMOH J, Oteri AJ, Mogekwu F, Onwu N, et al
    Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00259.
    PubMed     Abstract available


  1237. REPERANT LA, Osterhaus ADME
    COVID-19 vaccination and critical care capacity: Perilous months ahead.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00316.
    PubMed    


  1238. WENTZELL E, Racila AM
    The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00317.
    PubMed     Abstract available


  1239. LATKIN C, Dayton LA, Yi G, Konstantopoulos A, et al
    COVID-19 vaccine intentions in the United States, a social-ecological framework.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00238.
    PubMed     Abstract available


  1240. KWAK BO, Kwon YS, Hong YJ, Shin SH, et al
    Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean children: A prospective multicenter study.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00267.
    PubMed     Abstract available


  1241. STEFFEN CA, Henaff L, Durupt A, Omeiri NE, et al
    Evidence-informed vaccination decision-making in countries: Progress, challenges and opportunities.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00235.
    PubMed     Abstract available


  1242. GATWOOD J, Chiu CY, Shuvo S, Ramachandran S, et al
    Role of social determinants of health in pneumococcal vaccination among high-risk adults.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00241.
    PubMed     Abstract available


  1243. GUIDRY JPD, Perrin PB, Laestadius LI, Vraga EK, et al
    U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00306.
    PubMed     Abstract available


  1244. MINTA AA, Silva MWT, Shrestha A, de Quiroz-Castro M, et al
    Hepatitis B surface antigen seroprevalence among children in the Philippines, 2018.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00222.
    PubMed     Abstract available


  1245. SADARANGANI M, Abu Raya B, Conway JM, Iyaniwura SA, et al
    Importance of COVID-19 vaccine efficacy in older age groups.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00288.
    PubMed     Abstract available


  1246. KISZEWSKI AE, Cleary EG, Jackson MJ, Ledley FD, et al
    NIH funding for vaccine readiness before the COVID-19 pandemic.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00290.
    PubMed     Abstract available


  1247. PULLAN S, Dey M
    Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google Trends analysis.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00287.
    PubMed     Abstract available


  1248. DONADEL M, Panero MS, Ametewee L, Shefer AM, et al
    National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00239.
    PubMed     Abstract available


  1249. WILLIAMSON SL, Gadd E, Pillay T, Toldi G, et al
    Non-specific effects of BCG vaccination on neutrophil and lymphocyte counts of healthy neonates from a developed country.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00255.
    PubMed     Abstract available


  1250. HASNAN S, Tan NC
    Multi-domain narrative review of vaccine hesitancy in childhood.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00237.
    PubMed     Abstract available


  1251. BLACK SB, Law B, Chen RT, Dekker CL, et al
    The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00284.
    PubMed     Abstract available


  1252. PIRAS-DOUCE F, Raynal F, Raquin A, Girerd-Chambaz Y, et al
    Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00200.
    PubMed     Abstract available


  1253. YOKOMICHI H, Kojima R, Horiuchi S, Ooka T, et al
    Effectiveness of influenza vaccination in infants and toddlers with and without prior infection history: The Japan Environment and Children's Study.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00224.
    PubMed     Abstract available


  1254. DU Y, Xu Y, Feng J, Hu L, et al
    Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00274.
    PubMed     Abstract available


  1255. KUO H, Shapiro JR, Dhakal S, Morgan R, et al
    Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00227.
    PubMed     Abstract available


  1256. WOO EJ, Moro PL
    Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00232.
    PubMed     Abstract available


  1257. STURM L, Kasting ML, Head KJ, Hartsock JA, et al
    Influenza vaccination in the time of COVID-19: A national U.S. survey of adults.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00271.
    PubMed     Abstract available


  1258. HELMKAMP LJ, Szilagyi PG, Zimet G, Saville AW, et al
    A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00206.
    PubMed     Abstract available


  1259. JOURA EA, Ulied A, Vandermeulen C, Rua Figueroa M, et al
    Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45years of age compared to women 16-26years of age: An open-label phase 3 study.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00128.
    PubMed     Abstract available


  1260. WENDLAND EM, Kops NL, Bessel M, Comerlato J, et al
    Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00207.
    PubMed     Abstract available


  1261. FELL DB, Dimitris MC, Hutcheon JA, Ortiz JR, et al
    Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00261.
    PubMed     Abstract available


  1262. CUTTS FT, Danovaro-Holliday MC, Rhoda DA
    Challenges in measuring supplemental immunization activity coverage among measles zero-dose children.
    Vaccine. 2021;39:1359-1363.
    PubMed    


  1263. WANG Y, Huang C, Tang J, Liu G, et al
    Salmonella Pullorum spiC mutant is a desirable LASV candidate with proper virulence, high immune protection and easy-to-use oral administration.
    Vaccine. 2021;39:1383-1391.
    PubMed     Abstract available


    February 2021
  1264. STANLEY M, Joura E, Yen GP, Kothari S, et al
    Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.
    Vaccine. 2021 Feb 28. pii: S0264-410X(21)00099.
    PubMed     Abstract available


  1265. WANG J, Lyu Y, Zhang H, Jing R, et al
    Willingness to pay and financing preferences for COVID-19 vaccination in China.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00240.
    PubMed     Abstract available


  1266. SHEN M, Zu J, Fairley CK, Pagan JA, et al
    Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00236.
    PubMed     Abstract available


  1267. BERNSTEIN DN, Alokozai A, Humbyrd CJ
    Vaccinating America's children: A job for orthopaedic surgeons & other non-primary care specialists?
    Vaccine. 2021 Feb 26. pii: S0264-410X(21)00175.
    PubMed    


  1268. AYASSE M, Ahmed A, McCullum C, Espinosa ML, et al
    Vaccines do not cause atopic dermatitis: A systematic review and meta-analysis.
    Vaccine. 2021 Feb 26. pii: S0264-410X(21)00203.
    PubMed     Abstract available


  1269. WON H, Kim AR, Yoo JS, Chung GT, et al
    Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00055.
    PubMed     Abstract available


  1270. ANDERSEN AR, Kolmos SK, Flanagan KL, Benn CS, et al
    Systematic review and meta-analysis of the effect of pertussis vaccine in pregnancy on the risk of chorioamnionitis, non-pertussis infectious diseases and other adverse pregnancy outcomes.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00166.
    PubMed     Abstract available


  1271. SPENCER JA, Penfound T, Salehi S, Aranha MP, et al
    Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00129.
    PubMed     Abstract available


  1272. SANDBRINK JB, Koblentz GD
    Biosecurity risks associated with vaccine platform technologies.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00171.
    PubMed     Abstract available


  1273. LEE MHP, Tan CW, Tee HK, Ong KC, et al
    Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00172.
    PubMed     Abstract available


  1274. SELL TK, Gastfriend D, Watson M, Watson C, et al
    Building the global vaccine manufacturing capacity needed to respond to pandemics.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00165.
    PubMed    


  1275. MUNOZ FM, Cramer JP, Dekker CL, Dudley MZ, et al
    Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00094.
    PubMed     Abstract available


  1276. ALDAKAK L, Huber VM, Ruhli F, Bender N, et al
    Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00170.
    PubMed     Abstract available


  1277. BONANNI P, Villani A, Scotti S, Biasci P, et al
    The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies.
    Vaccine. 2021;39:1183-1186.
    PubMed     Abstract available


  1278. VERELST F, Beutels P, Hens N, Willem L, et al
    Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers' perspective.
    Vaccine. 2021 Feb 22. pii: S0264-410X(21)00168.
    PubMed     Abstract available


  1279. SU QD, Zou YN, Yi Y, Shen LP, et al
    Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Vaccine. 2021;39:1241-1247.
    PubMed     Abstract available


  1280. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.
    Vaccine. 2021;39:1248-1256.
    PubMed     Abstract available


  1281. CHOI UY, Kim KH, Lee J, Eun BW, et al
    Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
    Vaccine. 2021 Feb 21. pii: S0264-410X(21)00161.
    PubMed     Abstract available


  1282. REN S, Attia J, Li SC, Newby D, et al
    Pneumococcal polysaccharide vaccine is a cost saving strategy for prevention of acute coronary syndrome.
    Vaccine. 2021 Feb 21. pii: S0264-410X(21)00167.
    PubMed     Abstract available


  1283. MCPHERSON AS, Whittington RJ, Hall E, Cook EJ, et al
    A comparison of multivalent and bivalent vaccination strategies for the control of virulent ovine footrot.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00159.
    PubMed     Abstract available


  1284. KABIR A, Newall AT, Randall D, Menzies R, et al
    Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00163.
    PubMed     Abstract available


  1285. DAS SC, Price JD, Gosling K, MacLennan N, et al
    Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00158.
    PubMed     Abstract available


  1286. SAUER M, Vasudevan P, Meghani A, Luthra K, et al
    Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00107.
    PubMed     Abstract available


  1287. CHOI J, Jo HJ, Jung SS, Choi J, et al
    Evaluation of swine protection with foot-and-mouth disease O1/Campos and O/Primorsky/2014 vaccines against the O Mya-98 lineage virus from East Asia.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00173.
    PubMed     Abstract available


  1288. ORTIZ JR, Robertson J, Hsu JS, Yu SL, et al
    The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00204.
    PubMed     Abstract available


  1289. DENG L, Danchin M, Lewis G, Cheung A, et al
    Revaccination outcomes of children with vaccine proximate seizures.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00164.
    PubMed     Abstract available


  1290. MARTINON-TORRES F, Halperin SA, Nolan T, Tapiero B, et al
    Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00130.
    PubMed     Abstract available


  1291. CHANG LJ, Anderson EJ, Jeanfreau R, He Y, et al
    Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6months through<18years of age: A randomized controlled phase II dose-finding trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00162.
    PubMed     Abstract available


  1292. CONSTANTINOU CA, Ziogas DC, Venetsanopoulou A, Gamaletsou MN, et al
    A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness.
    Vaccine. 2021 Feb 17. pii: S0264-410X(21)00157.
    PubMed     Abstract available


  1293. PALMU AA, De Wals P, Toropainen M, Ladhani SN, et al
    Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America.
    Vaccine. 2021 Feb 17. pii: S0264-410X(21)00111.
    PubMed     Abstract available


  1294. KUTER BJ, Browne S, Momplaisir FM, Feemster KA, et al
    Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia.
    Vaccine. 2021 Feb 16. pii: S0264-410X(21)00185.
    PubMed     Abstract available


  1295. JUSTE RA, Geijo MV, Elguezabal N, Sevilla IA, et al
    Paratuberculosis vaccination specific and non-specific effects on cattle lifespan.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00097.
    PubMed     Abstract available


  1296. WU MJ, Chung JR, Kim SS, Jackson ML, et al
    Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00106.
    PubMed     Abstract available


  1297. TZANAKAKI G, Xirogianni A, Tsitsika A, Clark SA, et al
    Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Vaccine. 2021 Feb 14. pii: S0264-410X(21)00127.
    PubMed     Abstract available


  1298. RID A, Shah SK, Miller FG, Danis M, et al
    Ethical trade-offs in vaccine development and distribution-Response to Gurwitz.
    Vaccine. 2021;39:1028-1029.
    PubMed    


  1299. GURWITZ D
    Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries.
    Vaccine. 2021;39:1027.
    PubMed    


  1300. MCALISTER SM, van den Biggelaar AHJ, Woodman TL, Hutton H, et al
    An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers.
    Vaccine. 2021 Feb 12. pii: S0264-410X(21)00068.
    PubMed     Abstract available


  1301. NICACIO AAMF, Peracchi OAB, Yamada J, Fraga MM, et al
    Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
    Vaccine. 2021;39:1165-1172.
    PubMed     Abstract available


  1302. HAI NM, Dung ND, Pho DC, Son VT, et al
    Immunogenicity, safety and reactogenicity of ROTAVAC(R) in healthy infants aged 6-8 weeks in Vietnam.
    Vaccine. 2021;39:1140-1147.
    PubMed     Abstract available


  1303. DOCKRELL HM, Butkeviciute E
    Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
    Vaccine. 2021 Feb 11. pii: S0264-410X(21)00109.
    PubMed     Abstract available


  1304. KHETSURIANI N, Zaika O, Chitadze N, Slobodianyk L, et al
    Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017.
    Vaccine. 2021 Feb 11. pii: S0264-410X(21)00133.
    PubMed     Abstract available


  1305. LIN J, Dobbins T, Wood JG, Bernardo C, et al
    Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00108.
    PubMed     Abstract available


  1306. WARD BJ, Seguin A, Couillard J, Trepanier S, et al
    Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00004.
    PubMed     Abstract available


  1307. POLAND CM, Matthews AKS, Poland GA
    Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00154.
    PubMed    


  1308. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Corrigendum to "Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance" [Vaccine 38(43) (2020) 6757-6765].
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00105.
    PubMed    


  1309. CHU L, McPhee R, Huang W, Bennett H, et al
    A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00153.
    PubMed     Abstract available


  1310. VULPE SN, Rughinis C
    Social amplification of risk and "probable vaccine damage": A typology of vaccination beliefs in 28 European countries.
    Vaccine. 2021 Feb 8. pii: S0264-410X(21)00102.
    PubMed     Abstract available


  1311. SINGH A
    Why not the 'marker' or DIVA vaccines for the control of emerging infectious diseases of humans?
    Vaccine. 2021 Feb 8. pii: S0264-410X(21)00110.
    PubMed    


  1312. ROBINSON E, Jones A, Lesser I, Daly M, et al
    International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples.
    Vaccine. 2021 Feb 6. pii: S0264-410X(21)00140.
    PubMed     Abstract available


  1313. BAUER BU, Knittler MR, Prufer TL, Wolf A, et al
    Humoral immune response to Q fever vaccination of three sheep flocks naturally pre-infected with Coxiella burnetii.
    Vaccine. 2021 Feb 5. pii: S0264-410X(21)00101.
    PubMed     Abstract available


  1314. DUDLEY MZ, Taitel MS, Smith-Ray R, Singh T, et al
    Effect of educational and financial incentive-based interventions on immunization attitudes, beliefs, intentions and receipt among close contacts of pregnant women.
    Vaccine. 2021;39:961-967.
    PubMed     Abstract available


  1315. HODGKINSON B, Wang T, Byrnes J, Scuffham P, et al
    Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review.
    Vaccine. 2021 Feb 4. pii: S0264-410X(21)00100.
    PubMed     Abstract available


  1316. SPANOS KE, Kraschnewski JL, Moss JL, Wong A, et al
    Parent support for social media standards combatting vaccine misinformation.
    Vaccine. 2021 Feb 4. pii: S0264-410X(21)00005.
    PubMed     Abstract available


  1317. PINPATHOMRAT N, Bull N, Pasricha J, Harrington-Kandt R, et al
    Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model.
    Vaccine. 2021 Feb 3. pii: S0264-410X(21)00050.
    PubMed     Abstract available


  1318. DIACO M, Chang LJ, Seet B, Robertson CA, et al
    Introductory paper: High dose influenza vaccine.
    Vaccine. 2021 Feb 3. pii: S0264-410X(20)31147.
    PubMed     Abstract available


  1319. BABAKURA B, Nomhwange T, Jean Baptiste AE, Dede O, et al
    The challenges of insecurity on implementing vaccination campaign and its effect on measles elimination and control efforts: A case study of 2017/18 measles campaign in Borno state, Nigeria.
    Vaccine. 2021 Feb 2. pii: S0264-410X(21)00040.
    PubMed     Abstract available


  1320. SATO R, Thompson A, Sani I, Metiboba L, et al
    Effect of Vaccine Direct Delivery (VDD) on vaccine stockouts and number of vaccinations: Case study from Bauchi State, Nigeria.
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00053.
    PubMed     Abstract available


  1321. GAO J, Tang F, Wang Z, Yu J, et al
    Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019.
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00075.
    PubMed     Abstract available


  1322. WILCK MB, Jin Xu Z, Stek JE, Goveia MG, et al
    Protective immune responses against Haemophilus influenza type B elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS).
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00073.
    PubMed     Abstract available


    January 2021
  1323. AXELSEN PH, Poland GA
    Vaccines, masks, distancing and credibility: An urgent warning for pandemic management.
    Vaccine. 2021 Jan 31. pii: S0264-410X(21)00079.
    PubMed    


  1324. LIU Y, Li W, Dong Q, Chen M, et al
    Non-linear relationships between children age and pneumococcal vaccine coverage: Important implications for vaccine prevention strategies.
    Vaccine. 2021 Jan 30. pii: S0264-410X(21)00095.
    PubMed     Abstract available


  1325. LUANGASANATIP N, Mahikul W, Poovorawan K, Cooper BS, et al
    Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Vaccine. 2021 Jan 30. pii: S0264-410X(21)00078.
    PubMed     Abstract available


  1326. D'ARCO C, McCormick AA, Arnaboldi PM
    Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
    Vaccine. 2021 Jan 30. pii: S0264-410X(21)00067.
    PubMed     Abstract available


  1327. ANDANI A, van Damme P, Bunge EM, Salgado F, et al
    One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00054.
    PubMed     Abstract available


  1328. XU W, Yang M
    Genetic variation and evolution of foot-and-mouth disease virus serotype A in relation to vaccine matching.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00069.
    PubMed     Abstract available


  1329. COLRAT F, Thommes E, Largeron N, Alvarez FP, et al
    Economic evaluation of high-dose inactivated influenza vaccine in adults aged >/=65 years: A systematic literature review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(20)31603.
    PubMed     Abstract available


  1330. HAMPTON LM, Aggarwal R, Evans SJW, Law B, et al
    General determination of causation between Covid-19 vaccines and possible adverse events.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00096.
    PubMed    


  1331. KROLIK M, Csepregi L, Hartmann F, Engetschwiler C, et al
    Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge.
    Vaccine. 2021 Jan 28. pii: S0264-410X(21)00074.
    PubMed     Abstract available


  1332. SORUP S, Englund H, Laake I, Nieminen H, et al
    Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis.
    Vaccine. 2021 Jan 28. pii: S0264-410X(21)00044.
    PubMed     Abstract available


  1333. SEREMBA E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, et al
    Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
    Vaccine. 2021 Jan 27. pii: S0264-410X(21)00070.
    PubMed     Abstract available


  1334. LI AJ, Kyesi F, Mwengee W, Mphuru A, et al
    Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00052.
    PubMed    


  1335. LY TDA, Castaneda S, Hoang VT, Dao TL, et al
    Vaccine-preventable diseases other than tuberculosis, and homelessness: A scoping review of the published literature, 1980 to 2020.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00051.
    PubMed     Abstract available


  1336. JONSSON G, Hansson C, Mellhammar L, Gullstrand B, et al
    Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00007.
    PubMed     Abstract available


  1337. BELCHER T, Kammoun H, Coutte L, Debrie AS, et al
    Live attenuated Bordetella pertussis vaccine candidate BPZE1 transiently protects against lethal pneumococcal disease in mice.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00041.
    PubMed     Abstract available


  1338. KIM SH, Paldurai A, Xiao S, Collins PL, et al
    Retraction notice to "Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens" [Vaccine 32(35) (2014) 4428-4435].
    Vaccine. 2021;39:775.
    PubMed    


  1339. KNOBEL DL, Arega SM, Conan A
    Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00045.
    PubMed     Abstract available


  1340. AMANI A, Tatang CA, Bayiha CN, Woung M, et al
    A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00021.
    PubMed     Abstract available


  1341. HUTTON DW, McCullough JS, Prosser L, Ye W, et al
    Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31535.
    PubMed     Abstract available


  1342. OKOLI GN, Racovitan F, Abdulwahid T, Righolt CH, et al
    Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studie
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00048.
    PubMed     Abstract available


  1343. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    PubMed     Abstract available


  1344. JAMROZIK E, Littler K, Bull S, Emerson C, et al
    Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Vaccine. 2021;39:633-640.
    PubMed     Abstract available


  1345. MENZIES R, Stein AN, Booy R, Van Buynder PG, et al
    The impact of the changing pneumococcal national immunisation program among older Australians.
    Vaccine. 2021;39:720-728.
    PubMed     Abstract available


  1346. COX AD, Kuo Lee R, Ulanova M, Bruce MG, et al
    Proceedings of a workshop to discuss the epidemiology of invasive Haemophilus influenzae disease with emphasis on serotype a and b in the Americas, 2019.
    Vaccine. 2021;39:627-632.
    PubMed     Abstract available


  1347. JIANG R, Liu X, Sun X, Wang J, et al
    Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00043.
    PubMed     Abstract available


  1348. KLASSEN AC, Milliron BJ, Reynolds L, Bakhtibekova Z, et al
    Formative research to address vaccine hesitancy in Tajikistan.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00049.
    PubMed     Abstract available


  1349. ALDRICH C, Leroux-Roels I, Huang KB, Bica MA, et al
    Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
    Vaccine. 2021 Jan 21. pii: S0264-410X(20)31667.
    PubMed     Abstract available


  1350. NIYIBITEGEKA F, Riewpaiboon A, Youngkong S, Thavorncharoensap M, et al
    Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00047.
    PubMed     Abstract available


  1351. HAYMAN B, Bowles A, Evans B, Eyermann E, et al
    Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00009.
    PubMed     Abstract available


  1352. POLAND EG, McGuire DK, Ratishvili T, Poland GA, et al
    The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31694.
    PubMed    


  1353. WINOKUR P, El Sahly HM, Mulligan MJ, Frey SE, et al
    Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31504.
    PubMed     Abstract available


  1354. JAS D, Frances-Duvert V, Brunet S, Oberli F, et al
    Evaluation of safety and immunogenicity of feline vaccines with reduced volume.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00042.
    PubMed     Abstract available


  1355. MUGO N, Eckert LO, Odero L, Gakuo S, et al
    Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31587.
    PubMed     Abstract available


  1356. BALASUBRAMANI GK, Zimmerman RK, Eng H, Lyons J, et al
    Comparison of local influenza vaccine effectiveness using two methods.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00017.
    PubMed     Abstract available


  1357. DAL-RE R
    US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00077.
    PubMed    


  1358. LOIACONO MM, Pool V, van Aalst R
    DTaP combination vaccine use and adherence: A retrospective cohort study.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00013.
    PubMed     Abstract available


  1359. CAO L, Lou J, Zhao S, Chan RWY, et al
    In silico prediction of influenza vaccine effectiveness by sequence analysis.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00006.
    PubMed     Abstract available


  1360. EINARSDOTTIR S, Nicklasson M, Veje M, Bergstrom T, et al
    Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation.
    Vaccine. 2021 Jan 19. pii: S0264-410X(20)31670.
    PubMed     Abstract available


  1361. BROCATO RL, Kwilas SA, Josleyn MD, Long S, et al
    Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00002.
    PubMed     Abstract available


  1362. REEMERS S, Verstegen I, Basten S, Hubers W, et al
    A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00022.
    PubMed     Abstract available


  1363. FATOBA AJ, Maharaj L, Adeleke VT, Okpeku M, et al
    Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00003.
    PubMed     Abstract available


  1364. SCOTT EM, Stein R, Brown MF, Hershberger J, et al
    Vaccination patterns of the northeast Ohio Amish revisited.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00026.
    PubMed     Abstract available


  1365. OTERI J, Idi Hussaini M, Bawa S, Ibizugbe S, et al
    Application of the Geographic Information System (GIS) in immunisation service delivery; its use in the 2017/2018 measles vaccination campaign in Nigeria.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00025.
    PubMed     Abstract available


  1366. SOHN S, Hong K, Hwang H, Chun BC, et al
    Paradoxical health care utilization patterns among children in Korea who did not receive mandatory pneumococcal vaccination.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00016.
    PubMed     Abstract available


  1367. XU C, Lau CL, Clark J, Rafferty AC, et al
    Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00039.
    PubMed     Abstract available


  1368. WHITAKER JA, Parikh SA, Shanafelt TD, Kay NE, et al
    The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
    Vaccine. 2021 Jan 15. pii: S0264-410X(21)00001.
    PubMed     Abstract available


  1369. MOGEKWU FI, Oteri JA, Nsubuga P, Ezebilo O, et al
    Using data to improve outcomes of supplemental immunisation activities: 2017/2018 Nigeria measles vaccination campaign.
    Vaccine. 2021 Jan 15. pii: S0264-410X(20)31659.
    PubMed     Abstract available


  1370. ZHAO X, Zeng X, Dai Q, Hou Y, et al
    Immunogenicity and protection efficacy of a Salmonella enterica serovar Typhimurium fnr, arcA and fliC mutant.
    Vaccine. 2021;39:588-595.
    PubMed     Abstract available


  1371. VAN DEN BOOGAARD J, de Gier B, de Oliveira Bressane Lima P, Desai S, et al
    Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis.
    Vaccine. 2021 Jan 13. pii: S0264-410X(20)31691.
    PubMed     Abstract available


  1372. WHITWORTH HS, Schiller J, Markowitz LE, Jit M, et al
    Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule.
    Vaccine. 2021 Jan 13. pii: S0264-410X(20)31598.
    PubMed    


  1373. OTERI J, Bawa S, Christopher E, Nsubuga P, et al
    Potential for improving routine immunisation waste management using measles vaccination campaign 2017 in Kebbi State, Nigeria.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31654.
    PubMed     Abstract available


  1374. ATSMON J, Machluf N, Yagon-Gur V, Sabbah C, et al
    Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31630.
    PubMed     Abstract available


  1375. YANG R, Liu Q, Pang W, Gao F, et al
    Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31674.
    PubMed     Abstract available


  1376. ARCON N, Picchio MS, Fenoy IM, Moretta RE, et al
    Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31669.
    PubMed     Abstract available


  1377. GUALANO MR, Corradi A, Voglino G, Catozzi D, et al
    Healthcare Workers' (HCWs) attitudes towards mandatory influenza vaccination: A systematic review and meta-analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31655.
    PubMed     Abstract available


  1378. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    PubMed     Abstract available


  1379. FENTON ATHR, Orefice C, Eun TJ, Biancarelli D, et al
    Effect of provider recommendation style on the length of adolescent vaccine discussions.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31441.
    PubMed     Abstract available


  1380. KORNUTA CA, Langellotti CA, Bidart JE, Soria I, et al
    A plasmid encoding the extracellular domain of CD40 ligand and Montanide GEL01 as adjuvants enhance the immunogenicity and the protection induced by a DNA vaccine against BoHV-1.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31553.
    PubMed     Abstract available


  1381. SANTANA CP, Luhm KR, Shimakura SE
    Impact of Tdap vaccine during pregnancy on the incidence of pertussis in children under one year in Brazil - A time series analysis.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31636.
    PubMed     Abstract available


  1382. ACKERSON B, Qian L, Sy LS, Bruxvoort K, et al
    Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31673.
    PubMed     Abstract available


  1383. BURGER AE, Reither EN, Mamelund SE, Lim S, et al
    Black-white disparities in 2009 H1N1 vaccination among adults in the United States: A cautionary tale for the COVID-19 pandemic.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31666.
    PubMed     Abstract available


  1384. SINGH J, Malik D, Raina A
    Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00015.
    PubMed     Abstract available


  1385. RUIZ JB, Bell RA
    Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00014.
    PubMed     Abstract available


  1386. WIEMKEN TL, Rutschman AS
    Development of vaccines for influenza disease: Opportunity costs of the COVID-19 pandemic.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00018.
    PubMed    


  1387. BEIGI RH, Krubiner C, Jamieson DJ, Lyerly AD, et al
    The need for inclusion of pregnant women in COVID-19 vaccine trials.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31671.
    PubMed    


  1388. CHAUDHURY S, MacGill RS, Early AM, Bolton JS, et al
    Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31635.
    PubMed     Abstract available


  1389. ABDI I, Gidding H, Leong RN, Moore HC, et al
    Vaccine coverage in children born to migrant mothers in Australia: A population-based cohort study.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31638.
    PubMed     Abstract available


  1390. DESMET S, Wouters I, Heirstraeten LV, Beutels P, et al
    In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease.
    Vaccine. 2021;39:372-379.
    PubMed     Abstract available


  1391. MAITI S, Howlader DR, Halder P, Bhaumik U, et al
    Bivalent non-typhoidal Salmonella outer membrane vesicles immunized mice sera confer passive protection against gastroenteritis in a suckling mice model.
    Vaccine. 2021;39:380-393.
    PubMed     Abstract available


  1392. WILLIAMS J, Degeling C, McVernon J, Dawson A, et al
    How should we conduct pandemic vaccination?
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31639.
    PubMed     Abstract available


  1393. SHARMA H, Anil K, Parekh S, Pujari P, et al
    A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31656.
    PubMed     Abstract available


  1394. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    PubMed     Abstract available


  1395. KELSO JM
    Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31696.
    PubMed    


  1396. SU JR, McNeil MM, Welsh KJ, Marquez PL, et al
    Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31614.
    PubMed     Abstract available


  1397. NISAR MI, Ahmed S, Jehan F, Shahid S, et al
    Direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years of age in Matiari, Pakistan.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31662.
    PubMed     Abstract available


  1398. SCHEPPLER L, De Clercq N, McGoldrick M, Dias J, et al
    Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31569.
    PubMed     Abstract available


  1399. KOHLI M, Maschio M, Becker D, Weinstein MC, et al
    The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31690.
    PubMed     Abstract available


  1400. MIDDELDORP M, van Lier A, van der Maas N, Veldhuijzen I, et al
    Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31692.
    PubMed     Abstract available


  1401. WONG MCS, Wong ELY, Huang J, Cheung AWL, et al
    Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31695.
    PubMed     Abstract available


  1402. GODINOT LD, Sicsic J, Lachatre M, Bouvet E, et al
    Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers.
    Vaccine. 2021 Jan 5. pii: S0264-410X(20)31637.
    PubMed     Abstract available


  1403. SCHLEY K, Malerczyk C, Beier D, Schiffner-Rohe J, et al
    Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany.
    Vaccine. 2021 Jan 4. pii: S0264-410X(20)31615.
    PubMed     Abstract available


  1404. FIELDING J, Sullivan SG, Beard F, Macartney K, et al
    Constructing an ethical framework for priority allocation of pandemic vaccines.
    Vaccine. 2021 Jan 3. pii: S0264-410X(20)31633.
    PubMed     Abstract available


  1405. RUSSELL LB, Kim SY, Toscano C, Cosgriff B, et al
    Comparison of static and dynamic models of maternal immunization to prevent infant pertussis in Brazil.
    Vaccine. 2021;39:158-166.
    PubMed     Abstract available


  1406. BAGATTINI AM, Policena G, Minamisava R, Andrade ALS, et al
    The data used to build the models: Pertussis morbidity and mortality burden considering various Brazilian data sources.
    Vaccine. 2021;39:137-146.
    PubMed     Abstract available


  1407. RUSSELL LB, Sobanjo-Ter Meulen A, Toscano CM
    Evaluating the cost-effectiveness of maternal pertussis immunization in low- and middle-income countries: A review of lessons learnt.
    Vaccine. 2021;39:121-124.
    PubMed     Abstract available


  1408. MITCHELL T, Dalal W, Klosovsky A, Yen C, et al
    An immunization program for US-bound refugees: Development, challenges, and opportunities 2012-present.
    Vaccine. 2021;39:68-77.
    PubMed     Abstract available


    December 2020
  1409. JIANG X, Shang X, Lin J, Zhao Y, et al
    Impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in China: A quasi-experimental study.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31608.
    PubMed     Abstract available


  1410. GROVES PJ, Williamson SL, Ahaduzzaman M, Diamond M, et al
    Can a combination of vaccination, probiotic and organic acid treatment in layer hens protect against early life exposure to Salmonella Typhimurium and challenge at sexual maturity?
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31612.
    PubMed     Abstract available


  1411. DAMJANOVSKA S, Smith C, Sayin I, Burant CJ, et al
    Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31631.
    PubMed     Abstract available


  1412. SRINIVASA REDDY Y, Narendra Babu K, Uday Kumar P, Harishankar N, et al
    Nonclinical safety evaluation of oral recombinant anti-human papilloma virus vaccine (RHPV 16 & 18): Regulatory toxicology studies in mice, rats and rabbits - An innovative approach.
    Vaccine. 2020 Dec 30. pii: S0264-410X(20)31463.
    PubMed     Abstract available


  1413. PRETO C, Maron de Mello A, Cesario Pereira Maluf EM, Teixeira Krainski E, et al
    Vaccination coverage and adherence to a dengue vaccination program in the state of Parana, Brazil.
    Vaccine. 2020 Dec 29. pii: S0264-410X(20)31597.
    PubMed     Abstract available


  1414. GUPTA S, Tiku VR, Gauhar M, Khatoon K, et al
    Genetic diversity of G9 rotavirus strains circulating among diarrheic children in North India: A comparison with 116E rotavirus vaccine strain.
    Vaccine. 2020 Dec 29. pii: S0264-410X(20)31604.
    PubMed     Abstract available


  1415. TOMLJENOVIC M, Petrovic G, Antoljak N, Hansen L, et al
    Vaccination attitudes, beliefs and behaviours among primary health care workers in northern Croatia.
    Vaccine. 2020 Dec 29. pii: S0264-410X(20)31502.
    PubMed     Abstract available


  1416. ZHONG Y, Clapham HE, Aishworiya R, Chua YX, et al
    Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore.
    Vaccine. 2020 Dec 26. pii: S0264-410X(20)31634.
    PubMed     Abstract available


  1417. PITTET LF, Tebruegge M, Dutta B, Donath S, et al
    Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guerin (BCG) vaccine.
    Vaccine. 2020 Dec 25. pii: S0264-410X(20)31498.
    PubMed     Abstract available


  1418. SUAU R, Vidal M, Aguilar R, Ruiz-Olalla G, et al
    RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31606.
    PubMed     Abstract available


  1419. MORO PL, Marquez P
    Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31613.
    PubMed     Abstract available


  1420. ULANOVA M, Huska B, Desbiens A, Gaultier GN, et al
    Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and previously immunized adult patients with severe chronic kidney disease.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31602.
    PubMed     Abstract available


  1421. THANGARAJAH D, Malo JA, Field E, Andrews R, et al
    Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31579.
    PubMed     Abstract available


  1422. KOSKAN A, Klasko-Foster L, Stecher C, Rodriguez S, et al
    Human papillomavirus vaccine guideline adherence among Arizona's Medicaid beneficiaries.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31609.
    PubMed     Abstract available


  1423. CUI YA, Folaranmi T, Buchwald UK
    The Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial: Further reflections on the design and results.
    Vaccine. 2020 Dec 22. pii: S0264-410X(20)31600.
    PubMed     Abstract available


  1424. APARECIDO NUNES A, De Jesus Lopes De Abreu A, Cintra O, A C T Cintra M, et al
    Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
    Vaccine. 2020 Dec 22. pii: S0264-410X(20)31542.
    PubMed     Abstract available


  1425. GINI R, Dodd CN, Bollaerts K, Bartolini C, et al
    Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project.
    Vaccine. 2020;38 Suppl 2:B56-B64.
    PubMed     Abstract available


  1426. ITTEFAQ M, Baines A, Abwao M, Shah SFA, et al
    "Does Pakistan still have polio cases?": Exploring discussions on polio and polio vaccine in online news comments in Pakistan.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31607.
    PubMed     Abstract available


  1427. MCFADDEN K, Seale H
    A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31610.
    PubMed     Abstract available


  1428. RAMAKRISHNAN A, Joseph SS, Reynolds ND, Poncet D, et al
    Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model.
    Vaccine. 2020 Dec 20. pii: S0264-410X(20)31601.
    PubMed     Abstract available


  1429. MARCHAL C, Belhassen M, Guiso N, Jacoud F, et al
    Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data.
    Vaccine. 2020 Dec 20. pii: S0264-410X(20)31588.
    PubMed     Abstract available


  1430. DOUGLASS N, van Diepen MT, Chapman R, Galant S, et al
    Modifications to the HIV-1 SAAVI MVA-C vaccine improve in vitro expression and in vivo immunogenicity.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31591.
    PubMed     Abstract available


  1431. FAN S, Liao Y, Jiang G, Wang L, et al
    Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31552.
    PubMed     Abstract available


  1432. GRETER H, Ivol S, Oriol Mathieu V, Erismann S, et al
    Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31566.
    PubMed     Abstract available


  1433. BETLACH AM, Fano E, VanderWaal K, Pieters M, et al
    Effect of multiple vaccinations on transmission and degree of Mycoplasma hyopneumoniae infection in gilts.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31443.
    PubMed     Abstract available


  1434. KIM K, Hahn TW
    Evaluation of novel recombinant porcine circovirus type 2d (PCV2d) vaccine in pigs naturally infected with PCV2d.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31580.
    PubMed     Abstract available


  1435. SPARROW E, Wood JG, Chadwick C, Newall AT, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2019.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31585.
    PubMed     Abstract available


  1436. FULVINI AA, Tuteja A, Le J, Pokorny BA, et al
    HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31563.
    PubMed     Abstract available


  1437. BORRIELLO A, Master D, Pellegrini A, Rose JM, et al
    Preferences for a COVID-19 vaccine in Australia.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31599.
    PubMed     Abstract available


  1438. BOKEMPER SE, Huber GA, Gerber AS, James EK, et al
    Timing of COVID-19 vaccine approval and endorsement by public figures.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31616.
    PubMed     Abstract available


  1439. MONTGOMERY VA, Lindsey CY, Smith LA, Webb RP, et al
    Development of an o-pthalaldehyde (OPA) assay to measure protein content in Ricin Vaccine E. coli (RVEc).
    Vaccine. 2020 Dec 15. pii: S0264-410X(20)31573.
    PubMed     Abstract available


  1440. SANFTENBERG L, Kuehne F, Anraad C, Jung-Sievers C, et al
    Assessing the impact of shared decision making processes on influenza vaccination rates in adult patients in outpatient care: A systematic review and meta-analysis.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31581.
    PubMed     Abstract available


  1441. BROOCKMAN D, Kalla J, Guerrero A, Budolfson M, et al
    Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31555.
    PubMed     Abstract available


  1442. FLORES-VALDEZ MA, Segura-Cerda CA
    Preclinical evaluation of tuberculosis vaccine candidates: Is it time to harmonize study design and readouts for prioritizing their development?
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31556.
    PubMed    


  1443. STEVENS VW, Russo EM, Young-Xu Y, Leecaster M, et al
    Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trials.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31583.
    PubMed     Abstract available


  1444. BRAVO-GRANDE JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, et al
    Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31571.
    PubMed     Abstract available


  1445. CASTANO-ZUBIETA MR, Rossetti CA, Garcia-Gonzalez DG, Maurizio E, et al
    Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDeltavjbR strain in goats.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31473.
    PubMed     Abstract available


  1446. BOUCHEZ M, Ward JK, Bocquier A, Benamouzig D, et al
    Physicians' decision processes about the HPV vaccine: A qualitative study.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31586.
    PubMed     Abstract available


  1447. SARINHO E, Goudouris E, Sole D
    BCG vaccine: Worrying proposal for COVID-19.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31593.
    PubMed     Abstract available


  1448. DEGELING C, Williams J, Carter SM, Moss R, et al
    Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Vaccine. 2020 Dec 11. pii: S0264-410X(20)31577.
    PubMed     Abstract available


  1449. ZACHARIA A, Harberts E, Valencia SM, Myers B, et al
    Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
    Vaccine. 2020 Dec 10. pii: S0264-410X(20)31541.
    PubMed     Abstract available


  1450. DE OLIVEIRA EMERICK S, Vieira de Carvalho T, Meirelles Miranda B, Carneiro da Silva A, et al
    Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis.
    Vaccine. 2020 Dec 10. pii: S0264-410X(20)31539.
    PubMed     Abstract available


  1451. LIU C, Huang P, Zhao D, Xia M, et al
    Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine.
    Vaccine. 2020 Dec 10. pii: S0264-410X(20)31568.
    PubMed     Abstract available


  1452. HOLM MR, Poland GA
    Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31584.
    PubMed    


  1453. CARIAS C, Pawaskar M, Nyaku M, Conway JH, et al
    Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US).
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31557.
    PubMed     Abstract available


  1454. DULIN N, Spanier A, Merino K, Hutter JN, et al
    Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31495.
    PubMed     Abstract available


  1455. GHASWALLA PK, Bengtson LGS, Marshall GS, Buikema AR, et al
    Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31550.
    PubMed     Abstract available


  1456. RASTEGAR M, Tavana M, Meraj A, Mina H, et al
    An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31589.
    PubMed     Abstract available


  1457. WILLIAMS JTB, Robinson K, Abbott E, Rojop N, et al
    Adapting and piloting a vaccine hesitancy questionnaire in rural Guatemala.
    Vaccine. 2020 Dec 8. pii: S0264-410X(20)31551.
    PubMed     Abstract available


  1458. LUISI MLR
    From bad to worse II: Risk amplification of the HPV vaccine on Facebook.
    Vaccine. 2020 Dec 7. pii: S0264-410X(20)31540.
    PubMed     Abstract available


  1459. GHIGA I, Richardson S, Alvarez AMR, Kato M, et al
    PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31500.
    PubMed     Abstract available


  1460. DHAKAL S, Deshpande S, McMahon M, Strohmeier S, et al
    Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31510.
    PubMed